US20190320633A1 - Humanized mouse model with improved human innate immune cell development - Google Patents
Humanized mouse model with improved human innate immune cell development Download PDFInfo
- Publication number
- US20190320633A1 US20190320633A1 US16/465,006 US201716465006A US2019320633A1 US 20190320633 A1 US20190320633 A1 US 20190320633A1 US 201716465006 A US201716465006 A US 201716465006A US 2019320633 A1 US2019320633 A1 US 2019320633A1
- Authority
- US
- United States
- Prior art keywords
- human
- mouse
- genetically
- modified
- immunodeficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 360
- 238000011577 humanized mouse model Methods 0.000 title claims description 12
- 210000002865 immune cell Anatomy 0.000 title description 3
- 230000011712 cell development Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims abstract description 254
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 254
- 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 claims abstract description 193
- 102000053925 human CSF1 Human genes 0.000 claims abstract description 189
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims abstract description 179
- 102000055151 human KITLG Human genes 0.000 claims abstract description 177
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims abstract description 172
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims abstract description 165
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 151
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 118
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 86
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 45
- 210000000265 leukocyte Anatomy 0.000 claims description 127
- 210000004027 cell Anatomy 0.000 claims description 116
- 238000012360 testing method Methods 0.000 claims description 114
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 111
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 110
- 239000000126 substance Substances 0.000 claims description 109
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 40
- 230000000259 anti-tumor effect Effects 0.000 claims description 34
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 31
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 31
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 26
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 25
- 239000007787 solid Substances 0.000 claims description 24
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 19
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 210000002540 macrophage Anatomy 0.000 claims description 18
- 102000004127 Cytokines Human genes 0.000 claims description 17
- 108090000695 Cytokines Proteins 0.000 claims description 17
- 210000000822 natural killer cell Anatomy 0.000 claims description 16
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 14
- 102000056982 human CD33 Human genes 0.000 claims description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 11
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 10
- 230000003750 conditioning effect Effects 0.000 claims description 10
- 210000004443 dendritic cell Anatomy 0.000 claims description 10
- 210000003630 histaminocyte Anatomy 0.000 claims description 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 10
- 210000000066 myeloid cell Anatomy 0.000 claims description 10
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 10
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 9
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 9
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 9
- 102000052624 human CXCL8 Human genes 0.000 claims description 9
- 102000057041 human TNF Human genes 0.000 claims description 9
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 8
- 210000004180 plasmocyte Anatomy 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 229940116886 human interleukin-6 Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 230000000113 radiomimetic effect Effects 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 abstract description 8
- 210000000987 immune system Anatomy 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 238000011835 investigation Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 477
- 241000699670 Mus sp. Species 0.000 description 157
- 150000001413 amino acids Chemical group 0.000 description 82
- 150000007523 nucleic acids Chemical group 0.000 description 47
- 108020004707 nucleic acids Proteins 0.000 description 44
- 102000039446 nucleic acids Human genes 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 33
- 238000009396 hybridization Methods 0.000 description 28
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 24
- 210000000130 stem cell Anatomy 0.000 description 24
- 210000000601 blood cell Anatomy 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000002158 endotoxin Substances 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- -1 hGM-SCF Proteins 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- 108700019146 Transgenes Proteins 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 108010029485 Protein Isoforms Proteins 0.000 description 13
- 102000001708 Protein Isoforms Human genes 0.000 description 13
- 210000001671 embryonic stem cell Anatomy 0.000 description 13
- 210000001161 mammalian embryo Anatomy 0.000 description 13
- 229960002621 pembrolizumab Drugs 0.000 description 13
- 210000003995 blood forming stem cell Anatomy 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 9
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000003394 haemopoietic effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 7
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 7
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 210000002459 blastocyst Anatomy 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 101710189311 Cytokine receptor common subunit gamma Proteins 0.000 description 6
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 6
- 108010002386 Interleukin-3 Proteins 0.000 description 6
- 102000000646 Interleukin-3 Human genes 0.000 description 6
- 102100020880 Kit ligand Human genes 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 102000046699 human CD14 Human genes 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 229940076264 interleukin-3 Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000000287 oocyte Anatomy 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 5
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 5
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 5
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 102000049018 human NCAM1 Human genes 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 4
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 4
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 4
- 108010039445 Stem Cell Factor Proteins 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960003852 atezolizumab Drugs 0.000 description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229950009791 durvalumab Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 210000000777 hematopoietic system Anatomy 0.000 description 4
- 102000046157 human CSF2 Human genes 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 239000012270 PD-1 inhibitor Substances 0.000 description 3
- 239000012668 PD-1-inhibitor Substances 0.000 description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 229950002916 avelumab Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 102000055276 human IL3 Human genes 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000000472 morula Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102000005289 Eukaryotic Initiation Factor-4A Human genes 0.000 description 2
- 108010056472 Eukaryotic Initiation Factor-4A Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101100168718 Homo sapiens CSF1 gene Proteins 0.000 description 2
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 102000001392 Wiskott Aldrich Syndrome protein Human genes 0.000 description 2
- 108010093528 Wiskott Aldrich Syndrome protein Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 102000044493 human CDCA4 Human genes 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
- MFZSNESUTRVBQX-XEURHVNRSA-N (2S)-2-amino-6-[4-[[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]disulfanyl]pentanoylamino]hexanoic acid Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSSC(C)CCC(=O)NCCCC[C@H](N)C(O)=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 MFZSNESUTRVBQX-XEURHVNRSA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2r,3r,3as,9ar)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- OGPIBXIQNMQSPY-JPYJTQIMSA-N (R,R)-tubulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 OGPIBXIQNMQSPY-JPYJTQIMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- FFGSXKJJVBXWCY-UHFFFAOYSA-N 1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO FFGSXKJJVBXWCY-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- MMRCWWRFYLZGAE-ZBZRSYSASA-N 533u947v6q Chemical compound O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O MMRCWWRFYLZGAE-ZBZRSYSASA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 238000001135 Friedman test Methods 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 206010058002 Hypoglobulinaemia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- MHGVSUAAUXQULX-UHFFFAOYSA-N Vinepidine Natural products CCC1CC2CN(CCC3C(=Nc4ccccc34)C(C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)C7C(O)(C(OC(=O)C)C8(CC)C=CCN9CCC67C89)C(=O)OC)C1 MHGVSUAAUXQULX-UHFFFAOYSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2s)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229950005008 abituzumab Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229950003478 acodazole Drugs 0.000 description 1
- 229950000616 acronine Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 101150027964 ada gene Proteins 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229950008995 aducanumab Drugs 0.000 description 1
- 229950008459 alacizumab pegol Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- 229950011363 ametantrone Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229950006061 anatumomab mafenatox Drugs 0.000 description 1
- 229950006588 anetumab ravtansine Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229950000847 ascrinvacumab Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- 229950010231 brequinar Drugs 0.000 description 1
- 229950001478 brontictuzumab Drugs 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 229950011547 cantuzumab ravtansine Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229940034605 capromab pendetide Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229950010667 cedefingol Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229950011359 cirolemycin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229950010905 citatuzumab bogatox Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229950002595 clivatuzumab tetraxetan Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229950005458 coltuximab ravtansine Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229950007998 demcizumab Drugs 0.000 description 1
- 229950004079 denintuzumab mafodotin Drugs 0.000 description 1
- 229950008925 depatuxizumab mafodotin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950010621 dezaguanine Drugs 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 229950004255 emibetuzumab Drugs 0.000 description 1
- 229950003048 enavatuzumab Drugs 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229950001426 erbulozole Drugs 0.000 description 1
- KLEPCGBEXOCIGS-QPPBQGQZSA-N erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
- 229950005096 fazarabine Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229950005682 flurocitabine Drugs 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 229950010404 fostriecin Drugs 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229950002140 futuximab Drugs 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229950009672 glembatumumab vedotin Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 229950006905 ilmofosine Drugs 0.000 description 1
- 229950003680 imalumab Drugs 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229950011428 indatuximab ravtansine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229950000932 indusatumab vedotin Drugs 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 229950004529 lifastuzumab vedotin Drugs 0.000 description 1
- 229950001237 lilotomab Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950003526 lorvotuzumab mertansine Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 229950010079 lumretuzumab Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229950002676 menogaril Drugs 0.000 description 1
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N metoprine, methodichlorophen Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- 229950000035 mirvetuximab soravtansine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 mitindomide Drugs 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 229950005674 modotuximab Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- 229950003027 nacolomab tafenatox Drugs 0.000 description 1
- 229950009793 naptumomab estafenatox Drugs 0.000 description 1
- 229950008353 narnatumab Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 229950002697 nesvacumab Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 229950002104 ontuxizumab Drugs 0.000 description 1
- 229950009057 oportuzumab monatox Drugs 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229950000121 otlertuzumab Drugs 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940126618 pankomab Drugs 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
- 229950009351 perfosfamide Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229950010074 pinatuzumab vedotin Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
- 229950005230 rogletimide Drugs 0.000 description 1
- 229950000143 sacituzumab govitecan Drugs 0.000 description 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 1
- 229950008902 safingol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229950000106 samalizumab Drugs 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 229950008834 seribantumab Drugs 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 229950003763 sofituzumab vedotin Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 229950006050 spiromustine Drugs 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950007435 tarextumab Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229950010138 teloxantrone Drugs 0.000 description 1
- QDZIHWBJFUNKOF-UHFFFAOYSA-N teloxantrone Chemical compound OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC QDZIHWBJFUNKOF-UHFFFAOYSA-N 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229950005808 tovetumab Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229950005609 trestolone Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229950003138 tubulozole Drugs 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229950001876 vandortuzumab vedotin Drugs 0.000 description 1
- 229950008718 vantictumab Drugs 0.000 description 1
- 229950000449 vanucizumab Drugs 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229950010789 vesencumab Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229950001270 vinepidine Drugs 0.000 description 1
- KLFUUCHXSFIPMH-YBFGSCICSA-N vinepidine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 KLFUUCHXSFIPMH-YBFGSCICSA-N 0.000 description 1
- 229950008883 vinglycinate Drugs 0.000 description 1
- YNSIUGHLISOIRQ-SWSODSCOSA-N vinglycinate Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 YNSIUGHLISOIRQ-SWSODSCOSA-N 0.000 description 1
- 229950009832 vinleurosine Drugs 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229950003670 vinrosidine Drugs 0.000 description 1
- 229950005839 vinzolidine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950003017 zeniplatin Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Definitions
- a genetically-modified, immunodeficient mouse which expresses hSCF, hGM-CSF, hIL-3, and hCSF1, along with methods of use thereof.
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1.
- hSCF human stem cell factor
- hGM-CSF granulocyte-macrophage colony-stimulating factor
- hIL-3 human interleukin-3
- hCSF1 human colony-stimulating factor 1
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell.
- hSCF human stem cell factor
- hGM-CSF granulocyte-macrophage colony-stimulating factor
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a CD34 + human hematopoietic stem cell.
- hSCF human stem cell factor
- hGM-CSF granulocyte-macrophage colony-sti
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of a human mye
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45 leukocyte, CD20 + leukocyte
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, and further comprises a human xenograft comprising a human tumor cell.
- hSCF human stem cell factor
- hGM-CSF granulocyte-macrophage colony-stimulating factor
- hIL-3 human interle
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell, and further comprises a human xenograft comprising
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell, and further comprises a human xenografta nucleotide sequence encoding human stem cell factor (hSCF); (b
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of: a human mye
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45 + leukocyte, CD20 + leukocyte
- a genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NS)
- hSCF human stem cell factor
- hGM-CSF granul
- a genetically-modified, immunodeficient mouse wherein any one or more of the nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, or hCSF1 is operably-linked to a constitutive promoter.
- a genetically-modified, immunodeficient mouse comprising, in the absence of an immunological challenge, one, two, three or all of: at least about 20% of the human CD45 + leukocytes of the mouse are CD3 + CD45 + leukocytes; at least about 10% of the human CD45 + leukocytes of the mouse are CD33 + CD45 + leukocytes; at least about 5% of the human CD45 + leukocytes of the mouse are CD14 + CD45 + leukocytes; at least about 0.5% of the human CD45 + leukocytes of the mouse are CD56 + CD45 + leukocytes.
- a genetically-modified, immunodeficient mouse wherein the mouse expresses one or more of: a human cytokine selected from the group consisting of human interleukin-8, human interleukin-1 ⁇ , human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6.
- a human cytokine selected from the group consisting of human interleukin-8, human interleukin-1 ⁇ , human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6.
- a method of making a genetically-modified, immunodeficient humanized mouse model includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and administering human hematopoietic stem cells to the genetically-modified
- hSCF
- a method of making a genetically-modified, immunodeficient humanized mouse model includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdc
- a method of making a genetically-modified, immunodeficient humanized mouse model includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; administering human hematopoietic stem cells to the genetically-modified,
- hSCF
- a method of making a genetically-modified, immunodeficient humanized mouse model includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdc
- a method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention optionally includes conditioning the genetically-modified, immunodeficient mouse to reduce mouse hematopoietic cells of the mouse prior to administering human hematopoietic stem cells.
- a method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention optionally includes irradiating the genetically-modified, immunodeficient mouse and/or administering a radiomimetic drug to the genetically-modified, immunodeficient mouse.
- a method of making a genetically-modified, immunodeficient humanized mouse model includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; administering human hematopoietic stem cells to the genetically-modified,
- hSCF
- a method of making a genetically-modified, immunodeficient humanized mouse model includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdc
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human hematopoi
- hSCF
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hema
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematop
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the
- a method of identifying anti-tumor activity of a test substance includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il
- a method of identifying anti-tumor activity of a test substance optionally includes comparing the response to a standard to determine the effect of the test substance on the xenogeneic tumor cell, wherein an inhibitory effect of the test substance on the xenogeneic tumor cell identifies the test substance as having anti-tumor activity.
- the test substance can be an immunotherapeutic agent, such as an immune checkpoint inhibitor.
- Immune checkpoint inhibitors include, but are not limited to, a PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor.
- Immune checkpoint inhibitors include, but are not limited to, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, or pembrolizumab, or an antigen-binding fragment of any one of the foregoing.
- the test substance can be an antibody.
- the test substance can be an anti-cancer agent.
- FIG. 1A is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD45 as a percentage of total blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34 + hematopoietic stem cells.
- FIG. 1B is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD20 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34 + hematopoietic stem cells.
- FIG. 1C is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD3 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34 + hematopoietic stem cells.
- FIG. 1D is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD33 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34 + hematopoietic stem cells.
- FIG. 1E is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD14 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34 + hematopoietic stem cells.
- FIG. 1F is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD56 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34 + hematopoietic stem cells;
- FIG. 2A is a chart depicting the concentration of human IL8 in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34 + hematopoietic stem cells followed by 0.15 ⁇ g intravenous lipopolysaccharide 10-weeks later.
- the serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL8 was measured by bead-based immunoassay.
- FIG. 2B is a chart depicting the concentration of human IL1- ⁇ in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34 + hematopoietic stem cells followed by 0.15 ⁇ g intravenous lipopolysaccharide 10-weeks later.
- the serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL1- ⁇ was measured by bead-based immunoassay.
- FIG. 2C is a chart depicting the concentration of human TNF in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34 + hematopoietic stem cells followed by 0.15 ⁇ g intravenous lipopolysaccharide 10-weeks later.
- the serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human TNF was measured by bead-based immunoassay.
- FIG. 2D is a chart depicting the concentration of human IL12p70 in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34 + hematopoietic stem cells followed by 0.15 ⁇ g intravenous lipopolysaccharide 10-weeks later.
- the serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL12p70 was measured by bead-based immunoassay.
- FIG. 2E is a chart depicting the concentration of human IL6 in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34 + hematopoietic stem cells followed by 0.15 ⁇ g intravenous lipopolysaccharide 10-weeks later.
- the serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL6 was measured by bead-based immunoassay.
- FIG. 3A is a graph depicting the mean tumor volume of tumors formed by a patient-derived xenograft (PDX) of human BR1126 breast cancer cells in NSG-QUAD mice (also called hNSG-Quad mice) compared to the mean tumor volume of tumors formed by a PDX of human BR1126 breast cancer cells NSG-SGM3 mice (also called hNSG-SGM3 mice).
- PDX patient-derived xenograft
- FIG. 3B is a graph depicting the mean tumor volume of tumors formed by a PDX of human MDA-MB231 breast cancer cells in NSG-QUAD mice compared to the mean tumor volume of tumors formed by a PDX of human MDA-MB231 breast cancer cells NSG-SGM3 mice.
- FIG. 3C is a graph depicting the mean tumor volume of tumors formed by a PDX of human TM1149 breast cancer cells in NSG-QUAD mice compared to the mean tumor volume of tumors formed by a PDX of human TM1149 breast cancer cells in NSG-SGM3 mice.
- FIG. 3D is a graph depicting the mean tumor volume of tumors formed by a PDX of human BL0293 bladder cancer cells in NSG-QUAD mice compared to the mean tumor volume of tumors formed by a PDX of human BL0293 bladder cancer cells in NSG-SGM3 mice.
- FIG. 4A is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34 + hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later.
- PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD45-positive (hCD45 + ) in the population of total live cells in the sample is shown.
- FIG. 4B is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34 + hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later.
- PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD3-positive (hCD3 + ) in the population of CD45 + cells in the sample is shown.
- FIG. 4C is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34 + hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later.
- PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD20-positive (hCD20 + ) in the population of CD45 + cells in the sample is shown.
- FIG. 4D is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34 + hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later.
- PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD33-positive (hCD33 + ) in the population of CD45+ cells in the sample is shown.
- FIG. 4E is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34 + hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later.
- PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD14-positive (hCD14 + ) in the population of CD45 + cells in the sample is shown.
- FIG. 4F is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34 + hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later.
- PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD56-positive (hCD56 + ) in the population of CD45 + cells in the sample is shown.
- FIG. 5 is a graph comparing tumor volumes for NSG-Quad mice (Hu-NSG-Quad mice) that have human CD34 + hematopoietic stem cell xenografts and BL0293 patient-derived xenografts and received injections with either pembrolizumab (Keytruda®) or vehicle.
- the term “comprising” refers to an open group, e.g., a group comprising members A, B, and C can also include additional members.
- the term “consisting of” refers to a closed group, e.g., a group consisting of members A, B, and C does not include any additional members.
- xenogeneic is used herein with reference to a host cell or organism to indicate that the material referred to as “xenogeneic” is derived from another species than that of the host cell or organism.
- a genetically-modified, immunodeficient mouse which expresses human stem cell factor (hSCF), human granulocyte-macrophage colony-stimulating factor (hGM-CSF), human interleukin-3 (hIL-3), and human colony-stimulating factor 1 (hCSF1) (called an “immunodeficient QUAD mouse” herein) is provided according to aspects of the present invention.
- hSCF human stem cell factor
- hGM-CSF human granulocyte-macrophage colony-stimulating factor
- hIL-3 human interleukin-3
- hCSF1 human colony-stimulating factor 1
- Various aspects of the invention relate to an immunodeficient QUAD mouse including nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, and hCSF1 in its genome wherein the immunodeficient QUAD mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins. Nucleic acid sequences are shown and described herein which encode hSCF, hGM-CSF, hIL-3, hCSF1 proteins and variants thereof.
- human colony-stimulating factor 1 human CSF1
- hCSF1 human colony-stimulating factor 1
- the human CSF1 gene locus resides on chromosome 1, and it occurs as nucleotides 109,910,242-109,930,992 of the Genome Reference Consortium Human Reference 38 genome (GRCh38/hg38).
- the human CSF1 gene is expressed as at least four transcript variants (see, e.g., NCBI Reference Sequences NM_000757.5, NM_172210.2, NM_172211.3, and NM_172212.2), which produce at least three protein isoforms, a, b, and c (see, e.g., NCBI Reference Sequences NP_000748.3, NP_757349.1, NP_757350.1, and NP_757351.1).
- the term “hCSF1” includes variants of hCSF1 amino acid sequences specifically identified herein. Human CSF1 proteins are identified herein as SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and variants thereof are useful in the present invention.
- An immunodeficient QUAD mouse includes in its genome a nucleic acid encoding hCSF1 operably linked to a promoter wherein the hCSF1 includes the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:1 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:3 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under high stringency hybridization conditions.
- human stem cell factor “human SCF,” and “hSCF” are used synonymously herein to refer to a well-known cytokine that binds to the c-Kit receptor (CD117).
- SCF is also known as kit ligand, SF, Kitl, KL-1 and other names.
- kit ligand kit ligand
- SF kit ligand
- Kitl Kitl
- KL-1 kit ligand
- Various isoforms of SCF are known including transmembrane and soluble isoforms generated by alternative splicing.
- Particular isoforms include human membrane-associated stem cell factor 248 (SCF 248 ), human membrane-associated stem cell factor 220 (SCF 220 ) and soluble stem cell factor (SCF), see Anderson, D. M. et al., 1990, Cell 63, 235; Flannagan, J. G.
- hSCF includes variants of hSCF amino acid sequences specifically identified herein.
- Human SCF proteins are identified herein as SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:16, and variants thereof are useful in the present invention.
- An immunodeficient QUAD mouse includes in its genome a nucleic acid encoding hSCF operably linked to a promoter wherein the hSCF includes the amino acid sequence of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:16, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:12 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:14 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:15 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:17 under high stringency hybridization conditions.
- Human granulocyte-macrophage colony-stimulating factor “human GM-CSF,” and “hGM-CSF” are used synonymously herein.
- Human GM-CSF is a well-known cytokine that controls the production, differentiation, and function of granulocytes and macrophages.
- the term “GM-CSF” includes variants of GM-CSF amino acid sequences specifically identified herein. Human GM-CSF proteins are identified herein as SEQ ID NO:18, and SEQ ID NO:20 and variants thereof in the present invention.
- An immunodeficient QUAD mouse includes in its genome a nucleic acid encoding hGM-CSF operably linked to a promoter wherein the hGM-CSF includes the amino acid sequence of SEQ ID NO:18, SEQ ID NO:20, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:19 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:21 under high stringency hybridization conditions.
- IL-3 is a well-known cytokine that regulates blood-cell production by controlling the production, differentiation and function of granulocytes and macrophages.
- hIL-3 includes variants of hIL-3 amino acid sequences specifically identified herein. Human IL-3 proteins are identified herein as SEQ ID NO: 22, and SEQ ID NO: 24 and variants thereof in the present invention.
- An immunodeficient QUAD mouse includes in its genome a nucleic acid encoding hIL-3 operably linked to a promoter wherein the hIL-3 includes the amino acid sequence of SEQ ID NO:22, SEQ ID NO:24, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:23 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:25 under high stringency hybridization conditions.
- aspects of the present invention relate to an immunodeficient QUAD mouse whose genome includes a nucleotide sequence encoding hCSF1, a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, and a nucleotide sequence encoding hIL-3, wherein the immunodeficient QUAD mouse expresses hCSF1, hSCF, hGM-CSF, and hIL-3.
- the included nucleotide sequence encoding hCSF1 has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4 and encodes hCSF1 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
- the included nucleotide sequence encoding hSCF has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:17 and encodes hSCF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:16.
- the included nucleotide sequence encoding hSCF encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:17 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hSCF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:16.
- the included nucleotide sequence encoding hGM-CSF has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:19, or SEQ ID NO:21 and encodes hGM-CSF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:18, or SEQ ID NO:20.
- the included nucleotide sequence encoding hGM-CSF encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:19, or SEQ ID NO:21 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hGM-CSF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:18, or SEQ ID NO:20.
- the included nucleotide sequence encoding hIL-3 has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:23, or SEQ ID NO:25 and encodes hIL-3 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:22, or SEQ ID NO:24.
- the included nucleotide sequence encoding hIL-3 encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:23, or SEQ ID NO:25 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hIL-3 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:22, or SEQ ID NO:24.
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in a first amino acid or nucleotide sequence for optimal alignment with a second amino acid or nucleotide sequence using the default parameters of an alignment software program).
- the amino acids or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
- a non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, PNAS USA 87:2264-68, modified as in Karlin and Altschul, 1993, PNAS USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al, 1990, J. Mol. Biol. 215:403.
- Gapped BLAST can be utilized as described in Altschul et al, 1997, Nucleic Acids Res. 25:3389-02.
- PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (id.).
- the default parameters of the respective programs e.g., of XBLAST and NBLAST
- the default parameters of the respective programs e.g., of XBLAST and NBLAST
- a mathematical algorithm utilized to compare sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 is used. The Clustal suite of software programs provides an additional method for aligning sequences to determine percent sequence identity.
- the percent identity between two sequences is determined using techniques similar to those described above with or without allowing gaps. In calculating percent identity, only exact matches are typically counted.
- hybridization and “hybridizes” refer to pairing and binding of complementary nucleic acids. Hybridization occurs to varying extents between two nucleic acids depending on factors such as the degree of complementarity of the nucleic acids, the melting temperature, Tm, of the nucleic acids and the stringency of hybridization conditions, as is well known in the art.
- stringency of hybridization conditions refers to conditions of temperature, ionic strength, and composition of a hybridization medium with respect to particular common additives such as formamide and Denhardt's solution. Determination of particular hybridization conditions relating to a specified nucleic acid is routine and is well known in the art, for instance, as described in J. Sambrook and D. W.
- High stringency hybridization conditions are those which only allow hybridization of substantially complementary nucleic acids. Typically, nucleic acids having about 85-100% complementarity are considered highly complementary and hybridize under high stringency conditions. Intermediate stringency conditions are exemplified by conditions under which nucleic acids having intermediate complementarity, about 50-84% complementarity, as well as those having a high degree of complementarity, hybridize. In contrast, low stringency hybridization conditions are those in which nucleic acids having a low degree of complementarity hybridize.
- specific hybridization and “specifically hybridizes” refer to hybridization of a particular nucleic acid to a target nucleic acid without substantial hybridization to nucleic acids other than the target nucleic acid in a sample.
- Hybridization and conditions to achieve a desired hybridization stringency are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001; and Ausubel, F. et al., (Eds.), Short Protocols in Molecular Biology, Wiley, 2002.
- Mutations can be introduced using standard molecular biology techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
- site-directed mutagenesis and PCR-mediated mutagenesis.
- one or more amino acid mutations can be introduced without altering the functional properties of the hSCF, hGM-CSF, hIL-3, or hCSF1 proteins.
- Acidic amino acids include aspartate, glutamate; basic amino acids include histidine, lysine, arginine; aliphatic amino acids include isoleucine, leucine, and valine; aromatic amino acids include phenylalanine, tyrosine, and tryptophan; polar amino acids include aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine, and tyrosine; and hydrophobic amino acids include alanine, cysteine, phenylalanine, glycine, isoleucine, leucine, methionine, proline, valine, and tryptophan; and conservative substitutions include substitutions among amino acids within each group.
- Amino acids can also be described in terms of sterics or relative size, alanine, cysteine, aspartate, glycine, asparagine, proline, threonine, serine, and valine are all typically considered to be small.
- nucleic acid refers to RNA or DNA molecules having more than one nucleotide in any form including single-stranded, double-stranded, oligonucleotide, or polynucleotide.
- nucleotide sequence refers to the ordering of nucleotides in a nucleic acid.
- Nucleic acids encoding hSCF, hGM-CSF, hIL-3, hCSF1, and variants thereof can be isolated or generated recombinantly or synthetically using well-known methodology.
- a nucleotide sequence encoding hSCF, hGM-CSF, hIL-3, or hCSF1 can be operably-linked to a promoter.
- the promoter can be a constitutive promoter.
- the promoter can be capable of driving gene expression in a host mouse (e.g., an immunodeficient mouse).
- the promoter can be the CAG promoter.
- the CAG promoter includes the cytomegalovirus early enhancer element (“C”), the first exon and the first intron of the chicken beta-actin gene (“A”), and the splice acceptor of the rabbit beta-globulin gene (“G”).
- the CAG promoter is well known and displays robust expression in mouse cells (see, e.g., Jun-ichi et al, 1989, Gene, 79(2):269).
- the CAG promoter can be modified, for example, to remove exons.
- Other promoters are known to drive robust gene expression in mice including the cytomegalovirus (CMV) immediate-early promoter and the simian virus 40 (SV40) early promoter.
- CMV cytomegalovirus
- SV40 simian virus 40
- An immunodeficient QUAD mouse can includes nucleic acids encoding hSCF, hGM-CSF, hIL-3, and hCSF1, and each nucleic acid can be operably-linked to a constitutive promoter.
- Immunodeficient mice are provided according to embodiments of the present invention whose genomes include an expression cassette including a nucleotide sequence encoding xenogeneic CSF1, wherein the nucleotide sequence is operably-linked to a promoter and a polyadenylation signal, and the mouse expresses the encoded xenogeneic CSF1.
- expression construct and “expression cassette” are used herein to refer to a double-stranded recombinant nucleotide sequence containing a desired coding sequence and containing one or more regulatory elements necessary or desirable for the expression of the operably-linked coding sequence.
- regulatory element refers to a nucleotide sequence that controls some aspect of the expression of nucleotide sequences.
- Exemplary regulatory elements illustratively include an enhancer, an internal ribosome entry site (IRES), an intron, an origin of replication, a polyadenylation signal (pA), a promoter, a transcription termination sequence, and an upstream regulatory domain, which contribute to the replication, transcription, and post-transcriptional processing of a nucleotide sequence.
- IRES internal ribosome entry site
- pA polyadenylation signal
- promoter a transcription termination sequence
- upstream regulatory domain which contribute to the replication, transcription, and post-transcriptional processing of a nucleotide sequence.
- a regulatory element included in an expression cassette can be a promoter.
- the term “promoter” as used herein refers to a regulatory nucleotide sequence operably-linked to a coding nucleotide sequence to be transcribed such as a nucleotide sequence encoding a desired amino acid.
- a promoter is generally positioned upstream of a nucleotide sequence to be transcribed and provides a site for specific-binding by RNA polymerase and other transcription factors.
- a promoter can be a constitutive promoter or an inducible promoter.
- a promoter can optionally provide ubiquitous, tissue-specific, or cell-type specific expression.
- Ubiquitous promoters that can be included in an expression construct include, but are not limited to, a 3-phosphoglycerate kinase (PGK-1) promoter, a beta-actin promoter, a ROSA26 promoter, a heat shock protein 70 (Hsp70) promoter, an EF-1 alpha gene encoding elongation factor 1 alpha (EF-1) promoter, an eukaryotic initiation factor 4A (eIF-4A1) promoter, a chloramphenicol acetyltransferase (CAT) promoter, and a cytomegalovirus (CMV) promoter.
- PGK-1 3-phosphoglycerate kinase
- beta-actin beta-actin promoter
- ROSA26 promoter
- Hsp70 heat shock protein 70
- Hsp70 heat shock protein 70
- EF-1 alpha gene encoding elongation factor 1 alpha EF-1 promoter
- eIF-4A1 eukaryotic
- Tissue-specific promoters that can be included in an expression construct include, but are not limited to, a promoter of a gene expressed in the hematopoietic system, such as an hSCF promoter, an hCSF1 promoter, a hIL-3 promoter, a hGM-CSF, an IFN- ⁇ promoter, a Wiskott-Aldrich syndrome protein (WASP) promoter, a CD45 (also called leukocyte common antigen) promoter, a Flt-1 (fms-like tyrosine kinase, VEGF Receptor 1) promoter, an endoglin (CD105) promoter, and an ICAM-2 (Intracellular Adhesion Molecule 2) promoter.
- a promoter of a gene expressed in the hematopoietic system such as an hSCF promoter, an hCSF1 promoter, a hIL-3 promoter, a hGM-CSF, an IFN- ⁇ promoter
- one or more enhancer sequences can be included such as, but not limited to, the cytomegalovirus (CMV) early enhancer element and the SV40 enhancer element.
- CMV cytomegalovirus
- An expression construct can optionally include sequences necessary for amplification in bacterial cells, such as a selection marker (e.g., kanamycin or ampicillin resistance gene) and an origin of replication.
- a selection marker e.g., kanamycin or ampicillin resistance gene
- the expression construct can be linearized before injection into the embryo.
- the expression construct is injected into fertilized oocytes. Fertilized oocytes are collected from superovulated females the day after mating (0.5 days post coitum) and injected with the expression construct. The injected oocytes are either cultured overnight or transferred directly into oviducts of 0.5-day post coitum pseudopregnant females. Methods for superovulation, harvesting of oocytes, expression construct injection, and embryo transfer are known in the art and described, for example, in Manipulating the Mouse Embryo: A Laboratory Manual, 3 rd edition, Cold Spring Harbor Laboratory Press; Dec.
- Offspring can be tested for the presence of the expression construct, or relevant portion thereof, by DNA analysis, such as by PCR, Southern blot, or nucleic acid sequencing. Mice that carry the expression construct, or relevant portion thereof, can be tested for protein expression such as by ELISA or Western blot analysis.
- the xenogeneic nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, and hCSF1 can be integrated into the genome of some or all of the cells of the mouse.
- the xenogeneic nucleotide sequences are integrated into the genomes of germline cells of the mouse according to aspects of the present invention thereby enabling the inheritance of the genes to progeny of the mouse.
- embryonic stem cells are grown in media optimized for the particular cell line.
- embryonic stem cell media contains 15% fetal bovine serum (FBS) or synthetic or semi-synthetic equivalents, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 50 U/mL penicillin and streptomycin, 0.1 mM 2-mercaptoethanol, and 1000 U/mL LIF (plus, for some cell lines chemical inhibitors of differentiation) in Dulbecco's Modified Eagle Media (DMEM).
- FBS fetal bovine serum
- DMEM Dulbecco's Modified Eagle Media
- Selected cells incorporating the expression construct can be injected into preimplantation embryos.
- embryonic stem cells or induced pluripotent stem cells are rendered to single cells using a mixture of trypsin and EDTA, followed by resuspension in embryonic stem cell media.
- Groups of single cells are selected using a finely drawn-out glass needle (20-25 micrometer inside diameter) and introduced through the embryo's zona pellucida and into the blastocysts cavity (blastocoel) using an inverted microscope fitted with micromanipulators.
- Stem cells can also be injected into early stage embryos (e.g., 2-cell, 4-cell, 8-cell, premorula, or morula).
- Injection can be assisted with a laser or piezo-pulsed drilled opening in the zona pellucida.
- stem cells embryonic stem cells or induced pluripotent stem cells
- 8-cell stage embryo 6-9 stem cells per 4-cell stage embryo
- 6 stem cells 6 2-cell stage embryo.
- embryos are allowed to recover for a few hours at 37° C. in 5% CO 2 , 5% O 2 in nitrogen or cultured overnight before transfer into pseudopregnant recipient females.
- stem cells can be aggregated with morula stage embryos. All of these methods are well established and can be used to produce stem cell chimeras.
- Pseudopregnant embryo recipients are prepared using methods known in the art. Briefly, fertile female animals between 6-8 weeks of age are mated with vasectomized or sterile males to induce a hormonal state conductive to supporting surgically introduced embryos. At 2.5 days post coitum (dpc) up to 15 of the stem cell containing blastocysts are introduced into the uterine horn very near to the uterus-oviduct junction. For early stage embryos and morula, such embryos are either cultured in vitro into blastocysts or implanted into the oviducts of 0.5 dpc or 1.5 dpc pseudopregnant females according to the embryo stage.
- dpc coitum
- Chimeric pups from the implanted embryos are born 16-20 days after the transfer depending on the embryo age at implantation. Chimeric males are selected for breeding.
- Offspring can be analyzed for transmission of the embryonic stem cell genome by coat color and genetic analysis, such as PCR, Southern blot, or nucleic acid sequencing. Protein expression (e.g., of hSCF, hGM-SCF, hIL-3, and/or hCSF1) can be analyzed by protein analysis (Western blot, ELISA) or other functional assays.
- Offspring expressing the desired genetic modification can be intercrossed to create non-human animals homozygous for the genetic modification.
- the genetically modified mice can be crossed with immunodeficient mice to create a congenic immunodeficient strain genetically modified to express hSCF, hGM-SCF, hIL-3, and hCSF1.
- a nucleotide sequence encoding a protein to be expressed can be targeted into a specific locus of the stem cell genome that is known to result in reliable expression such as the Hprt or the ROSA26 locus.
- a targeting construct can be made using recombinant DNA techniques.
- the targeting construct can optionally include 5′ and 3′ sequences that are homologous to the endogenous gene target.
- the targeting construct can optionally further include a selectable marker such as neomycin phosphotransferase, hygromycin, or puromycin, a nucleic acid encoding hSCF, hGM-SCF, hIL-3, and/or hCSF1, and a polyadenylation signal, for example.
- the sequence is either in frame with the endogenous gene locus, or a splice acceptor site and internal ribosome entry site (IRES) sequence are included.
- IRES internal ribosome entry site
- Such a targeting construct can be transfected into stem cells, and the stem cells can be screened to detect the homologous recombination event using PCR, Southern blot, or nucleic acid sequencing. Cells with the correct homologous recombination event can be further analyzed for transgene expression by protein analysis, such as by ELISA or Western blot analysis. If desired, the selectable marker can be removed by treating the stem cells with Cre recombinase.
- the cells are analyzed for the presence of the nucleotide sequence encoding the expression construct or relevant portion thereof.
- Cells with the correct genomic event can be selected and injected into preimplantation embryos as described above. Chimeric males are selected for breeding.
- Offspring can be analyzed for transmission of the embryonic stem cell genome by coat color and genetic analysis, such as PCR, Southern blot, or nucleotide sequencing, and can be tested for xenogeneic protein expression such as by protein analysis (Western blot, ELISA) or other functional assays.
- Offspring expressing the desired genetic modification can be intercrossed to create animals homozygous for the genetic modification.
- mice genetically modified to express hSCF, hGM-SCF, hIL-3, and hCSF1 can then be crossed with immunodeficient animals to create a congenic immunodeficient strain genetically modified to express hSCF, hGM-SCF, hIL-3, and hCSF1.
- One or multiple copies (such as concatamers) of the nucleotide sequence encoding hSCF, the nucleotide sequence encoding hGM-CSF, the nucleotide sequence encoding hIL-3, and/or the nucleotide sequence encoding hCSF1 can be integrated into the genomes of the cells of the immunodeficient QUAD mouse.
- any of various methods can be used to introduce a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1 into an immunodeficient mouse to produce an immunodeficient QUAD mouse.
- Such techniques are well-known in the art and include, but are not limited to, pronuclear microinjection and transformation of embryonic stem cells.
- Methods for generating genetically modified mice include, but are not limited to, those described in Sundberg and Ichiki, (Eds.), Genetically Engineered Mice Handbook, CRC Press, 2006; Hofker and van Deursen, (Eds.), Transgenic Mouse Methods and Protocols, Humana Press, 2002; Joyner, Gene Targeting: A Practical Approach, Oxford University Press, 2000; Manipulating the Mouse Embryo: A Laboratory Manual, 3 rd edition, Cold Spring Harbor Laboratory Press, Dec. 15, 2002, ISBN-10: 0879695919; Turksen (Ed.), Embryonic stem cells: methods and protocols in Methods Mol Biol. 2002, 185, Humana Press; Current Protocols in Stem Cell Biology, ISBN: 978047015180; Meyer et al, PNAS USA, 107 (34):15022-26.
- Homology-based recombination gene modification strategies can be used to genetically modify an immunodeficient mouse by “knock-in” to introduce a nucleic acid encoding an exogenous protein or proteins e.g., a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1 into the genome of the immunodeficient mouse, such as homing endonucleases, integrases, meganucleases, transposons, nuclease-mediated processes using a zinc finger nuclease (ZFN), a Transcription Activator-Like (TAL), a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas, or a Drosophila Recombination-Associated Protein (DRAP) approach.
- ZFN zinc finger nuclease
- An immunodeficient QUAD mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, each at a serum concentration of at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng
- An immunodeficient QUAD mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, each at a serum concentration of about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 pg/mL,
- an immunodeficient QUAD mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, each at a serum concentration of about 1 ng/mL to about 10 ng/mL.
- immunodeficient mouse refers to a mouse characterized by one or more of: a lack of functional immune cells, such as T cells and B cells; a DNA repair defect; a defect in the rearrangement of genes encoding antigen-specific receptors on lymphocytes; and a lack of immune functional molecules such as IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA.
- Immunodeficient mice can be characterized by one or more deficiencies in a gene involved in immune function, such as Rag1 and Rag2 (Oettinger, M. A et al., Science, 248:1517-1523, 1990; and Schatz, D. G. et al., Cell, 59:1035-1048, 1989) Immunodeficient mice may have any of these or other defects which result in abnormal immune function in the mice.
- an immunodeficient QUAD mouse has a defect in its endogenous gene encoding interleukin-2 receptor ⁇ subunit (IL-2RG) which causes the mouse to express a defective endogenous interleukin-2 receptor ⁇ subunit and/or a reduced amount of endogenous interleukin-2 receptor ⁇ subunit, or the mouse may not express an endogenous interleukin-2 receptor ⁇ subunit at all.
- the immunodeficient QUAD can optionally be IL-2RG null such that it lacks a functional endogenous IL-2RG gene.
- a immunodeficient QUAD mouse has a defect in its endogenous gene encoding DNA-dependent protein kinase, catalytic subunit (Prkdc) which causes the mouse to express a defective endogenous DNA-dependent protein kinase, catalytic subunit and/or a reduced amount of endogenous DNA-dependent protein kinase, catalytic subunit, or the mouse may not express endogenous DNA-dependent protein kinase, catalytic subunit at all.
- the immunodeficient QUAD mouse can optionally be Prkdc null such that it lacks a functional endogenous Prkdc gene).
- Endogenous refers to genes present in the genome of the mouse at their native gene locus.
- an immunodeficient QUAD mouse has severe-combined immunodeficiency.
- severe combined immune deficiency refers to a condition characterized by the absence or severe reduction of function of T cells and B cells.
- SCID Common forms include: X-linked SCID, which is characterized by gamma chain gene mutations in the IL-2RG gene and the lymphocyte phenotype T( ⁇ ) B(+) NK( ⁇ ). and autosomal recessive SCID.
- Autosomal recessive SCID can be characterized by Jak3 gene mutations and the lymphocyte phenotype T( ⁇ ) B(+) NK( ⁇ ), ADA gene mutations and the lymphocyte phenotype T( ⁇ ) B( ⁇ ) NK( ⁇ ), IL-7R alpha-chain mutations and the lymphocyte phenotype T( ⁇ ) B(+) NK(+), CD3 delta or epsilon mutations and the lymphocyte phenotype T( ⁇ ) B(+) NK(+), RAG1/RAG2 mutations and the lymphocyte phenotype T( ⁇ ) B( ⁇ ) NK(+), Artemis gene mutations and the lymphocyte phenotype T( ⁇ ) B( ⁇ ) NK(+), and CD45 gene mutations and the lymphocyte phenotype T( ⁇ ) B(+) NK(+).
- an immunodeficient QUAD mouse has the severe combined immunodeficiency mutation (Prkdc scid ), commonly referred to as the scid mutation.
- the scid mutation is well-known and located on mouse chromosome 16 as described in Bosma et al, 1989, Immunogenetics 29:54-56. Mice homozygous for the scid mutation are characterized by an absence of functional T cells and B cells, lymphopenia, hypoglobulinemia, and a normal hematopoetic microenvironment.
- the scid mutation can be detected, for example, by the detection of markers for the scid mutation using well-known methods such as PCR or flow cytometry.
- a genetically modified immunodeficient mouse has an IL-2 receptor gamma chain deficiency.
- the term “IL-2 receptor gamma chain deficiency” refers to decreased IL-2 receptor gamma chain. Decreased IL-2 receptor gamma chain can be due to gene deletion or mutation. Decreased IL-2 receptor gamma chain can be detected, for example, by detection of IL-2 receptor gamma chain gene deletion or mutation and/or detection of decreased IL-2 receptor gamma chain expression using well-known methods.
- An immunodeficient QUAD mouse according to aspects of the present invention has severe combined immunodeficiency or an IL-2 receptor gamma chain deficiency in combination with severe combined immunodeficiency.
- An immunodeficient QUAD mouse has the scid mutation or an IL-2 receptor gamma chain deficiency in combination with the scid mutation.
- the immunodeficient QUAD mouse is a genetically modified NSG mouse, a genetically modified NRG mouse or a genetically modified NOG mouse, wherein the genome of the genetically-modified NSG, NRG or NOG mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, wherein the mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins.
- NSG mice lack mature mouse T, B, and NK cells, and they are deficient in multiple mouse cytokine signaling pathways. NSG mice are characterized by a lack of mouse IL-2R- ⁇ (gamma c) expression, no detectable mouse serum immunoglobulin, no mouse hemolytic complement, no mature mouse T lymphocytes, and no mature mouse natural killer cells.
- mouse IL-2R- ⁇ gamma c
- NSG mouse that expresses hSCF, hGM-CSF, hIL-3, and hCSF1 is referred to as a “NSG-QUAD” mouse, which indicates that the genome of the genetically-modified NSG, mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, on the NOD.Cg-Prkdc scid /L-2rg tm1Wjl /SzJ background, wherein the mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins.
- NSG-QUAD mice exhibit a significantly heightened level of CD33 + /CD14 + human monocytes and CD56 + human NK cells in the blood when engrafted with human hematopoietic stem cells when compared with NSG mice.
- NSG-QUAD mice also exhibit a surprising property of an enhanced development of human monocytes and NK cells when engrafted with human hematopoietic stem cells.
- LPS lipopolysaccharide
- NRG mouse that expresses hSCF, hGM-CSF, hIL-3, and hCSF1 is referred to as a “NRG-QUAD” mouse, which indicates that the genome of the genetically-modified NRG, mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, on the NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl /SzJ background, wherein the mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins.
- NOG mice are well-known as NOD.Cg-Prkdc scid Il2rg Tm1Sug /JicTac, described in detail in Ito, M. et al., Blood 100,3175-3182 (2002).
- a NOG mouse that expresses hSCF, hGM-CSF, hIL-3, and hCSF1 is referred to as a “NOG-QUAD” mouse, which indicates that the genome of the genetically-modified NOG, mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, on the NOD.Cg-Prkdc scid Il2rg Tm1Sug /JicTac background.
- Various aspects of the invention relate to administering xenogeneic hematopoietic stem cells (HSC) to an immunodeficient QUAD mouse, producing an immunodeficient QUAD mouse having engrafted HSC.
- HSC xenogeneic hematopoietic stem cells
- the xenogeneic HSC are human HSC according to aspects of the present invention.
- xenogeneic HSC refers to multipotent stem cells expressing c-Kit receptor.
- multipotent stem cells expressing c-Kit receptor include, but are not limited to, hematopoietic stem cells, also known as hemocytoblasts.
- C-Kit receptor is well-known in the art, for example as described in Vandenbark G R et al., 1992, Cloning and structural analysis of the human c-kit gene, Oncogene 7(7): 1259-66; and Edling C E, Hallberg B, 2007, c-Kit—a hematopoietic cell essential receptor tyrosine kinase, Int. J. Biochem. Cell Biol. 39(11):1995-8.
- Isolation of xenogeneic HSC, administration of the xenogeneic HSC to a host mouse and methods for assessing engraftment in the host mouse thereof are well-known in the art.
- Hematopoietic stem cells for administration to an immunodeficient QUAD mouse can be obtained from any tissue containing HSC such as, but not limited to, umbilical cord blood, bone marrow, GM-CSF-mobilized peripheral blood and fetal liver.
- Xenogeneic HSC can be administered into newborn mice by administration via various routes, such as, but not limited to, into the heart, liver and/or facial vein.
- Xenogeneic HSC can be administered into adult mice by various routes, such as, but not limited to, administration into the tail vein, into the femur bone marrow cavity or into the spleen.
- fetal liver containing the xenogeneic HSC can be engrafted under the renal capsule.
- Administering xenogeneic cells to a mouse can include administering a composition comprising xenogeneic cells to the mouse.
- the composition can further include, for example, water, a tonicity-adjusting agent (e.g., a salt such as sodium chloride), a pH buffer (e.g., citrate), and/or a sugar (e.g., glucose).
- a tonicity-adjusting agent e.g., a salt such as sodium chloride
- a pH buffer e.g., citrate
- sugar e.g., glucose
- Engraftment of xenogeneic hematopoietic stem cells in immunodeficient animals is characterized by the presence of differentiated xenogeneic hematopoietic cells in the immunodeficient QUAD mice.
- Engraftment of xenogeneic HSC can be assessed by any of various methods, such as, but not limited to, flow cytometric analysis of cells in the animals to which the xenogeneic HSC are administered at one or more time points following the administration of HSC.
- the xenogeneic HSC administered to an immunodeficient QUAD mouse are isolated from an original source material to obtain a population of cells enriched in HSCs.
- the isolated xenogeneic HSCs may or may not be pure.
- xenogeneic HSCs are purified by selection for a cell marker, such as CD34.
- administered xenogeneic HSCs are a population of cells in which CD34 + cells constitute about 1-100% of total cells, although a population of cells in which CD34 + cells constitute fewer than about 1% of total cells can be used.
- administered xenogeneic HSCs are T cell depleted cord blood cells in which CD34 + cells make up about 1-3% of total cells, lineage depleted cord blood cells in which CD34 + cells make up about 50% of total cells, or CD34 + positively selected cells in which CD34 + cells make up about 90% of total cells.
- the number of xenogeneic HSCs administered is not considered limiting with regard to generation of a xenogeneic hematopoietic and immune system in an immunodeficient QUAD mouse.
- a single xenogeneic HSC can generate a hematopoietic and immune system in a host immunodeficient QUAD mouse.
- the number of administered xenogeneic HSCs is generally in the range of about 1 ⁇ 10 3 to 1 ⁇ 10 6 (1,000 to 1,000,000) CD34 + cells where the recipient is a mouse, although more or fewer can be used.
- a method according to aspects of the present invention can include administering about 10 3 (1000) to about 10 6 (1,000,000), about 10 3 to about 10 5 , about 10 4 to about 10 6 , about 10 5 to about 10 7 , about 1 ⁇ 10 3 to about 1 ⁇ 10 4 , about 5 ⁇ 10 3 to about 5 ⁇ 10 4 , about 1 ⁇ 10 4 to about 1 ⁇ 10 5 , about 5 ⁇ 10 4 to about 5 ⁇ 10 5 , about 1 ⁇ 10 5 to about 1 ⁇ 10 6 , about 5 ⁇ 10 5 to about 5 ⁇ 10 6 , about 1 ⁇ 10 6 to about 1 ⁇ 10 7 , about 2 ⁇ 10 4 to about 5 ⁇ 10 5 , or about 5 ⁇ 10 4 to about 2 ⁇ 10 5 xenogeneic HSC, such as human hematopoietic stem cells, to the immunodeficient QUAD mouse.
- HSC hematopoietic stem cells
- the method can include administering at least about 1 ⁇ 10 2 , about 2 ⁇ 10 2 , about 3 ⁇ 10 2 , about 4 ⁇ 10 2 , about 5 ⁇ 10 2 , about 6 ⁇ 10 2 , about 7 ⁇ 10 2 , about 8 ⁇ 10 2 , about 9 ⁇ 10 2 , about 1 ⁇ 10 3 , about 2 ⁇ 10 3 , about 3 ⁇ 10 3 , about 4 ⁇ 10 3 , about 5 ⁇ 10 3 , about 6 ⁇ 10 3 about 7 ⁇ 10 3 , about 8 ⁇ 10 3 , about 9 ⁇ 10 3 , about 1 ⁇ 10 4 , about 2 ⁇ 10 4 , about 3 ⁇ 10 4 about 4 ⁇ 10 4 , about 5 ⁇ 10 4 , about 6 ⁇ 10 4 , about 7 ⁇ 10 4 , about 8 ⁇ 10 4 , about 9 ⁇ 10 4 about 1 ⁇ 10 5 , about 2 ⁇ 10 5 , about 3 ⁇ 10 5 , about 4 ⁇ 10 5 , about 6 ⁇ 10 5 , about 7 ⁇ 10 5 , about 8 ⁇ 10 4 , about 9 ⁇ 10 4 about 1 ⁇ 10 5 , about 2
- the method can include administering about 1 ⁇ 10 2 , about 2 ⁇ 10 2 , about 3 ⁇ 10 2 , about 4 ⁇ 10 2 , about 5 ⁇ 10 2 , about 6 ⁇ 10 2 , about 7 ⁇ 10 2 , about 8 ⁇ 10 2 , about 9 ⁇ 10 2 , about 1 ⁇ 10 3 , about 2 ⁇ 10 3 , about 3 ⁇ 10 3 , about 4 ⁇ 10 3 , about 5 ⁇ 10 3 , about 6 ⁇ 10 3 , about 7 ⁇ 10 3 , about 8 ⁇ 10 3 , about 9 ⁇ 10 3 , about 1 ⁇ 10 4 , about 2 ⁇ 10 4 , about 3 ⁇ 10 4 , about 4 ⁇ 10 4 , about 5 ⁇ 10 4 , about 6 ⁇ 10 4 , about 7 ⁇ 10 4 , about 8 ⁇ 10 4 , about 9 ⁇ 10 4 , about 1 ⁇ 10 5 , about 2 ⁇ 10 5 , about 3 ⁇ 10 5 , about 4 ⁇ 10 5 , about 6 ⁇ 10 5 , about 7 ⁇ 10 5 , about 8 ⁇ 10 5 , about 9 ⁇ 10 4 , about 1 ⁇
- Engraftment is successful where xenogenic HSCs and/or cells differentiated from the xenogeneic HSCs in the recipient immunodeficient QUAD mouse are detected at a time when the majority of any administered non-HSC have degenerated. Detection of differentiated xenogeneic HSC cells can be achieved by detection of xenogeneic DNA in the recipient immunodeficient QUAD mouse or detection of intact xenogeneic HSCs and cells differentiated from the xenogeneic HSCs, for example. Serial transfer of CD34 + cells into a secondary recipient and engraftment of a xenogeneic hematopoietic system is a further test of HSC engraftment in the primary recipient.
- Engraftment can be detected by flow cytometry as 0.05% or greater xenogeneic CD45 + cells in the blood, spleen or bone marrow of the recipient immunodeficient QUAD mouse at 6-12 weeks after administration of the xenogeneic HSC.
- Engraftment of xenogeneic haematopoietic stem cells (HSC) in an immunodeficient QUAD mouse includes “conditioning” of the immunodeficient QUAD mouse prior to administration of the xenogeneic HSC, for example by sub-lethal irradiation of the recipient animal with high frequency electromagnetic radiation, or gamma radiation, or treatment with a radiomimetic drug such as busulfan or nitrogen mustard. Conditioning is believed to reduce numbers of host hematopoietic cells, create appropriate microenvironmental factors for engraftment of xenogeneic HSC, and/or create microenvironmental niches for engraftment of xenogeneic HSC. Standard methods for conditioning are known in the art, such as described herein and in J. Hayakawa et al, 2009, Stem Cells, 27(1):175-182.
- Methods are provided according to aspects of the present invention which include administration of xenogeneic HSC to an immunodeficient QUAD mouse without “conditioning” the immunodeficient QUAD mouse prior to administration of the xenogeneic HSC.
- Methods are provided according to aspects of the present invention which include administration of xenogeneic HSC to an immunodeficient QUAD mouse without “conditioning” by radiation or radiomimetic drugs of the immunodeficient QUAD mouse prior to administration of the xenogeneic HSC.
- Various aspects of the invention relate to administering xenogeneic hematopoietic stem cells (HSC) to an immunodeficient QUAD mouse, producing an immunodeficient QUAD mouse having engrafted HSC.
- HSC xenogeneic hematopoietic stem cells
- the engrafted xenogeneic HSC differentiate to produce an immunodeficient QUAD mouse with a xenogeneic immune system or components thereof.
- xenogeneic HSC to an immunodeficient QUAD mouse results in the production of differentiated xenogeneic cells of hematopoietic lineage in the mouse.
- administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of xenogeneic myeloid-lineage and xenogeneic lymphoid-lineage cells by the mouse such as xenogeneic CD33 + myeloid cells, xenogeneic myeloid progenitor cells, xenogeneic mast cells, xenogeneic myeloid dendritic cells, xenogeneic B cells, xenogeneic T cells, xenogeneic T helper cells, xenogeneic cytotoxic T cells, and/or xenogeneic T reg cells.
- human HSC are administered to an immunodeficient QUAD mouse which differentiate such that the mouse includes one or more of: human CD33 + myeloid cells, human myeloid progenitor cells, human mast cells, human myeloid dendritic cells, human B cells, human T cells, human T helper cells, human cytotoxic T cells, and/or human T reg cells.
- xenogeneic HSC to an immunodeficient QUAD mouse results in the production of differentiated xenogeneic cells of hematopoietic lineage that can be characterized by flow cytometry.
- administration of human HSC to an immunodeficient QUAD mouse results in the production of differentiated human cells of hematopoietic lineage that can be characterized by flow cytometry, including human leukocytes selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of CD45 + , CD20 + , CD20 + CD45 + , CD3 + , CD3 + CD45 + , CD33 + , CD33 + CD45 + , CD14 + , CD14 + CD45 + , CD56 + , and CD56 + CD45 + human leukocytes.
- administration of human HSC to an immunodeficient QUAD mouse results in the production of differentiated human cells of hematopoietic lineage such as human CD45 + leukocytes, wherein at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more of the human CD45 + leukocytes of the mouse are CD3 + CD45 + leukocytes; at least about 10%, 15%, 20%, 25%, 30%, 35%, or more of the human CD45 + leukocytes of the mouse are CD33 + CD45 + leukocytes; at least about 5%, 10%, 15%, 20%, or more of the human CD45 + leukocytes of the mouse are CD14 + CD45 + leukocytes; and/or at least about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, or more of the human CD45 + leukocytes of the mouse
- administration of human HSC to an immunodeficient QUAD mouse results in the production of differentiated human cells of hematopoietic lineage such as human leukocytes, wherein at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more of the human leukocytes of the mouse are either cytotoxic T-cells or T-helper cells; at least about 10%, 15%, 20%, 25%, 30%, 35%, or more of the human leukocytes of the mouse are myeloid-lineage cells; at least about 5%, 10%, 15%, 20%, or more of the human leukocytes of the mouse are macrophages; and/or at least about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, or more of the human leukocytes of the mouse are natural killer cells (e.g., in the absence of an immunological challenge such as
- administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of xenogeneic cytokines by the mouse such as interleukin-8, interleukin-1 ⁇ , tumor-necrosis factor, interleukin-12p70, and/or interleukin-6.
- administration of human HSC to an immunodeficient QUAD mouse results in the production of 1, 2, 3, 4, or all of human interleukin-8, human interleukin-1 ⁇ , human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6.
- administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of xenogeneic cytokines in response to an immune challenge, e.g., at a detectable level and/or at a level capable of mediating a xenogeneic immune response against the challenge.
- administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, or more serum human interleuk
- administration of human HSC to an immunodeficient QUAD mouse results in the production of at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, or more serum human interleukin-1p in the mouse.
- administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL,
- administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, or more serum human interleukin-12p′70 in the mouse.
- administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL,
- administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to
- administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to
- administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to
- administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to
- administration of human HSC to an immunodeficient QUAD mouse results in about 5-15 ng/mL serum human interleukin-8, about 5-250 pg/mL serum human interleukin-1 ⁇ , about 10-50 ng/mL serum human tumor-necrosis factor, about 20-100 pg/mL serum human interleukin-12p70, and/or about 15-30 ng/mL serum human interleukin-6 (e.g., when challenged with about 50-250 ng intravenous lipopolysaccharide) in the mouse.
- serum human interleukin-8 results in about 5-15 ng/mL serum human interleukin-8, about 5-250 pg/mL serum human interleukin-1 ⁇ , about 10-50 ng/mL serum human tumor-necrosis factor, about 20-100 pg/mL serum human interleukin-12p70, and/or about 15-30 ng/mL serum human interleukin-6 (e.g., when challenged with about 50-250
- administration of xenogeneic HSC to an immunodeficient QUAD mouse results in production of xenogeneic leukocytes that migrate into a tumor, such as xenogeneic tumor-infiltrating lymphocytes and xenogeneic myeloid-derived suppressor cells, in the immunodeficient QUAD mouse.
- administration of human HSC to an immunodeficient QUAD mouse results in production of human leukocytes that migrate into a tumor, such as human tumor-infiltrating lymphocytes and human myeloid-derived suppressor cells, in the immunodeficient QUAD mouse.
- tumor-infiltrating leukocytes are selected from CD20 + , CD3 + , CD33 + , CD14 + , and CD56 + leukocytes.
- Various aspects of the invention relate to administering xenogeneic tumor cells to an immunodeficient QUAD mouse.
- Xenogeneic tumor cells administered to immunodeficient QUAD mice of the present invention can be any of various tumor cells, including but not limited to, cells of a tumor cell line and primary tumor cells.
- the xenogeneic tumor cells may be derived from any of various organisms, preferably mammalian, including human, non-human primate, rat, guinea pig, rabbit, cat, dog, horse, cow, goat, pig and sheep.
- the xenogeneic tumor cells are human tumor cells.
- the human tumor cells are present in a sample obtained from the human, such as, but not limited to, in a blood sample, tissue sample, or sample obtained by biopsy of a human tumor.
- Tumor cells obtained from a human can be administered directly to an immunodeficient QUAD mouse of the present invention or may be cultured in vitro prior to administration to the immunodeficient QUAD mouse.
- tumor refers to cells characterized by unregulated growth including, but not limited to, pre-neoplastic hyperproliferation, cancer in-situ, neoplasms, metastases and solid and non-solid tumors.
- tumors are those caused by cancer include, but are not limited to, lymphoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, triple negative breast cancer, central or peripheral nervous system cancers, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, gall bladder cancer, gastrointestinal cancer, glioblastoma, head and neck cancer, kidney cancer, liver cancer, nasopharyngeal cancer, nasal cavity cancer, oropharyngeal cancer, oral cavity cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pituitary cancer, prostate cancer, retinoblastoma, sarcoma, salivary gland cancer, skin cancer, small intestine cancer, stomach cancer,
- the tumor cells can include BR1126, MDA-MB-231, TM1149, or BL0293 cells.
- Administering the tumor cells to the immunodeficient QUAD mouse can be any method that is suitable as recognized in the art.
- administration can include administering cells into an organ, body cavity, or blood vessel such as by injection or implantation, such as subcutaneous and/or intraperitoneal implantation.
- the tumor cells may be administered as a tumor mass, clumps of tumor cells or as dissociated cells.
- Tumor cells can be administered by various routes, such as, but not limited to, by subcutaneous injection, intraperitoneal injection or injection into the tail vein.
- Engraftment of xenogeneic tumor cells can be assessed by any of various methods, such as, but not limited to, visual inspection of the mouse for signs of tumor formation.
- Any of various methods can be used to measure growth of xenogeneic tumors, including but not limited to, measurement in living mice, measurement of tumors excised from living mice or measurement of tumors in situ or excised from dead mice.
- Measurements can be obtained using a measuring instrument such as a caliper, measurement using one or more imaging techniques such as ultrasonography, computed tomography, positron emission tomography, fluorescence imaging, bioluminescence imaging, magnetic resonance imaging and combinations of any two or more of these or other tumor measurement methods.
- the number of tumor cells in a sample obtained from a mouse bearing xenogeneic tumor cells can be used to measure tumor growth, particularly for non-solid tumors.
- the number of non-solid tumor cells in a blood sample can be assessed to obtain a measurement of growth of a non-solid tumor in a mouse.
- the number of tumor cells administered is not considered limiting. A single tumor cell can expand into a detectable tumor in the genetically modified immunodeficient animals described herein.
- the number of administered tumor cells is generally in the range of 1,000-1 ⁇ 10 6 tumor cells, although more or fewer can be administered.
- a method according to aspects of the present invention can include administering about 10 2 (100) to about 10 7 (10,000,000), about 10 3 to about 10 5 , about 10 4 to about 10 6 , about 10 5 to about 10 7 , about 1 ⁇ 10 3 to about 1 ⁇ 10 4 , about 5 ⁇ 10 3 to about 5 ⁇ 10 4 , about 1 ⁇ 10 4 to about 1 ⁇ 10 5 , about 5 ⁇ 10 4 to about 5 ⁇ 10 5 , about 1 ⁇ 10 5 to about 1 ⁇ 10 6 , about 5 ⁇ 10 5 to about 5 ⁇ 10 6 , about 1 ⁇ 10 6 to about 1 ⁇ 10 7 , about 2 ⁇ 10 4 to about 5 ⁇ 10 5 , or about 5 ⁇ 10 4 to about 2 ⁇ 10 5 xenogeneic tumor cells, such as human tumor cells, to the immunodeficient QUAD mouse.
- xenogeneic tumor cells such as human tumor cells
- the method can include administering at least about 1 ⁇ 10 2 , about 2 ⁇ 10 2 , about 3 ⁇ 10 2 , about 4 ⁇ 10 2 , about 5 ⁇ 10 2 , about 6 ⁇ 10 2 , about 7 ⁇ 10 2 , about 8 ⁇ 10 2 , about 9 ⁇ 10 2 , about 1 ⁇ 10 3 , about 2 ⁇ 10 3 , about 3 ⁇ 10 3 , about 4 ⁇ 10 3 , about 5 ⁇ 10 3 , about 6 ⁇ 10 3 , about 7 ⁇ 10 3 , about 8 ⁇ 10 3 , about 9 ⁇ 10 3 , about 1 ⁇ 10 4 , about 2 ⁇ 10 4 , about 3 ⁇ 10 4 , about 4 ⁇ 10 4 , about 5 ⁇ 10 4 , about 6 ⁇ 10 4 , about 7 ⁇ 10 4 , about 8 ⁇ 10 4 , about 9 ⁇ 10 4 , about 1 ⁇ 10 5 , about 2 ⁇ 10 5 , about 3 ⁇ 10 5 , about 4 ⁇ 10 5 , about 6 ⁇ 10 4 , about 7 ⁇ 10 4 , about 8 ⁇ 10 4 , about 9 ⁇ 10 4 , about
- the method can include administering about 1 ⁇ 10 2 , about 2 ⁇ 10 2 , about 3 ⁇ 10 2 , about 4 ⁇ 10 2 , about 5 ⁇ 10 2 , about 6 ⁇ 10 2 , about 7 ⁇ 10 2 , about 8 ⁇ 10 2 , about 9 ⁇ 10 2 , about 1 ⁇ 10 3 , about 2 ⁇ 10 3 , about 3 ⁇ 10 3 , about 4 ⁇ 10 3 , about 5 ⁇ 10 3 , about 6 ⁇ 10 3 , about 7 ⁇ 10 3 , about 8 ⁇ 10 3 , about 9 ⁇ 10 3 , about 1 ⁇ 10 4 , about 2 ⁇ 10 4 , about 3 ⁇ 10 4 , about 4 ⁇ 10 4 , about 5 ⁇ 10 4 , about 6 ⁇ 10 4 , about 7 ⁇ 10 4 , about 8 ⁇ 10 4 , about 9 ⁇ 10 4 , about 1 ⁇ 10 5 , about 2 ⁇ 10 5 , about 3 ⁇ 10 5 , about 4 ⁇ 10 5 , about 6 ⁇ 10 5 , about 7 ⁇ 10 5 , about 8 ⁇ 10 5 , about 9 ⁇ 10 4 , about 1 ⁇
- xenogeneic tumor cells and xenogeneic HSC are administered to an immunodeficient QUAD mouse.
- the xenogeneic tumor cells and xenogeneic HSC can be administered at the same time or at different times.
- the tumor cells are derived from the same species as the administered HSC. According to aspects, both the tumor cells and the HSC administered to an immunodeficient QUAD mouse are human cells.
- the administered HSC and tumor cells are human leukocyte antigen (HLA) matched (e.g., MHC Class I matched and/or MHC class II matched).
- HLA-matching may reduce the likelihood of a graft-versus-graft immune response against HLA cell-surface proteins. An immune response against HLA may falsely suggest that xenogeneic immune cells are successfully targeting xenogeneic cancer cells.
- the administered HSC and tumor cells can include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 matching HLA alleles.
- the administered HSC and tumor cells can include at least 2, 3, 4, 5, 6, 7, or 8 matching HLA alleles selected from the alleles for HLA-A, HLA-B, HLA-C, and HLA-DRB1. Perfect HLA matching is rarely possible without genetic engineering, and perfect HLA matching may be unnecessary. Control experiments, for example, can account for any HLA-mediated graft-versus-graft immune response.
- Methods and immunodeficient QUAD mice provided according to aspects of the present invention have various utilities such as, in vivo testing of substances directed against human cancer.
- Methods for identifying anti-tumor activity of a test substance include providing an immunodeficient QUAD mouse, wherein the immunodeficient QUAD mouse has engrafted xenogeneic HSC; administering xenogeneic tumor cells to the immunodeficient QUAD mouse, wherein the xenogeneic tumor cells form a solid or non-solid tumor in the immunodeficient QUAD mouse; administering a test substance to the immunodeficient QUAD mouse; assaying a response of the xenogeneic tumor and/or tumor cells to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- Methods for identifying anti-tumor activity of a test substance include providing an immunodeficient QUAD mouse, wherein the immunodeficient QUAD mouse has engrafted human HSC; administering human tumor cells to the immunodeficient QUAD mouse, wherein the human tumor cells form a solid or non-solid tumor in the immunodeficient QUAD mouse; administering a test substance to the immunodeficient QUAD mouse; assaying a response of the human tumor and/or tumor cells to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- An immunodeficient QUAD mouse used in an assay for identifying anti-tumor activity of a test substance is an NSG-QUAD mouse, an NRG-QUAD mouse or a NOG-QUAD mouse.
- inhibitory effect refers to an effect of the test substance to inhibit one or more of: tumor growth, tumor cell metabolism and tumor cell division.
- Assaying a response of the xenogeneic tumor and/or tumor cells to the test substance includes comparing the response to a standard to determine the effect of the test substance on the xenogeneic tumor cells according to aspects of methods of the present invention, wherein an inhibitory effect of the test substance on the xenogeneic tumor cells identifies the test substance as an anti-tumor composition.
- Standards are well-known in the art and the standard used can be any appropriate standard.
- a standard is a compound known to have an anti-tumor effect.
- non-treatment of a comparable xenogeneic tumor provides a base level indication of the tumor growth without treatment for comparison of the effect of a test substance.
- a standard may be a reference level of expected tumor growth previously determined in an individual comparable mouse or in a population of comparable mice and stored in a print or electronic medium for recall and comparison to an assay result.
- Assay results can be analyzed using statistical analysis by any of various methods to determine whether the test substance has an inhibitory effect on a tumor, exemplified by parametric or non-parametric tests, analysis of variance, analysis of covariance, logistic regression for multivariate analysis, Fisher's exact test, the chi-square test, Student's T-test, the Mann-Whitney test, Wilcoxon signed ranks test, McNemar test, Friedman test and Page's L trend test.
- test substance used in a method of the present invention can be any chemical entity, illustratively including a synthetic or naturally occurring compound or a combination of a synthetic or naturally occurring compound, a small organic or inorganic molecule, a protein, a peptide, a nucleic acid, a carbohydrate, an oligosaccharide, a lipid or a combination of any of these.
- the test substance is an immunotherapeutic.
- a test substance is an anti-cancer agent.
- the test substance is an anti-cancer immunotherapeutic, such as an anti-cancer antibody or antigen binding fragment thereof.
- Anti-cancer agents are described, for example, in Brunton et al. (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th Ed., Macmillan Publishing Co., 2011.
- Anti-cancer agents illustratively include acivicin, aclarubicin, acodazole, acronine, adozelesin, aldesleukin, alitretinoin, allopurinol, altretamine, ambomycin, ametantrone, amifostine, aminoglutethimide, amsacrine, anastrozole, anthramycin, arsenic trioxide, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene, bisnafide dimesylate, bizelesin, bleomycin, brequinar, bropirimine, busulfan, cactinomycin, calusterone, capecitabine, caracemide, carbetimer, carboplatin, carmustine, carubicin, carzelesin, cedef
- an anti-cancer agent is an anti-cancer antibody.
- An anti-cancer antibody used can be any antibody effective to inhibit at least one type of tumor, particularly a human tumor.
- Anti-cancer antibodies include, but are not limited to, 3F8, 8H9, abagovomab, abituzumab, adalimumab, adecatumumab, aducanumab, afutuzumab, alacizumab pegol, alemtuzumab, amatuximab, anatumomab mafenatox, anetumab ravtansine, apolizumab, arcitumomab, ascrinvacumab, atezolizumab, bavituximab, belimumab, bevacizumab, bivatuzumab mertansine, brentuximab vedotin, brontictuzumab, can
- a test substance is one that specifically binds one or more of: 1) a cell-surface protein such as a cluster of differentiation (CD) cell-surface molecule; 2) an intracellular protein such as a kinase; and 3) an extracellular protein such as a shed cell-surface receptor or the soluble ligand of a cell-surface receptor.
- a cell-surface protein such as a cluster of differentiation (CD) cell-surface molecule
- an intracellular protein such as a kinase
- an extracellular protein such as a shed cell-surface receptor or the soluble ligand of a cell-surface receptor.
- a test substance is one that specifically binds a protein that is expressed by leukocytes (e.g., lymphocytes or myeloid-lineage leukocytes).
- a test substance is one that specifically binds a ligand of a leukocyte.
- a test substance is one that specifically binds a molecule that is expressed by a cancer cell.
- a test substance is a chemotherapeutic agent or an immunotherapeutic agent.
- a test substance can specifically binds PD-1, PD-L1, or CTLA-4.
- a test substance can be an immune checkpoint inhibitor such as a PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor.
- a test substance is an immune checkpoint inhibitor selected from atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and an antigen-binding fragment of any one of the foregoing.
- test substance can be administered by any suitable route of administration, such as, but not limited to, oral, rectal, buccal, nasal, intramuscular, vaginal, ocular, otic, subcutaneous, transdermal, intratumoral, intravenous, and intraperitoneal.
- suitable route of administration such as, but not limited to, oral, rectal, buccal, nasal, intramuscular, vaginal, ocular, otic, subcutaneous, transdermal, intratumoral, intravenous, and intraperitoneal.
- inventive compositions and methods are illustrated in the following examples. These examples are provided for illustrative purposes and are not considered limitations on the scope of inventive compositions and methods.
- mice that constitutively express a transgene encoding human colony stimulating factor 1 were generated in an NSG background using routine techniques and are referred to herein as “NSG-CSF1” mice.
- NSG-CSF1 human colony stimulating factor 1
- a transgene encoding human CSF1 hCSF1
- Expression of hCSF1 is driven by a human cytomegalovirus promoter/enhancer sequence, and is followed by a human growth hormone cassette and a polyadenylation (polyA) sequence.
- the hCSF1 transgene is microinjected into fertilized C57BL/6 ⁇ C3H/HeN oocytes.
- mice carrying the hCSF1transgene are backcrossed to BALB/c-Prkdc scid mice for several generations and subsequently backcrossed to NOD.CB17-Prkdc scid mice for several generations. These mice are backcrossed to NOD.Cg-Prkdc scid Il2rg tm1Wjl mice, and are then intercrossed until all offspring are homozygous for the hCSF1 transgene and the IL2rg targeted mutation. These transgenic mice are bred to NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice (NSG mice, Jackson Laboratory Stock No.
- NSG-CSF1 are maintained on the NOD.Cg-Prkdc scid Il2 tm1Wjl /SzJ mouse (Stock No. 005557) background and constitutively produce detectable serum levels of human CSF1.
- NSG-SGM3 mice express human transgenes for stem cell factor (hSCF), granulocyte-macrophage-colony stimulating factor (hGM-CSF), and interleukin-3 (hIL-3).
- hSCF stem cell factor
- hGM-CSF granulocyte-macrophage-colony stimulating factor
- hIL-3 interleukin-3
- NSG-SGM3 mice contain three transgenes, human interleukin-3 (IL-3), human granulocyte/macrophage-stimulating factor (GM-CSF), and human Steel factor (SF) gene, each driven by a human cytomegalovirus promoter/enhancer sequence.
- IL-3 human interleukin-3
- GM-CSF granulocyte/macrophage-stimulating factor
- SF human Steel factor
- mice To make the NSG-SGM3 mice, three separate transgenes were designed each carrying one of: the human interleukin-3 (IL-3) gene, the human granulocyte/macrophage-stimulating factor (GM-CSF) gene, or human Steel factor (SF) gene. Expression of each gene is driven by a human cytomegalovirus promoter/enhancer sequence, and is followed by a human growth hormone cassette and a polyadenylation (polyA) sequence. The three transgenes were microinjected into fertilized C57BL/6 ⁇ C3H/HeN oocytes.
- IL-3 human interleukin-3
- GM-CSF granulocyte/macrophage-stimulating factor
- SF human Steel factor
- mice carrying all three transgenes (3GS) were backcrossed to BALB/c-Prkdc scid mice for several generations and subsequently backcrossed to NOD.CB17-Prkdc scid mice for at least 11 generations. These mice were bred to NOD.Cg-Prkdc scid Il2rg tm1Wjl mice, and were then intercrossed until all offspring were homozygous for 3GS and the IL2rg targeted mutation. These transgenic mice were bred to NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice (NSG mice, Jackson Laboratory Stock No.
- NSG-SGM3 are maintained on the NOD.
- NSG-SGM3 can be obtained commercially from The Jackson Laboratory (Maine; Stock No. 013062).
- NSG-Quad mice were irradiated with 50 cGy whole body radiation.
- NSG-SGM3 mice were irradiated with 50 cGy whole body radiation and NSG mice were irradiated with 100 cGy whole body radiation as controls.
- Each mouse received about 100,000 human CD34 + hematopoietic stem cells from the same donor by injection. Blood cells obtained by retro-orbital bleeding at 10 weeks post-engraftment were assessed by flow cytometry for mouse CD45, human CD45, human CD20, human CD3, human CD33, human CD14, and human CD56 ( FIG. 1A-F ). Live cells were gated using LIVE/DEAD® (ThermFisher Scientific).
- NSG-Quad mice displayed fewer numbers of human CD20 + cells, increased numbers of human CD3 + cells, CD33 + cells, CD14 + cells, and CD56 + cells as a proportion of human CD45 + cells relative to NSG mice, which suggests that NSG-Quad mice are better able to differentiate human hematopoietic progenitor cells into T-lymphocytes, macrophages, and natural killer cells than NSG mice ( FIG. 1B-F ).
- NSG-Quad mice displayed increased numbers of human CD14 + cells and CD56 + cells as a proportion of human CD45 + cells relative to NSG-SGM3 mice, which suggests that NSG-Quad mice are better able to differentiate human hematopoietic progenitor cells into macrophages (myeloid lineage) and natural killer cells (lymphoid lineage) than NSG-SGM3 mice ( FIG. 1E-F ).
- NSG-Quad mice trended toward increased human CD3 + cell counts and increased human CD33 + cell counts as a proportion of human CD45 + cells relative to NSG-SGM3 mice, although these trends did not display statistical significance ( FIG. 1C-D ). The trend toward increased human CD3 + cell counts nevertheless suggests that the addition of CSF1, which is believed to be a myeloid-lineage cytokine, to the NSG-SGM3 mouse had an effect on lymphoid-lineage cells.
- NSG-Quad mice, NSG-SGM3 hemizygous mice, NSG-SGM3 homozygous mice, and NSG mice engrafted with human CD34 + cells as described in Example 1 were administered an intravenous injection of 0.15 ⁇ g lipopolysaccharide (LPS) 10-weeks post xenograft. Serum was collected 6 hours after the LPS challenge, and human cytokine concentrations were determined using the BDTM Cytometric Bead Array (BD Biosciences). The NSG-Quad mice displayed increased concentrations of macrophage-secreted cytokines relative to NSG-SGM3 hemizygous mice, NSG-SGM3 homozygous mice, and NSG mice ( FIG. 2A-E ).
- BR1126, MDA-MB-231, TM1149, and BL0293 tumor cells were separately implanted subcutaneously into NSG-Quad and NSG-SGM3 mice at 7-12 weeks post-CD34 + -cell engraftment (see Example 1). Tumor sizes were measured with calipers.
- the BR1126, TM1149, and BL0293 tumors displayed similar growth in both the NSG-Quad and NSG-SGM3 mice ( FIG. 3A, 3C, 3D ).
- the NSG-Quad mice displayed significantly smaller tumors day 15 after implantation with MDA-MB-231 tumor cells ( FIG. 3B ).
- Human TM1149 (breast cancer) tumors were harvested from NSG-Quad and NSG-SGM3 mice at 17-weeks post tumor-cell engraftment, and cells were analyzed by flow cytometry for mouse CD45, human CD45, human CD20, human CD3, human CD33, human CD14, and human CD56 ( FIG. 4A-F ). Live cells were gated using LIVE/DEAD® (ThermoFisher Scientific). NSG-Quad displayed significantly more intratumoral leukocytes than NSG-SGM3 mice ( FIG. 4A ). Interestingly, the NSG-Quad mice trended toward increased human CD20 + cell counts, although this trend did not display statistical significance ( FIG. 4C ).
- NSG-Quad mice xenografted with human BL0293 tumor cells were grouped when tumors reached 60-100 mm 3 , and mice were then administered intravenous pembrolizumab at 10 mg/kg on day 0 followed by 5 mg/kg on days 5, 10, and 15. Tumor sizes were measured by calipers. Pembrolizumab reduced tumor growth rates in NSG-Quad mice ( FIG. 5 ).
- FIG. 1 consists of 6 panels, labeled FIG. 1A , FIG. 1B , FIG. 1C , FIG. 1D , FIG. 1E , and FIG. 1F .
- FIGS. 1A, 1B, 1C, 1D, 1E, and 1F is a chart depicting percentages of flow-cytometry-gated blood cells observed in mice. Each data point corresponds to a single mouse.
- the x-axis labels identify three mouse strains, NSG, NSG-SGM3, and NSG-Quad, each of which is described herein.
- the y-axis identifies percentages of gated cells.
- NSG, NSG-SGM3, and NSG-Quad mice were each administered 100,000 human CD34 + hematopoietic stem cells, and blood cells were collected for flow cytometry analysis by retro-orbital bleeds 10-weeks post-engraftment. Statistically significant results are shown as p-values.
- the NSG-Quad mice displayed statistically significant increases in the relative number of human CD14 + cells (macrophages) and human CD56 + cells (natural killer cells) relative to NSG-SGM3 mice. Additionally, NSG-Quad mice trended toward increased human CD3 + cells (T-lymphocytes) relative to NSG-SGM3 mice, but this observation did not achieve statistical significance.
- FIG. 2 consists of 5 panels, labeled FIG. 2A , FIG. 2B , FIG. 2C , FIG. 2D , and FIG. 2E .
- FIGS. 2A, 2B, 2C, 2D, and 2E is a chart depicting the concentration of cytokines observed in mouse serum. Each data point corresponds to a single mouse.
- the x-axis labels identify four mouse strains, NSG, NSG-SGM3/+, NSG-SGM3/SGM3, and NSG-Quad, each of which is described herein.
- the y-axis identifies concentrations of cytokines.
- NSG, NSG-SGM3/+, NSG-SGM3/SGM3, and NSG-Quad mice were each administered 100,000 human CD34 + hematopoietic stem cells followed by 0.15 pg intravenous lipopolysaccharide 10-weeks later. Serum cytokine concentrations were measured 6 hours after lipopolysaccharide administration using the BDTM Cytometric Bead Array for macrophage-associated cytokines. NSG-Quad mice, which constitutively express the human macrophage differentiation cytokine hCSF1, displayed elevated concentrations of macrophage-associated cytokines relative to control animals.
- FIG. 3 consists of 6 panels, labeled FIG. 3A , FIG. 3B , FIG. 3C , and FIG. 3D .
- FIGS. 3A, 3B, 3C, and 3D is a graph depicting the average tumor volume of mice having patient-derived xenografts (PDX).
- PDX patient-derived xenografts
- Each data point corresponds to an average tumor volume observed in a group of mice at a specific time-point.
- Circles ( ) correspond to the NSG-Quad group of mice and squares ( ) correspond to the NSG-SGM3 group.
- the x-axis identifies the number of days after a mouse received a patient-derived xenograft.
- the y-axis identifies the average tumor volume in mm 3 .
- Error bars correspond to standard error.
- Each patient-derived xenograft displayed similar growth in the NSG-Quad group and the NSG-SGM3 group except for the human MDA-MB-231 xenograft, which displayed significantly less growth in the NSG-Quad group relative to the NSG-SGM3 group beginning at day 15 post-engraftment.
- FIG. 4 consists of 6 panels, labeled FIG. 4A , FIG. 4B , FIG. 4C , FIG. 4D , FIG. 4E , and FIG. 4F .
- FIGS. 4A, 4B, 4C, 4D, 4E, and 4F is a chart depicting percentages of flow-cytometry-gated intratumor leukocytes observed in mice. Each data point corresponds to a single mouse.
- the x-axis labels identify two mouse strains, NSG-SGM3 and NSG-Quad, each of which is described herein.
- the y-axis identifies percentages of gated cells.
- NSG-SGM3 and NSG-Quad mice were each administered 100,000 human CD34 + hematopoietic stem cells followed by a subcutaneous TM1149 xenograft 7-12 weeks later. Tumors were harvested 17 weeks after the TM1149 xenograft and analyzed by flow cytometry. Statistically significant results are shown as p-values.
- NSG-Quad mice displayed a statistically significant increase in total human CD45 + cells (leukocytes) relative to NSG-SGM3 mice, which suggests that NSG-Quad mice may be superior to NSG-SGM3 mice for studying tumor-infiltrating lymphocyte-dependent cancer immunotherapies.
- NSG-Quad mice trended toward increased numbers of human CD3 + cells (T-lymphocytes) relative to NSG-SGM3 mice, but this observation did not display statistical significance.
- FIG. 5 is a graph depicting tumor volumes for NSG-Quad mice that have human CD34 + hematopoietic stem cell xenografts and BL0293 patient-derived xenografts and receiving either pembrolizumab (Keytruda®) or vehicle. Each data point corresponds to a single mouse at a specific time-point. Circles ( ) correspond to vehicle-treated mice and squares ( ) correspond to pembrolizumab-treated mice. The x-axis identifies the number of days after a mouse began receiving pembrolizumab or vehicle. The y-axis identifies the average tumor volume in mm 3 . NSG-Quad mice treated with pembrolizumab displayed slower tumor growth on average than mice receiving vehicle.
- mice and methods described herein are presently representative of preferred embodiments, exemplary, and not intended as limitations on the scope of the invention. Modifications thereto and additional uses will occur to those skilled in the art. Such modifications and uses can be made without departing from the scope of the invention as set forth in the claims.
- a genetically-modified, immunodeficient mouse comprising: (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1.
- hSCF human stem cell factor
- hGM-CSF granulocyte-macrophage colony-stimulating factor
- hIL-3 human interleukin-3
- hCSF1 human colony-stimulating
- Item 2 The genetically-modified, immunodeficient mouse of item 1, wherein the mouse is a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl /SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdc scid Il2rg tm1Sug /JicTac (NOG) mouse.
- NSG genetically modified NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ
- NSG genetically modified NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl /SzJ
- NOG genetically modified NOD.Cg-Prkdc scid Il2rg t
- Item 3 The genetically-modified, immunodeficient mouse of any one of the preceding items, wherein any one or more of the nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, or hCSF1 is operably-linked to a constitutive promoter.
- Item 4 The genetically-modified, immunodeficient mouse of any one of the preceding items, further comprising a human hematopoietic stem cell.
- Item 5 The genetically-modified, immunodeficient mouse of any one of the preceding items, wherein the mouse comprises a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33 + myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human T reg cell, and a human natural killer cell.
- a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33 + myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a
- Item 6 The genetically-modified, immunodeficient mouse of any one of the preceding items, wherein the mouse comprises a human leukocyte selected from the group consisting of CD45 + , CD20 + , CD20 + CD45 + , CD3 + , CD3 + CD45 + , CD33 + , CD33 + CD45 + , CD14 + , CD14 + CD45 + , CD56 + , and CD56 + CD45 + leukocyte.
- a human leukocyte selected from the group consisting of CD45 + , CD20 + , CD20 + CD45 + , CD3 + , CD3 + CD45 + , CD33 + , CD33 + CD45 + , CD14 + , CD14 + CD45 + , CD56 + , and CD56 + CD45 + leukocyte.
- Item 7 The genetically-modified, immunodeficient mouse of item 6, wherein said mouse comprises, in the absence of an immunological challenge one, two, three or all of: at least about 20% of the human CD45 + leukocytes of the mouse are CD3 + CD45 + leukocytes; at least about 10% of the human CD45 + leukocytes of the mouse are CD33 + CD45 + leukocytes; at least about 5% of the human CD45 + leukocytes of the mouse are CD14 + CD45 + leukocytes; at least about 0.5% of the human CD45 + leukocytes of the mouse are CD56 + CD45 + leukocytes.
- Item 8 The genetically-modified, immunodeficient mouse of any one of items 4 to 7, wherein the mouse expresses a human cytokine selected from the group consisting of human interleukin-8, human interleukin-1 ⁇ , human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6.
- Item 9 The genetically-modified, immunodeficient mouse of any one of the preceding items, further comprising a human xenograft comprising a human tumor cell.
- Item 10 A method of making a genetically-modified, immunodeficient humanized mouse model, comprising: providing a genetically-modified, immunodeficient mouse according to any one of items 1 to 3; and administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse.
- Item 11 The method of item 10, further comprising the step of: conditioning the genetically-modified, immunodeficient mouse to reduce mouse hematopoietic cells of the mouse prior to administering human hematopoietic stem cells.
- Item 12 The method of item 11, wherein the conditioning step comprises irradiating the genetically-modified, immunodeficient mouse and/or administering a radiomimetic drug to the genetically-modified, immunodeficient mouse.
- Item 13 The method of any one of items 10 to 12, further comprising the step of: administering a human xenograft comprising a human tumor cell to the genetically-modified, immunodeficient mouse.
- Item 14 The method of item 13, wherein the human hematopoietic stem cell and the human tumor cell comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 matching HLA alleles.
- Item 15 A method of identifying anti-tumor activity of a test substance, comprising: providing a genetically-modified, immunodeficient mouse according to any one of items 1 to 8; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell form a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity
- Item 16 The method of item 15, further comprising comparing the response to a standard to determine the effect of the test substance on the xenogeneic tumor cell, wherein an inhibitory effect of the test substance on the xenogeneic tumor cell identifies the test substance as having anti-tumor activity.
- Item 17 The method of item 15 or 16, wherein the test substance is an immunotherapeutic agent.
- Item 18 The method of any one of items 15 to 17, wherein the test substance is an immune checkpoint inhibitor.
- Item 19 The method of item 18, wherein the immune checkpoint inhibitor is a PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor.
- Item 20 The method of item 18 or 19, wherein the immune checkpoint inhibitor is atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, or pembrolizumab, or the immune checkpoint inhibitor comprises an antigen-binding fragment of any one of the foregoing.
- Item 21 The method of any of items 15 to 20, wherein the test substance is an antibody.
- Item 22 The method of any of items 15 to 21, wherein the test substance is an anti-cancer agent.
- Item 23 A genetically-modified, immunodeficient mouse substantially as described or shown herein.
- Item 24 A method of making a genetically-modified, immunodeficient humanized mouse model substantially as described or shown herein.
- Item 25 A method of identifying anti-tumor activity of a test substance substantially as described or shown herein.
- SEQ ID NO: 1 Homo sapiens colony stimulating factor 1 (CSF1), transcript variant 1 encoding isoform a (based on NM_000757.5), 1662 nucleotides ATGACCGCCGGGCGCCGCCGGGCGCTGCCCTCCCACGACATGGCTGGGCTCCCTGCT GTTGTTGGTCTGTCCTGGCGAGCAGGAGTATCACCGAGGAGGTGTCGGAGTACTGTA GCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCCAGT GTGCTACCTTAAGAAGGCATTTCTCCTGGTACAAGACATAATGGAGGACACCATGCGCT TCAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACTCTCTTTGAGG CTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGACATAATGGAGGACACCATGCGCT TCAGAG
- human SCF 220 (245 aa) MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVP GMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKEN SSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKGKAK NPPGDSSLHWAAMALPALFSLIIGFAFGALYWKKRQPSLTRAVENIQINEEDNEISMLQ EKEREFQEV SEQ ID NO.
- human SCF 248 (273 aa) MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVP GMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKEN SSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRV SVTKPFMLPPVAASSLRNDSSSSNRKAKNPPGDSSLHWAAMALPALFSLIIGFAFGALY WKKRQPSLTRAVENIQINEEDNEISMLQEKEREFQEV SEQ ID NO.
- nucleotide sequence encoding human SCF 248 including 5′ and 3′ non-coding sequences 1405 nucleotides CCGCCTCGCCGAGACTAGAAGCGCTGCGGGAAGCAGGGACAGTGGAGAGGGCGCTGC GCTCGGGCTACCCAATGCGTGGACTATCTGCCGCCGCTGTTCGTGCAATATGCTGGAGC TCCAGAACAGCTAAACGGAGTCGCCACACCACTGTTTGTGCTGGATCGCAGCGCTGCCT TTCCTTATGAAGAAGACACAAACTTGGATTCTCACTTGCATTTATCTTCAGCTGCTCCT ATTTAATCCTCTCGTCAAAACTGAAGGGATCTGCAGGAATCGTGTGACTAATAATGTAA AAGACGTCACTAAATTGGTGGCAAATCTTCCAAAAGACTACATGATAACCCTCAAATAT GTCCCCGGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATT GTCAGACAGCTTCTGGACAAGTTTTCAA
- human soluble SCF (164 aa and 25 aa N-terminal signal peptide) MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVP GMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKEN SSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRV SVTKPFMLPPVA SEQ ID NO.
- nucleotide sequence encoding human soluble SCF (164 aa and 25 aa N-terminal signal peptide), 567 nucleotides ATGAAGAAGACACAAACTTGGATTCTCACTTGCATTTATCTTCAGCTGCTCCTATTTAA TCCTCGTCAAAACTGAAGGGATCTGCAGGAATCGTGTGACTAATAATGTAAAAGACG TCACTAAATTGGTGGCAAATCTTCCAAAAGACTACATGATAACCCTCAAATATGTCCCC GGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATTGTCAGA CAGCTTGACTGATCTTCTGGACAAGTTTTCAAATATTTCTGAAGGCTTGAGTAATTATT CCATCATAGACAAACTTGTGAATATAGTGGATGACCTTGTGGAGTGCGTGAAAGAAAAC TCATCTAAGGATCTAAAAAAATCATTCAAGAGCCCAGAACCCAGGCTCTTTACTCCTGA AGAATTCTTTTAATACCTGAACCCAGGCTCT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Patent Application Serial Nos. 62/428,131, filed Nov. 30, 2016 and 62/565,783, filed Sep. 29, 2017, the entire content of both of which is incorporated herein by reference.
- This invention was made with government support under Grant Nos. CA034196, ODO18259, DK104218, and AI132963, awarded by the National Institutes of Health. The Government has certain rights in the invention.
- General aspects of the disclosure related to mouse models of interactions between the human immune system and human cancer. According to specific aspects, a genetically-modified, immunodeficient mouse is provided which expresses hSCF, hGM-CSF, hIL-3, and hCSF1, along with methods of use thereof.
- There is a continuing need for new “humanized” mouse models that allow robust engraftment of human hematopoietic stem cells along with human-patient derived tumor xenografts and/or human tumor cell lines to enable in vivo investigation of the interactions between the human immune system and human cancer.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, a human natural killer cell, and any two or more thereof.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, a human natural killer cell, and any two or more thereof.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45 leukocyte, CD20+ leukocyte, CD20+CD45+ leukocyte, CD3+ leukocyte, CD3+CD45+ leukocyte, CD33+ leukocyte, CD33+CD45+ leukocyte, CD14+ leukocyte, CD14+CD45+ leukocyte, CD56+ leukocyte, CD56+CD45+ leukocyte, and any two or more thereof.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45+ leukocyte, CD20+ leukocyte, CD20+CD45+ leukocyte, CD3+ leukocyte, CD3+CD45+ leukocyte, CD33+ leukocyte, CD33+CD45+ leukocyte, CD14+ leukocyte, CD14+CD45+ leukocyte, CD56+ leukocyte, CD56+CD45+ leukocyte, and any two or more thereof.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of: a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, a human natural killer cell, and any two or more thereof, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of: a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, a human natural killer cell, and any two or more thereof, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45+ leukocyte, CD20+ leukocyte, CD20+CD45+ leukocyte, CD3+ leukocyte, CD3+CD45+ leukocyte, CD33+ leukocyte, CD33+CD45+ leukocyte, CD14+ leukocyte, CD14+CD45+ leukocyte, CD56+ leukocyte, CD56+CD45+ leukocyte, and any two or more thereof, and further comprises a human xenograft comprising a human tumor cell.
- A genetically-modified, immunodeficient mouse is provided according to aspects of the present invention, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45+ leukocyte, CD20+ leukocyte, CD20+CD45+ leukocyte, CD3+ leukocyte, CD3+CD45+ leukocyte, CD33+ leukocyte, CD33+CD45+ leukocyte, CD14+ leukocyte, CD14+CD45+ leukocyte, CD56+ leukocyte, CD56+CD45+ leukocyte, and any two or more thereof, and further comprises a human xenograft comprising a human tumor cell.
- According to aspects of the present invention, a genetically-modified, immunodeficient mouse is provided wherein any one or more of the nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, or hCSF1 is operably-linked to a constitutive promoter.
- According to aspects of the present invention, a genetically-modified, immunodeficient mouse is provided wherein said mouse comprises, in the absence of an immunological challenge, one, two, three or all of: at least about 20% of the human CD45+ leukocytes of the mouse are CD3+CD45+ leukocytes; at least about 10% of the human CD45+ leukocytes of the mouse are CD33+CD45+ leukocytes; at least about 5% of the human CD45+ leukocytes of the mouse are CD14+CD45+ leukocytes; at least about 0.5% of the human CD45+ leukocytes of the mouse are CD56+CD45+ leukocytes.
- According to aspects of the present invention, a genetically-modified, immunodeficient mouse is provided wherein the mouse expresses one or more of: a human cytokine selected from the group consisting of human interleukin-8, human interleukin-1β, human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse; and administering a human xenograft comprising a human tumor cell to the genetically-modified, immunodeficient mouse.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse; and administering a human xenograft comprising a human tumor cell to the genetically-modified, immunodeficient mouse.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention optionally includes conditioning the genetically-modified, immunodeficient mouse to reduce mouse hematopoietic cells of the mouse prior to administering human hematopoietic stem cells. For example, a method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention optionally includes irradiating the genetically-modified, immunodeficient mouse and/or administering a radiomimetic drug to the genetically-modified, immunodeficient mouse.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse; and administering a human xenograft comprising a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human hematopoietic stem cell and the human tumor cell comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 matching HLA alleles.
- A method of making a genetically-modified, immunodeficient humanized mouse model according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 and wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse; and administering a human xenograft comprising a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human hematopoietic stem cell and the human tumor cell comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 matching HLA alleles.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a human hematopoietic stem cell; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a CD34+ human hematopoietic stem cell; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, a human natural killer cell, and any two or more thereof; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, a human natural killer cell, and any two or more thereof; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1; and wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45+ leukocyte, CD20+ leukocyte, CD20+CD45+ leukocyte, CD3+ leukocyte, CD3+CD45+ leukocyte, CD33+ leukocyte, CD33+CD45+ leukocyte, CD14+ leukocyte, CD14+CD45+ leukocyte, CD56+ leukocyte, CD56+CD45+ leukocyte, and any two or more thereof; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention includes providing a genetically-modified, immunodeficient mouse, wherein the genetically-modified, immunodeficient mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse; and wherein the genetically-modified, immunodeficient mouse includes a human leukocyte selected from the group consisting of: CD45+ leukocyte, CD20+ leukocyte, CD20+CD45+ leukocyte, CD3+ leukocyte, CD3+CD45+ leukocyte, CD33+ leukocyte, CD33+CD45+ leukocyte, CD14+ leukocyte, CD14+CD45+ leukocyte, CD56+ leukocyte, CD56+CD45+ leukocyte, and any two or more thereof; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell forms a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- A method of identifying anti-tumor activity of a test substance according to aspects of the present invention optionally includes comparing the response to a standard to determine the effect of the test substance on the xenogeneic tumor cell, wherein an inhibitory effect of the test substance on the xenogeneic tumor cell identifies the test substance as having anti-tumor activity.
- The test substance can be an immunotherapeutic agent, such as an immune checkpoint inhibitor. Immune checkpoint inhibitors include, but are not limited to, a PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor. Immune checkpoint inhibitors include, but are not limited to, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, or pembrolizumab, or an antigen-binding fragment of any one of the foregoing. The test substance can be an antibody. The test substance can be an anti-cancer agent.
-
FIG. 1A is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD45 as a percentage of total blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34+ hematopoietic stem cells. -
FIG. 1B is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD20 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34+ hematopoietic stem cells. -
FIG. 1C is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD3 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34+ hematopoietic stem cells. -
FIG. 1D is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD33 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34+ hematopoietic stem cells. -
FIG. 1E is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD14 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34+ hematopoietic stem cells. -
FIG. 1F is a chart depicting percentages of flow-cytometry-gated blood cells expressing human CD56 as a percentage of CD45-positive blood cells in samples from NSG mice, NSG-SGM3 mice and NSG-QUAD mice 10-weeks after administration of 100,000 human CD34+ hematopoietic stem cells; -
FIG. 2A is a chart depicting the concentration of human IL8 in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34+ hematopoietic stem cells followed by 0.15 μg intravenous lipopolysaccharide 10-weeks later. The serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL8 was measured by bead-based immunoassay. -
FIG. 2B is a chart depicting the concentration of human IL1-β in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34+ hematopoietic stem cells followed by 0.15 μg intravenous lipopolysaccharide 10-weeks later. The serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL1-β was measured by bead-based immunoassay. -
FIG. 2C is a chart depicting the concentration of human TNF in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34+ hematopoietic stem cells followed by 0.15 μg intravenous lipopolysaccharide 10-weeks later. The serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human TNF was measured by bead-based immunoassay. -
FIG. 2D is a chart depicting the concentration of human IL12p70 in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34+ hematopoietic stem cells followed by 0.15 μg intravenous lipopolysaccharide 10-weeks later. The serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL12p70 was measured by bead-based immunoassay. -
FIG. 2E is a chart depicting the concentration of human IL6 in serum samples from NSG mice, NSG-SGM3/+ mice, NSG-SGM3/SGM3, and NSG-QUAD mice which were administered 100,000 human CD34+ hematopoietic stem cells followed by 0.15 μg intravenous lipopolysaccharide 10-weeks later. The serum samples were obtained 6 hours after administration of the lipopolysaccharide and the human IL6 was measured by bead-based immunoassay. -
FIG. 3A is a graph depicting the mean tumor volume of tumors formed by a patient-derived xenograft (PDX) of human BR1126 breast cancer cells in NSG-QUAD mice (also called hNSG-Quad mice) compared to the mean tumor volume of tumors formed by a PDX of human BR1126 breast cancer cells NSG-SGM3 mice (also called hNSG-SGM3 mice). -
FIG. 3B is a graph depicting the mean tumor volume of tumors formed by a PDX of human MDA-MB231 breast cancer cells in NSG-QUAD mice compared to the mean tumor volume of tumors formed by a PDX of human MDA-MB231 breast cancer cells NSG-SGM3 mice. -
FIG. 3C is a graph depicting the mean tumor volume of tumors formed by a PDX of human TM1149 breast cancer cells in NSG-QUAD mice compared to the mean tumor volume of tumors formed by a PDX of human TM1149 breast cancer cells in NSG-SGM3 mice. -
FIG. 3D is a graph depicting the mean tumor volume of tumors formed by a PDX of human BL0293 bladder cancer cells in NSG-QUAD mice compared to the mean tumor volume of tumors formed by a PDX of human BL0293 bladder cancer cells in NSG-SGM3 mice. -
FIG. 4A is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34+ hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later. PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD45-positive (hCD45+) in the population of total live cells in the sample is shown. -
FIG. 4B is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34+ hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later. PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD3-positive (hCD3+) in the population of CD45+ cells in the sample is shown. -
FIG. 4C is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34+ hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later. PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD20-positive (hCD20+) in the population of CD45+ cells in the sample is shown. -
FIG. 4D is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34+ hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later. PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD33-positive (hCD33+) in the population of CD45+ cells in the sample is shown. -
FIG. 4E is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34+ hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later. PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD14-positive (hCD14+) in the population of CD45+ cells in the sample is shown. -
FIG. 4F is a chart showing characteristics of blood cells obtained from NSG-SGM3 and NSG-Quad mice to which 100,000 human CD34+ hematopoietic stem cells were administered followed by a subcutaneous TM1149 xenograft 7-12 weeks later. PDX tumors harvested 17 weeks after xenograft administration were analyzed by flow cytometry and the percent of human CD56-positive (hCD56+) in the population of CD45+ cells in the sample is shown. -
FIG. 5 is a graph comparing tumor volumes for NSG-Quad mice (Hu-NSG-Quad mice) that have human CD34+ hematopoietic stem cell xenografts and BL0293 patient-derived xenografts and received injections with either pembrolizumab (Keytruda®) or vehicle. - Scientific and technical terms used herein are intended to have the meanings commonly understood by those of ordinary skill in the art. Such terms are found defined and used in context in various standard references illustratively including J. Sambrook and D. W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F. M. Ausubel, Ed., Short Protocols in Molecular Biology, Current Protocols; 5th Ed., 2002; B. Alberts et al., Molecular Biology of the Cell, 4th Ed., Garland, 2002; D. L. Nelson and M. M. Cox, Lehninger Principles of Biochemistry, 4th Ed., W. H. Freeman & Company, 2004; Herdewijn, P. (Ed.), Oligonucleotide Synthesis: Methods and Applications, Methods in Molecular Biology, Humana Press, 2004; A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer, Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press; Dec. 15, 2002, ISBN-10: 0879695919; and Kursad Turksen (Ed.), Embryonic stem cells: methods and protocols in Methods Mol Biol. 2002; 185, Humana Press; Current Protocols in Stem Cell Biology, ISBN: 9780470151808.
- The singular terms “a,” “an,” and “the” are not intended to be limiting and include plural referents unless explicitly stated otherwise or the context clearly indicates otherwise.
- The term “comprising” refers to an open group, e.g., a group comprising members A, B, and C can also include additional members. The term “consisting of” refers to a closed group, e.g., a group consisting of members A, B, and C does not include any additional members.
- The term “xenogeneic” is used herein with reference to a host cell or organism to indicate that the material referred to as “xenogeneic” is derived from another species than that of the host cell or organism.
- A genetically-modified, immunodeficient mouse which expresses human stem cell factor (hSCF), human granulocyte-macrophage colony-stimulating factor (hGM-CSF), human interleukin-3 (hIL-3), and human colony-stimulating factor 1 (hCSF1) (called an “immunodeficient QUAD mouse” herein) is provided according to aspects of the present invention.
- Various aspects of the invention relate to an immunodeficient QUAD mouse including nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, and hCSF1 in its genome wherein the immunodeficient QUAD mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins. Nucleic acid sequences are shown and described herein which encode hSCF, hGM-CSF, hIL-3, hCSF1 proteins and variants thereof. It will be appreciated by those of ordinary skill in the art that, due to the degenerate nature of the genetic code, alternate nucleic acid sequences encode hCSF1, hGM-SCF, hSCF, hIL-3 and variants thereof and that such alternate nucleic acids may be used in compositions and methods described herein.
- The terms “human colony-stimulating
factor 1,” “human CSF1,” and “hCSF1” are used synonymously herein to refer to a cytokine involved in the proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells. The human CSF1 gene locus resides onchromosome 1, and it occurs as nucleotides 109,910,242-109,930,992 of the Genome Reference Consortium Human Reference 38 genome (GRCh38/hg38). The human CSF1 gene is expressed as at least four transcript variants (see, e.g., NCBI Reference Sequences NM_000757.5, NM_172210.2, NM_172211.3, and NM_172212.2), which produce at least three protein isoforms, a, b, and c (see, e.g., NCBI Reference Sequences NP_000748.3, NP_757349.1, NP_757350.1, and NP_757351.1). The term “hCSF1” includes variants of hCSF1 amino acid sequences specifically identified herein. Human CSF1 proteins are identified herein as SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and variants thereof are useful in the present invention. - An immunodeficient QUAD mouse according to aspects of the present invention includes in its genome a nucleic acid encoding hCSF1 operably linked to a promoter wherein the hCSF1 includes the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:1 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:3 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under high stringency hybridization conditions.
- The terms “human stem cell factor,” “human SCF,” and “hSCF” are used synonymously herein to refer to a well-known cytokine that binds to the c-Kit receptor (CD117). SCF is also known as kit ligand, SF, Kitl, KL-1 and other names. Various isoforms of SCF are known including transmembrane and soluble isoforms generated by alternative splicing. Particular isoforms include human membrane-associated stem cell factor 248 (SCF248), human membrane-associated stem cell factor 220 (SCF220) and soluble stem cell factor (SCF), see Anderson, D. M. et al., 1990, Cell 63, 235; Flannagan, J. G. et al., 1991, Cell 64, 1025; Anderson, D. M. et al., 1991, Cell Growth Differ. 2, 373; Martin, F. H. et al., Cell, 63:203, 1990; Huang E. J. et al., Mol. Biol. Cell, 3:349, 1992; and Huang E. et al., Cell, 63:225, 1990. Amino acid sequences of human soluble SCF, human SCF22° and human SCF248 along with exemplary nucleic acid sequences encoding human soluble SCF, human SCF22° or human SCF248 are shown herein. The term “hSCF” includes variants of hSCF amino acid sequences specifically identified herein. Human SCF proteins are identified herein as SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:16, and variants thereof are useful in the present invention.
- An immunodeficient QUAD mouse according to aspects of the present invention includes in its genome a nucleic acid encoding hSCF operably linked to a promoter wherein the hSCF includes the amino acid sequence of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:16, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:12 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:14 under high stringency hybridization conditions, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:15 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:17 under high stringency hybridization conditions.
- The terms “human granulocyte-macrophage colony-stimulating factor,” “human GM-CSF,” and “hGM-CSF” are used synonymously herein. Human GM-CSF is a well-known cytokine that controls the production, differentiation, and function of granulocytes and macrophages. The term “GM-CSF” includes variants of GM-CSF amino acid sequences specifically identified herein. Human GM-CSF proteins are identified herein as SEQ ID NO:18, and SEQ ID NO:20 and variants thereof in the present invention.
- An immunodeficient QUAD mouse according to aspects of the present invention includes in its genome a nucleic acid encoding hGM-CSF operably linked to a promoter wherein the hGM-CSF includes the amino acid sequence of SEQ ID NO:18, SEQ ID NO:20, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:19 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:21 under high stringency hybridization conditions.
- The terms “human interleukin-3,” “human IL-3,” and “hIL-3” are used synonymously herein. IL-3 is a well-known cytokine that regulates blood-cell production by controlling the production, differentiation and function of granulocytes and macrophages. The term “hIL-3” includes variants of hIL-3 amino acid sequences specifically identified herein. Human IL-3 proteins are identified herein as SEQ ID NO: 22, and SEQ ID NO: 24 and variants thereof in the present invention.
- An immunodeficient QUAD mouse according to aspects of the present invention includes in its genome a nucleic acid encoding hIL-3 operably linked to a promoter wherein the hIL-3 includes the amino acid sequence of SEQ ID NO:22, SEQ ID NO:24, the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:23 under high stringency hybridization conditions, or the amino acid sequence encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:25 under high stringency hybridization conditions.
- Aspects of the present invention relate to an immunodeficient QUAD mouse whose genome includes a nucleotide sequence encoding hCSF1, a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, and a nucleotide sequence encoding hIL-3, wherein the immunodeficient QUAD mouse expresses hCSF1, hSCF, hGM-CSF, and hIL-3.
- According to aspects of the present invention, the included nucleotide sequence encoding hCSF1 has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4 and encodes hCSF1 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
- According to aspects of the present invention, the included nucleotide sequence encoding hCSF1 encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hCSF1 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
- According to aspects of the present invention, the included nucleotide sequence encoding hSCF has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:17 and encodes hSCF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:16.
- According to aspects of the present invention, the included nucleotide sequence encoding hSCF encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:17 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hSCF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:16.
- According to aspects of the present invention, the included nucleotide sequence encoding hGM-CSF has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:19, or SEQ ID NO:21 and encodes hGM-CSF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:18, or SEQ ID NO:20.
- According to aspects of the present invention, the included nucleotide sequence encoding hGM-CSF encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:19, or SEQ ID NO:21 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hGM-CSF having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:18, or SEQ ID NO:20.
- According to aspects of the present invention, the included nucleotide sequence encoding hIL-3 has a nucleotide sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:23, or SEQ ID NO:25 and encodes hIL-3 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:22, or SEQ ID NO:24.
- According to aspects of the present invention, the included nucleotide sequence encoding hIL-3 encodes an mRNA transcript having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the nucleotide sequence set forth in SEQ ID NO:23, or SEQ ID NO:25 wherein the deoxythymidine bases of the foregoing sequences are substituted with uridine and wherein the mRNA encodes hIL-3 having an amino acid sequence that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or greater sequence identity with the amino acid sequence set forth in SEQ ID NO:22, or SEQ ID NO:24.
- To determine the percent identity of two amino acid sequences or two nucleotide sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in a first amino acid or nucleotide sequence for optimal alignment with a second amino acid or nucleotide sequence using the default parameters of an alignment software program). The amino acids or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical aligned positions ÷ total number of aligned positions×100%). In some embodiments, the two sequences have the same length.
- The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, PNAS USA 87:2264-68, modified as in Karlin and Altschul, 1993, PNAS USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al, 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can optionally be performed with the NBLAST nucleotide program parameter set, e.g., for score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the present invention. BLAST protein searches can optionally be performed with the XBLAST program parameter set, e.g., to score 50, wordlength=3 to obtain amino acid sequences homologous to a protein molecule of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al, 1997, Nucleic Acids Res. 25:3389-02. Alternatively, PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (id.). When utilizing BLAST, Gapped BLAST, and PSI Blast, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) are used (see, e.g., the NCBI website). Another preferred, non-limiting example of a mathematical algorithm utilized to compare sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 is used. The Clustal suite of software programs provides an additional method for aligning sequences to determine percent sequence identity.
- The percent identity between two sequences is determined using techniques similar to those described above with or without allowing gaps. In calculating percent identity, only exact matches are typically counted.
- The terms “hybridization” and “hybridizes” refer to pairing and binding of complementary nucleic acids. Hybridization occurs to varying extents between two nucleic acids depending on factors such as the degree of complementarity of the nucleic acids, the melting temperature, Tm, of the nucleic acids and the stringency of hybridization conditions, as is well known in the art. The term “stringency of hybridization conditions” refers to conditions of temperature, ionic strength, and composition of a hybridization medium with respect to particular common additives such as formamide and Denhardt's solution. Determination of particular hybridization conditions relating to a specified nucleic acid is routine and is well known in the art, for instance, as described in J. Sambrook and D. W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; and F. M. Ausubel, Ed., Short Protocols in Molecular Biology, Current Protocols; 5th Ed., 2002. High stringency hybridization conditions are those which only allow hybridization of substantially complementary nucleic acids. Typically, nucleic acids having about 85-100% complementarity are considered highly complementary and hybridize under high stringency conditions. Intermediate stringency conditions are exemplified by conditions under which nucleic acids having intermediate complementarity, about 50-84% complementarity, as well as those having a high degree of complementarity, hybridize. In contrast, low stringency hybridization conditions are those in which nucleic acids having a low degree of complementarity hybridize.
- The terms “specific hybridization” and “specifically hybridizes” refer to hybridization of a particular nucleic acid to a target nucleic acid without substantial hybridization to nucleic acids other than the target nucleic acid in a sample.
- Stringency of hybridization and washing conditions depends on several factors, including the Tm of the probe and target and ionic strength of the hybridization and wash conditions, as is well-known to the skilled artisan. Hybridization and conditions to achieve a desired hybridization stringency are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001; and Ausubel, F. et al., (Eds.), Short Protocols in Molecular Biology, Wiley, 2002.
- Mutations can be introduced using standard molecular biology techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. One of skill in the art will recognize that one or more amino acid mutations can be introduced without altering the functional properties of the hSCF, hGM-CSF, hIL-3, or hCSF1 proteins.
- Conservative amino acid substitutions can be made in the hSCF, hGM-CSF, hIL-3, or hCSF1 proteins to produce hSCF, hGM-CSF, hIL-3, or hCSF1 protein variants. Conservative amino acid substitutions are art recognized substitutions of one amino acid for another amino acid having similar characteristics. For example, each amino acid can be described as having one or more of the following characteristics: electropositive, electronegative, aliphatic, aromatic, polar, hydrophobic, and hydrophilic. A conservative substitution is a substitution of one amino acid having a specified structural or functional characteristic for another amino acid having the same characteristic. Acidic amino acids include aspartate, glutamate; basic amino acids include histidine, lysine, arginine; aliphatic amino acids include isoleucine, leucine, and valine; aromatic amino acids include phenylalanine, tyrosine, and tryptophan; polar amino acids include aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine, and tyrosine; and hydrophobic amino acids include alanine, cysteine, phenylalanine, glycine, isoleucine, leucine, methionine, proline, valine, and tryptophan; and conservative substitutions include substitutions among amino acids within each group. Amino acids can also be described in terms of sterics or relative size, alanine, cysteine, aspartate, glycine, asparagine, proline, threonine, serine, and valine are all typically considered to be small.
- The term “nucleic acid” refers to RNA or DNA molecules having more than one nucleotide in any form including single-stranded, double-stranded, oligonucleotide, or polynucleotide. The term “nucleotide sequence” refers to the ordering of nucleotides in a nucleic acid.
- Nucleic acids encoding hSCF, hGM-CSF, hIL-3, hCSF1, and variants thereof can be isolated or generated recombinantly or synthetically using well-known methodology.
- A nucleotide sequence encoding hSCF, hGM-CSF, hIL-3, or hCSF1 can be operably-linked to a promoter. The promoter can be a constitutive promoter. The promoter can be capable of driving gene expression in a host mouse (e.g., an immunodeficient mouse). For example, the promoter can be the CAG promoter. The CAG promoter includes the cytomegalovirus early enhancer element (“C”), the first exon and the first intron of the chicken beta-actin gene (“A”), and the splice acceptor of the rabbit beta-globulin gene (“G”). The CAG promoter is well known and displays robust expression in mouse cells (see, e.g., Jun-ichi et al, 1989, Gene, 79(2):269). The CAG promoter can be modified, for example, to remove exons. Other promoters are known to drive robust gene expression in mice including the cytomegalovirus (CMV) immediate-early promoter and the simian virus 40 (SV40) early promoter. Methods for designing genes and positioning promoters in expression constructs are known (see, e.g., Haruyama et al, 2009, Curr. Protoc. Cell Biol., 19.10).
- An immunodeficient QUAD mouse can includes nucleic acids encoding hSCF, hGM-CSF, hIL-3, and hCSF1, and each nucleic acid can be operably-linked to a constitutive promoter.
- Immunodeficient mice are provided according to embodiments of the present invention whose genomes include an expression cassette including a nucleotide sequence encoding xenogeneic CSF1, wherein the nucleotide sequence is operably-linked to a promoter and a polyadenylation signal, and the mouse expresses the encoded xenogeneic CSF1.
- The terms “expression construct” and “expression cassette” are used herein to refer to a double-stranded recombinant nucleotide sequence containing a desired coding sequence and containing one or more regulatory elements necessary or desirable for the expression of the operably-linked coding sequence. The term “regulatory element” as used herein refers to a nucleotide sequence that controls some aspect of the expression of nucleotide sequences. Exemplary regulatory elements illustratively include an enhancer, an internal ribosome entry site (IRES), an intron, an origin of replication, a polyadenylation signal (pA), a promoter, a transcription termination sequence, and an upstream regulatory domain, which contribute to the replication, transcription, and post-transcriptional processing of a nucleotide sequence. Those of ordinary skill in the art are capable of selecting and using these and other regulatory elements in an expression construct with no more than routine experimentation. Expression constructs can be generated recombinantly or synthetically using well-known methodology.
- The term “operably-linked” as used herein refers to a nucleotide sequence in a functional relationship with a second nucleotide sequence.
- A regulatory element included in an expression cassette can be a promoter. The term “promoter” as used herein refers to a regulatory nucleotide sequence operably-linked to a coding nucleotide sequence to be transcribed such as a nucleotide sequence encoding a desired amino acid. A promoter is generally positioned upstream of a nucleotide sequence to be transcribed and provides a site for specific-binding by RNA polymerase and other transcription factors. A promoter can be a constitutive promoter or an inducible promoter. A promoter can optionally provide ubiquitous, tissue-specific, or cell-type specific expression.
- Ubiquitous promoters that can be included in an expression construct include, but are not limited to, a 3-phosphoglycerate kinase (PGK-1) promoter, a beta-actin promoter, a ROSA26 promoter, a heat shock protein 70 (Hsp70) promoter, an EF-1 alpha gene
encoding elongation factor 1 alpha (EF-1) promoter, an eukaryotic initiation factor 4A (eIF-4A1) promoter, a chloramphenicol acetyltransferase (CAT) promoter, and a cytomegalovirus (CMV) promoter. - Tissue-specific promoters that can be included in an expression construct include, but are not limited to, a promoter of a gene expressed in the hematopoietic system, such as an hSCF promoter, an hCSF1 promoter, a hIL-3 promoter, a hGM-CSF, an IFN-β promoter, a Wiskott-Aldrich syndrome protein (WASP) promoter, a CD45 (also called leukocyte common antigen) promoter, a Flt-1 (fms-like tyrosine kinase, VEGF Receptor 1) promoter, an endoglin (CD105) promoter, and an ICAM-2 (Intracellular Adhesion Molecule 2) promoter.
- These and other promoters are known in the art as exemplified in Abboud et al, 2003, J. Histochem & Cytochem., 51(7):941-49; Schorpp et al, 1996, Nucl. Acids Res., 24(9):1787-88; McBurney et al, 1994, Devel. Dynamics, 200:278-93; and Majumder et al, 1996, Blood, 87(8):3203-11.
- In addition to a promoter, one or more enhancer sequences can be included such as, but not limited to, the cytomegalovirus (CMV) early enhancer element and the SV40 enhancer element.
- Additional included sequences include an intron sequence such as the beta globin intron or a generic intron, a transcription termination sequence, and an mRNA polyadenylation (pA) sequence such as, but not limited to SV40-pA, beta-globin-pA, hIL-3-pA, hGM-CSF-pA, hSCF-pA, and hCSF1-pA.
- An expression construct can optionally include sequences necessary for amplification in bacterial cells, such as a selection marker (e.g., kanamycin or ampicillin resistance gene) and an origin of replication.
- For methods of DNA injection of an expression construct into a mouse preimplantation embryo, the expression construct can be linearized before injection into the embryo. Preferably, the expression construct is injected into fertilized oocytes. Fertilized oocytes are collected from superovulated females the day after mating (0.5 days post coitum) and injected with the expression construct. The injected oocytes are either cultured overnight or transferred directly into oviducts of 0.5-day post coitum pseudopregnant females. Methods for superovulation, harvesting of oocytes, expression construct injection, and embryo transfer are known in the art and described, for example, in Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press; Dec. 15, 2002, ISBN-10: 0879695919. Offspring can be tested for the presence of the expression construct, or relevant portion thereof, by DNA analysis, such as by PCR, Southern blot, or nucleic acid sequencing. Mice that carry the expression construct, or relevant portion thereof, can be tested for protein expression such as by ELISA or Western blot analysis.
- The xenogeneic nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, and hCSF1 can be integrated into the genome of some or all of the cells of the mouse. For example, the xenogeneic nucleotide sequences are integrated into the genomes of germline cells of the mouse according to aspects of the present invention thereby enabling the inheritance of the genes to progeny of the mouse.
- Alternatively, an expression construct can be transfected into stem cells (embryonic stem cells or induced pluripotent stem cells) using well-known methods, such as electroporation, calcium-phosphate precipitation, or lipofection. The cells are screened for integration of the expression construct, or relevant portion thereof, by DNA analysis, such as PCR, Southern blot, or nucleic acid sequencing. Cells with the correct integration can be tested for functional expression by protein analysis for hSCF, hGM-CSF, hIL-3, and/or hCSF1 using, for example, ELISA or Western blot analysis.
- Embryonic stem cells are grown in media optimized for the particular cell line. Typically, embryonic stem cell media contains 15% fetal bovine serum (FBS) or synthetic or semi-synthetic equivalents, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 50 U/mL penicillin and streptomycin, 0.1 mM 2-mercaptoethanol, and 1000 U/mL LIF (plus, for some cell lines chemical inhibitors of differentiation) in Dulbecco's Modified Eagle Media (DMEM). A detailed description is known in the art (Tremml et al, 2008, Current Protocols in Stem Cell Biology, Chapter 1:Unit 1C.4). For a review of inhibitors of embryonic stem cell differentiation, see Buehr et al, 2003, Genesis of embryonic stem cells, Philosophical Transactions of the Royal Society B: Biological Sciences 358:1397-1402.
- Selected cells incorporating the expression construct can be injected into preimplantation embryos. For microinjection, embryonic stem cells or induced pluripotent stem cells are rendered to single cells using a mixture of trypsin and EDTA, followed by resuspension in embryonic stem cell media. Groups of single cells are selected using a finely drawn-out glass needle (20-25 micrometer inside diameter) and introduced through the embryo's zona pellucida and into the blastocysts cavity (blastocoel) using an inverted microscope fitted with micromanipulators. Stem cells can also be injected into early stage embryos (e.g., 2-cell, 4-cell, 8-cell, premorula, or morula). Injection can be assisted with a laser or piezo-pulsed drilled opening in the zona pellucida. Approximately 9-10 selected stem cells (embryonic stem cells or induced pluripotent stem cells) are injected per blastocyst, or 8-cell stage embryo, 6-9 stem cells per 4-cell stage embryo, and about 6 stem cells per 2-cell stage embryo. Following stem cell introduction, embryos are allowed to recover for a few hours at 37° C. in 5% CO2, 5% O2 in nitrogen or cultured overnight before transfer into pseudopregnant recipient females. In a further alternative to stem cell injection, stem cells can be aggregated with morula stage embryos. All of these methods are well established and can be used to produce stem cell chimeras. For a more detailed description, see, e.g., Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition (Nagy, Gertsenstein, Vintersten, and Behringer, Cold Spring Harbor Laboratory Press, Dec. 15, 2002, ISBN-10: 0879695919; see also Nagy et al, 1990, Development 110:815-821; Kraus et al, 2010, Genesis 48:394-399; and U.S. Pat. Nos. 7,576,259, 7,659,442, and 7,294,754).
- Pseudopregnant embryo recipients are prepared using methods known in the art. Briefly, fertile female animals between 6-8 weeks of age are mated with vasectomized or sterile males to induce a hormonal state conductive to supporting surgically introduced embryos. At 2.5 days post coitum (dpc) up to 15 of the stem cell containing blastocysts are introduced into the uterine horn very near to the uterus-oviduct junction. For early stage embryos and morula, such embryos are either cultured in vitro into blastocysts or implanted into the oviducts of 0.5 dpc or 1.5 dpc pseudopregnant females according to the embryo stage. Chimeric pups from the implanted embryos are born 16-20 days after the transfer depending on the embryo age at implantation. Chimeric males are selected for breeding. Offspring can be analyzed for transmission of the embryonic stem cell genome by coat color and genetic analysis, such as PCR, Southern blot, or nucleic acid sequencing. Protein expression (e.g., of hSCF, hGM-SCF, hIL-3, and/or hCSF1) can be analyzed by protein analysis (Western blot, ELISA) or other functional assays. Offspring expressing the desired genetic modification can be intercrossed to create non-human animals homozygous for the genetic modification. The genetically modified mice can be crossed with immunodeficient mice to create a congenic immunodeficient strain genetically modified to express hSCF, hGM-SCF, hIL-3, and hCSF1.
- A nucleotide sequence encoding a protein to be expressed can be targeted into a specific locus of the stem cell genome that is known to result in reliable expression such as the Hprt or the ROSA26 locus. For targeted transgenics, a targeting construct can be made using recombinant DNA techniques. The targeting construct can optionally include 5′ and 3′ sequences that are homologous to the endogenous gene target. The targeting construct can optionally further include a selectable marker such as neomycin phosphotransferase, hygromycin, or puromycin, a nucleic acid encoding hSCF, hGM-SCF, hIL-3, and/or hCSF1, and a polyadenylation signal, for example. To ensure correct transcription and translation of a nucleotide sequence encoding a desired xenogeneic protein, for example, the sequence is either in frame with the endogenous gene locus, or a splice acceptor site and internal ribosome entry site (IRES) sequence are included. Such a targeting construct can be transfected into stem cells, and the stem cells can be screened to detect the homologous recombination event using PCR, Southern blot, or nucleic acid sequencing. Cells with the correct homologous recombination event can be further analyzed for transgene expression by protein analysis, such as by ELISA or Western blot analysis. If desired, the selectable marker can be removed by treating the stem cells with Cre recombinase. After Cre recombinase treatment, the cells are analyzed for the presence of the nucleotide sequence encoding the expression construct or relevant portion thereof. Cells with the correct genomic event can be selected and injected into preimplantation embryos as described above. Chimeric males are selected for breeding. Offspring can be analyzed for transmission of the embryonic stem cell genome by coat color and genetic analysis, such as PCR, Southern blot, or nucleotide sequencing, and can be tested for xenogeneic protein expression such as by protein analysis (Western blot, ELISA) or other functional assays. Offspring expressing the desired genetic modification can be intercrossed to create animals homozygous for the genetic modification. Mice genetically modified to express hSCF, hGM-SCF, hIL-3, and hCSF1 can then be crossed with immunodeficient animals to create a congenic immunodeficient strain genetically modified to express hSCF, hGM-SCF, hIL-3, and hCSF1.
- Embodiments of the invention provide a genetically modified immunodeficient QUAD mouse that includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1 in substantially all of their cells, as well as a genetically modified immunodeficient QUAD mouse that includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1 in some, but not all of their cells. One or multiple copies (such as concatamers) of the nucleotide sequence encoding hSCF, the nucleotide sequence encoding hGM-CSF, the nucleotide sequence encoding hIL-3, and/or the nucleotide sequence encoding hCSF1 can be integrated into the genomes of the cells of the immunodeficient QUAD mouse.
- Any of various methods can be used to introduce a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1 into an immunodeficient mouse to produce an immunodeficient QUAD mouse. Such techniques are well-known in the art and include, but are not limited to, pronuclear microinjection and transformation of embryonic stem cells. Methods for generating genetically modified mice that can be used include, but are not limited to, those described in Sundberg and Ichiki, (Eds.), Genetically Engineered Mice Handbook, CRC Press, 2006; Hofker and van Deursen, (Eds.), Transgenic Mouse Methods and Protocols, Humana Press, 2002; Joyner, Gene Targeting: A Practical Approach, Oxford University Press, 2000; Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, Dec. 15, 2002, ISBN-10: 0879695919; Turksen (Ed.), Embryonic stem cells: methods and protocols in Methods Mol Biol. 2002, 185, Humana Press; Current Protocols in Stem Cell Biology, ISBN: 978047015180; Meyer et al, PNAS USA, 107 (34):15022-26.
- Homology-based recombination gene modification strategies can be used to genetically modify an immunodeficient mouse by “knock-in” to introduce a nucleic acid encoding an exogenous protein or proteins e.g., a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1 into the genome of the immunodeficient mouse, such as homing endonucleases, integrases, meganucleases, transposons, nuclease-mediated processes using a zinc finger nuclease (ZFN), a Transcription Activator-Like (TAL), a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas, or a Drosophila Recombination-Associated Protein (DRAP) approach. See, for example, Cerbini et al., PLoS One. 2015; 10(1): e0116032; Shen et al., PLoS ONE 8(10): e77696; and Wang et al., Protein & Cell, February 2016, Volume 7,
Issue 2, pp 152-156. - An immunodeficient QUAD mouse according to aspects of the present invention expresses hSCF, hGM-CSF, hIL-3, and hCSF1, each at a serum concentration of at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 40 ng/mL, 50 ng/mL, 60 ng/mL, 75 ng/mL, 100 ng/mL, 150 ng/mL, 200 ng/mL, 250 ng/mL, 300 ng/mL, 400 ng/mL, 500 ng/mL, 600 ng/mL, or 750 ng/mL.
- An immunodeficient QUAD mouse according to aspects of the present invention expresses hSCF, hGM-CSF, hIL-3, and hCSF1, each at a serum concentration of about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to about 1 pg/mL, about 0.5 pg/mL to about 5 pg/mL, about 1 pg/mL to about 10 pg/mL, about 5 pg/mL to about 50 pg/mL, about 10 pg/mL to about 100 pg/mL, about 50 pg/mL to about 500 pg/mL, about 100 pg/mL to about 1 ng/mL, about 500 pg/mL to about 5 ng/mL, about 1 ng/mL to about 10 ng/mL, about 5 ng/mL to about 50 ng/mL, about 10 ng/mL to about 100 ng/mL, about 50 ng/mL to about 500 ng/mL, about 0.5 ng/mL to about 50 ng/mL, about 1 ng/mL to about 25 ng/mL, about 0.5 ng/mL to about 20 ng/mL, about 0.1 ng/mL to about 5 ng/mL, about 0.5 ng/mL to about 10 ng/mL, about 2 ng/mL to about 20 ng/mL, about 1 ng/mL to about 5 ng/mL, or about 2 ng/mL to about 4 ng/mL.
- Aspects of the present invention, an immunodeficient QUAD mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1, each at a serum concentration of about 1 ng/mL to about 10 ng/mL.
- Immunodeficiency
- The term “immunodeficient mouse” refers to a mouse characterized by one or more of: a lack of functional immune cells, such as T cells and B cells; a DNA repair defect; a defect in the rearrangement of genes encoding antigen-specific receptors on lymphocytes; and a lack of immune functional molecules such as IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA. Immunodeficient mice can be characterized by one or more deficiencies in a gene involved in immune function, such as Rag1 and Rag2 (Oettinger, M. A et al., Science, 248:1517-1523, 1990; and Schatz, D. G. et al., Cell, 59:1035-1048, 1989) Immunodeficient mice may have any of these or other defects which result in abnormal immune function in the mice.
- According to particular aspects, an immunodeficient QUAD mouse has a defect in its endogenous gene encoding interleukin-2 receptor γ subunit (IL-2RG) which causes the mouse to express a defective endogenous interleukin-2 receptor γ subunit and/or a reduced amount of endogenous interleukin-2 receptor γ subunit, or the mouse may not express an endogenous interleukin-2 receptor γ subunit at all. The immunodeficient QUAD can optionally be IL-2RG null such that it lacks a functional endogenous IL-2RG gene.
- In further aspects, a immunodeficient QUAD mouse has a defect in its endogenous gene encoding DNA-dependent protein kinase, catalytic subunit (Prkdc) which causes the mouse to express a defective endogenous DNA-dependent protein kinase, catalytic subunit and/or a reduced amount of endogenous DNA-dependent protein kinase, catalytic subunit, or the mouse may not express endogenous DNA-dependent protein kinase, catalytic subunit at all. The immunodeficient QUAD mouse can optionally be Prkdc null such that it lacks a functional endogenous Prkdc gene).
- “Endogenous,” as used herein in relation to genes and the proteins they encode, refers to genes present in the genome of the mouse at their native gene locus.
- In various aspects of the present invention, an immunodeficient QUAD mouse is IL-2rg null and/or Prkdc null, lacking functional endogenous IL-2rg and Prkdc genes. The immunodeficient QUAD mouse can optionally include a Prkdc knockout and/or an IL-2rg knockout. In various aspects of the present invention, the immunodeficient QUAD mouse does not express IL-2RG, does not express Prkdc, or does not express both IL-2RG and Prkdc.
- In various aspects of the present invention, an immunodeficient QUAD mouse has severe-combined immunodeficiency. The term “severe combined immune deficiency” or “SCID” refers to a condition characterized by the absence or severe reduction of function of T cells and B cells.
- Common forms of SCID include: X-linked SCID, which is characterized by gamma chain gene mutations in the IL-2RG gene and the lymphocyte phenotype T(−) B(+) NK(−). and autosomal recessive SCID. Autosomal recessive SCID can be characterized by Jak3 gene mutations and the lymphocyte phenotype T(−) B(+) NK(−), ADA gene mutations and the lymphocyte phenotype T(−) B(−) NK(−), IL-7R alpha-chain mutations and the lymphocyte phenotype T(−) B(+) NK(+), CD3 delta or epsilon mutations and the lymphocyte phenotype T(−) B(+) NK(+), RAG1/RAG2 mutations and the lymphocyte phenotype T(−) B(−) NK(+), Artemis gene mutations and the lymphocyte phenotype T(−) B(−) NK(+), and CD45 gene mutations and the lymphocyte phenotype T(−) B(+) NK(+).
- According to aspects of the present invention, an immunodeficient QUAD mouse has the severe combined immunodeficiency mutation (Prkdcscid), commonly referred to as the scid mutation. The scid mutation is well-known and located on mouse chromosome 16 as described in Bosma et al, 1989, Immunogenetics 29:54-56. Mice homozygous for the scid mutation are characterized by an absence of functional T cells and B cells, lymphopenia, hypoglobulinemia, and a normal hematopoetic microenvironment. The scid mutation can be detected, for example, by the detection of markers for the scid mutation using well-known methods such as PCR or flow cytometry.
- A genetically modified immunodeficient mouse according to aspects of the present invention has an IL-2 receptor gamma chain deficiency. The term “IL-2 receptor gamma chain deficiency” refers to decreased IL-2 receptor gamma chain. Decreased IL-2 receptor gamma chain can be due to gene deletion or mutation. Decreased IL-2 receptor gamma chain can be detected, for example, by detection of IL-2 receptor gamma chain gene deletion or mutation and/or detection of decreased IL-2 receptor gamma chain expression using well-known methods.
- An immunodeficient QUAD mouse according to aspects of the present invention has severe combined immunodeficiency or an IL-2 receptor gamma chain deficiency in combination with severe combined immunodeficiency.
- An immunodeficient QUAD mouse according to aspects of the present invention has the scid mutation or an IL-2 receptor gamma chain deficiency in combination with the scid mutation.
- In various aspects of the present invention, the immunodeficient QUAD mouse is a genetically modified NSG mouse, a genetically modified NRG mouse or a genetically modified NOG mouse, wherein the genome of the genetically-modified NSG, NRG or NOG mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, wherein the mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins.
- The terms “NOD scid gamma,” “NOD-scid IL2rgnull” and “NSG” are used interchangeably herein to refer to a well-known immunodeficient mouse strain NOD.Cg-Prkdcscid IL-2rgtm1Wjl/SzJ, described in detail in Shultz L D et al, 2005, J. Immunol, 174:6477-89. NSG mice combine multiple immune deficits from the NOD/ShiLtJ background, the severe combined immune deficiency (scid) mutation, and a complete knockout of the interleukin-2 receptor gamma chain. As a result, NSG mice lack mature mouse T, B, and NK cells, and they are deficient in multiple mouse cytokine signaling pathways. NSG mice are characterized by a lack of mouse IL-2R-γ (gamma c) expression, no detectable mouse serum immunoglobulin, no mouse hemolytic complement, no mature mouse T lymphocytes, and no mature mouse natural killer cells.
- An NSG mouse that expresses hSCF, hGM-CSF, hIL-3, and hCSF1 is referred to as a “NSG-QUAD” mouse, which indicates that the genome of the genetically-modified NSG, mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, on the NOD.Cg-Prkdcscid/L-2rgtm1Wjl/SzJ background, wherein the mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins.
- NRG mice are well-known as NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ, described in detail in Shultz L D et al, 2008 Clin Exp Immunol 154(2):270-84.
- Advantageously, NSG-QUAD mice exhibit a significantly heightened level of CD33+/CD14+ human monocytes and CD56+ human NK cells in the blood when engrafted with human hematopoietic stem cells when compared with NSG mice.
- NSG-QUAD mice also exhibit a surprising property of an enhanced development of human monocytes and NK cells when engrafted with human hematopoietic stem cells. There is disclosed an enhanced functional human immune response to innate stimulation with lipopolysaccharide (LPS) in the HSC-engrafted NSG-QUAD mice, making this mouse model particularly valuable in the study of human immune responses to various stimuli.
- An NRG mouse that expresses hSCF, hGM-CSF, hIL-3, and hCSF1 is referred to as a “NRG-QUAD” mouse, which indicates that the genome of the genetically-modified NRG, mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, on the NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ background, wherein the mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1 proteins.
- NOG mice are well-known as NOD.Cg-Prkdcscid Il2rgTm1Sug/JicTac, described in detail in Ito, M. et al.,
Blood 100,3175-3182 (2002). - A NOG mouse that expresses hSCF, hGM-CSF, hIL-3, and hCSF1 is referred to as a “NOG-QUAD” mouse, which indicates that the genome of the genetically-modified NOG, mouse includes a nucleotide sequence encoding hSCF, a nucleotide sequence encoding hGM-CSF, a nucleotide sequence encoding hIL-3, and a nucleotide sequence encoding hCSF1, on the NOD.Cg-Prkdcscid Il2rgTm1Sug/JicTac background.
- Hematopoietic Stem Cell Xenografts
- Various aspects of the invention relate to administering xenogeneic hematopoietic stem cells (HSC) to an immunodeficient QUAD mouse, producing an immunodeficient QUAD mouse having engrafted HSC.
- The xenogeneic HSC are human HSC according to aspects of the present invention.
- The term “xenogeneic HSC” as used herein refers to multipotent stem cells expressing c-Kit receptor. Examples of multipotent stem cells expressing c-Kit receptor include, but are not limited to, hematopoietic stem cells, also known as hemocytoblasts. C-Kit receptor is well-known in the art, for example as described in Vandenbark G R et al., 1992, Cloning and structural analysis of the human c-kit gene, Oncogene 7(7): 1259-66; and Edling C E, Hallberg B, 2007, c-Kit—a hematopoietic cell essential receptor tyrosine kinase, Int. J. Biochem. Cell Biol. 39(11):1995-8.
- Isolation of xenogeneic HSC, administration of the xenogeneic HSC to a host mouse and methods for assessing engraftment in the host mouse thereof are well-known in the art.
- Hematopoietic stem cells for administration to an immunodeficient QUAD mouse can be obtained from any tissue containing HSC such as, but not limited to, umbilical cord blood, bone marrow, GM-CSF-mobilized peripheral blood and fetal liver.
- Xenogeneic HSC can be administered into newborn mice by administration via various routes, such as, but not limited to, into the heart, liver and/or facial vein. Xenogeneic HSC can be administered into adult mice by various routes, such as, but not limited to, administration into the tail vein, into the femur bone marrow cavity or into the spleen. In a further example, fetal liver containing the xenogeneic HSC can be engrafted under the renal capsule.
- Administering xenogeneic cells to a mouse can include administering a composition comprising xenogeneic cells to the mouse. The composition can further include, for example, water, a tonicity-adjusting agent (e.g., a salt such as sodium chloride), a pH buffer (e.g., citrate), and/or a sugar (e.g., glucose).
- Engraftment of xenogeneic hematopoietic stem cells in immunodeficient animals is characterized by the presence of differentiated xenogeneic hematopoietic cells in the immunodeficient QUAD mice. Engraftment of xenogeneic HSC can be assessed by any of various methods, such as, but not limited to, flow cytometric analysis of cells in the animals to which the xenogeneic HSC are administered at one or more time points following the administration of HSC.
- Exemplary methods for isolation of xenogeneic HSC, administration of the xenogeneic HSC to a host mouse and methods for assessing engraftment thereof are described herein and in T. Pearson et al., Curr. Protoc. Immunol. 81:15.21.1-15.21.21, 2008; Ito, M. et al, Blood 100: 3175-3182; Traggiai, E. et al, Science 304: 104-107; Ishikawa, F. et al, Blood 106: 1565-1573; Shultz, L. D. et al, J. Immunol. 174: 6477-6489; Holyoake T L et al, Exp Hematol., 1999, 27(9):1418-27.
- According to aspects of the present invention, the xenogeneic HSC administered to an immunodeficient QUAD mouse are isolated from an original source material to obtain a population of cells enriched in HSCs. The isolated xenogeneic HSCs may or may not be pure. According to aspects, xenogeneic HSCs are purified by selection for a cell marker, such as CD34. According to aspects, administered xenogeneic HSCs are a population of cells in which CD34+ cells constitute about 1-100% of total cells, although a population of cells in which CD34+ cells constitute fewer than about 1% of total cells can be used. According to embodiments, administered xenogeneic HSCs are T cell depleted cord blood cells in which CD34+ cells make up about 1-3% of total cells, lineage depleted cord blood cells in which CD34+ cells make up about 50% of total cells, or CD34+ positively selected cells in which CD34+ cells make up about 90% of total cells.
- The number of xenogeneic HSCs administered is not considered limiting with regard to generation of a xenogeneic hematopoietic and immune system in an immunodeficient QUAD mouse. A single xenogeneic HSC can generate a hematopoietic and immune system in a host immunodeficient QUAD mouse. Thus, the number of administered xenogeneic HSCs is generally in the range of about 1×103 to 1×106 (1,000 to 1,000,000) CD34+ cells where the recipient is a mouse, although more or fewer can be used.
- Thus, a method according to aspects of the present invention can include administering about 103 (1000) to about 106 (1,000,000), about 103 to about 105, about 104 to about 106, about 105 to about 107, about 1×103 to about 1×104, about 5×103 to about 5×104, about 1×104 to about 1×105, about 5×104 to about 5×105, about 1×105 to about 1×106, about 5×105 to about 5×106, about 1×106 to about 1×107, about 2×104 to about 5×105, or about 5×104 to about 2×105 xenogeneic HSC, such as human hematopoietic stem cells, to the immunodeficient QUAD mouse. The method can include administering at least about 1×102, about 2×102, about 3×102, about 4×102, about 5×102, about 6×102, about 7×102, about 8×102, about 9×102, about 1×103, about 2×103, about 3×103, about 4×103, about 5×103, about 6×103 about 7×103, about 8×103, about 9×103, about 1×104, about 2×104, about 3×104 about 4×104, about 5×104, about 6×104, about 7×104, about 8×104, about 9×104 about 1×105, about 2×105, about 3×105, about 4×105, about 5×105, about 6×105 about 7×105, about 8×105, about 9×105, about 1×106, about 2×106, about 3×106, about 4×106, about 5×106, about 6×106, about 7×106, about 8×106, about 9×106, or about 1×107 xenogeneic HSC, such as human hematopoietic stem cells, to the immunodeficient QUAD mouse. The method can include administering about 1×102, about 2×102, about 3×102, about 4×102, about 5×102, about 6×102, about 7×102, about 8×102, about 9×102, about 1×103, about 2×103, about 3×103, about 4×103, about 5×103, about 6×103, about 7×103, about 8×103, about 9×103, about 1×104, about 2×104, about 3×104, about 4×104, about 5×104, about 6×104, about 7×104, about 8×104, about 9×104, about 1×105, about 2×105, about 3×105, about 4×105, about 5×105, about 6×105, about 7×105, about 8×105, about 9×105, about 1×106, about 2×106, about 3×106, about 4×106, about 5×106, about 6×106, about 7×106, about 8×106, about 9×106, or about 1×107 xenogeneic HSC, such as human HSC, to the immunodeficient QUAD mouse. Those of ordinary skill will be able to determine a number of xenogeneic cells that should be administered to a specific mouse using no more than routine experimentation.
- Engraftment is successful where xenogenic HSCs and/or cells differentiated from the xenogeneic HSCs in the recipient immunodeficient QUAD mouse are detected at a time when the majority of any administered non-HSC have degenerated. Detection of differentiated xenogeneic HSC cells can be achieved by detection of xenogeneic DNA in the recipient immunodeficient QUAD mouse or detection of intact xenogeneic HSCs and cells differentiated from the xenogeneic HSCs, for example. Serial transfer of CD34+ cells into a secondary recipient and engraftment of a xenogeneic hematopoietic system is a further test of HSC engraftment in the primary recipient. Engraftment can be detected by flow cytometry as 0.05% or greater xenogeneic CD45+ cells in the blood, spleen or bone marrow of the recipient immunodeficient QUAD mouse at 6-12 weeks after administration of the xenogeneic HSC.
- Engraftment of xenogeneic haematopoietic stem cells (HSC) in an immunodeficient QUAD mouse according to aspects of the present invention includes “conditioning” of the immunodeficient QUAD mouse prior to administration of the xenogeneic HSC, for example by sub-lethal irradiation of the recipient animal with high frequency electromagnetic radiation, or gamma radiation, or treatment with a radiomimetic drug such as busulfan or nitrogen mustard. Conditioning is believed to reduce numbers of host hematopoietic cells, create appropriate microenvironmental factors for engraftment of xenogeneic HSC, and/or create microenvironmental niches for engraftment of xenogeneic HSC. Standard methods for conditioning are known in the art, such as described herein and in J. Hayakawa et al, 2009, Stem Cells, 27(1):175-182.
- Methods are provided according to aspects of the present invention which include administration of xenogeneic HSC to an immunodeficient QUAD mouse without “conditioning” the immunodeficient QUAD mouse prior to administration of the xenogeneic HSC. Methods are provided according to aspects of the present invention which include administration of xenogeneic HSC to an immunodeficient QUAD mouse without “conditioning” by radiation or radiomimetic drugs of the immunodeficient QUAD mouse prior to administration of the xenogeneic HSC.
- Various aspects of the invention relate to administering xenogeneic hematopoietic stem cells (HSC) to an immunodeficient QUAD mouse, producing an immunodeficient QUAD mouse having engrafted HSC. The engrafted xenogeneic HSC differentiate to produce an immunodeficient QUAD mouse with a xenogeneic immune system or components thereof.
- Administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of differentiated xenogeneic cells of hematopoietic lineage in the mouse. For example, administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of xenogeneic myeloid-lineage and xenogeneic lymphoid-lineage cells by the mouse such as xenogeneic CD33+ myeloid cells, xenogeneic myeloid progenitor cells, xenogeneic mast cells, xenogeneic myeloid dendritic cells, xenogeneic B cells, xenogeneic T cells, xenogeneic T helper cells, xenogeneic cytotoxic T cells, and/or xenogeneic Treg cells. According to aspects of the present invention, human HSC are administered to an immunodeficient QUAD mouse which differentiate such that the mouse includes one or more of: human CD33+ myeloid cells, human myeloid progenitor cells, human mast cells, human myeloid dendritic cells, human B cells, human T cells, human T helper cells, human cytotoxic T cells, and/or human Treg cells.
- Administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of differentiated xenogeneic cells of hematopoietic lineage that can be characterized by flow cytometry. For example, administration of human HSC to an immunodeficient QUAD mouse results in the production of differentiated human cells of hematopoietic lineage that can be characterized by flow cytometry, including human leukocytes selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of CD45+, CD20+, CD20+CD45+, CD3+, CD3+CD45+, CD33+, CD33+CD45+, CD14+, CD14+CD45+, CD56+, and CD56+CD45+ human leukocytes.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in the production of differentiated human cells of hematopoietic lineage such as human CD45+ leukocytes, wherein at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more of the human CD45+ leukocytes of the mouse are CD3+CD45+ leukocytes; at least about 10%, 15%, 20%, 25%, 30%, 35%, or more of the human CD45+ leukocytes of the mouse are CD33+CD45+ leukocytes; at least about 5%, 10%, 15%, 20%, or more of the human CD45+ leukocytes of the mouse are CD14+CD45+ leukocytes; and/or at least about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, or more of the human CD45+ leukocytes of the mouse are CD56+CD45+ leukocytes (e.g., in the absence of an immunological challenge such as a tumor or antigen challenge).
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in the production of differentiated human cells of hematopoietic lineage such as human leukocytes, wherein at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more of the human leukocytes of the mouse are either cytotoxic T-cells or T-helper cells; at least about 10%, 15%, 20%, 25%, 30%, 35%, or more of the human leukocytes of the mouse are myeloid-lineage cells; at least about 5%, 10%, 15%, 20%, or more of the human leukocytes of the mouse are macrophages; and/or at least about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, or more of the human leukocytes of the mouse are natural killer cells (e.g., in the absence of an immunological challenge such as a tumor or antigen challenge).
- According to aspects disclosed herein, administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of xenogeneic cytokines by the mouse such as interleukin-8, interleukin-1β, tumor-necrosis factor, interleukin-12p70, and/or interleukin-6. For example, administration of human HSC to an immunodeficient QUAD mouse results in the production of 1, 2, 3, 4, or all of human interleukin-8, human interleukin-1β, human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6.
- According to aspects disclosed herein, administration of xenogeneic HSC to an immunodeficient QUAD mouse results in the production of xenogeneic cytokines in response to an immune challenge, e.g., at a detectable level and/or at a level capable of mediating a xenogeneic immune response against the challenge. According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, or more serum human interleukin-8 in the mouse. According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in the production of at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, or more serum human interleukin-1p in the mouse. According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 40 ng/mL, 50 ng/mL, or more serum human tumor-necrosis factor in the mouse. According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, or more serum human interleukin-12p′70 in the mouse. According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in at least about 0.1 pg/mL, 0.5 pg/mL, 1 pg/mL, 2 pg/mL, 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 40 pg/mL, 50 pg/mL, 60 pg/mL, 75 pg/mL, 100 pg/mL, 150 pg/mL, 200 pg/mL, 250 pg/mL, 300 pg/mL, 400 pg/mL, 500 pg/mL, 600 pg/mL, 750 pg/mL, 1 ng/mL, 2 ng/mL, 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, or more serum human interleukin-6 in the mouse.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to about 1 pg/mL, about 0.5 pg/mL to about 5 pg/mL, about 1 pg/mL to about 10 pg/mL, about 5 pg/mL to about 50 pg/mL, about 10 pg/mL to about 100 pg/mL, about 50 pg/mL to about 500 pg/mL, about 100 pg/mL to about 1 ng/mL, about 500 pg/mL to about 5 ng/mL, about 1 ng/mL to about 10 ng/mL, about 5 ng/mL to about 50 ng/mL, about 10 ng/mL to about 100 ng/mL, about 50 ng/mL to about 500 ng/mL, about 0.5 ng/mL to about 50 ng/mL, about 1 ng/mL to about 25 ng/mL, about 0.5 ng/mL to about 20 ng/mL, about 0.1 ng/mL to about 5 ng/mL, about 0.5 ng/mL to about 10 ng/mL, or about 2 ng/mL to about 20 ng/mL serum human interleukin-8 in the mouse.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to about 1 pg/mL, about 0.5 pg/mL to about 5 pg/mL, about 1 pg/mL to about 10 pg/mL, about 5 pg/mL to about 50 pg/mL, about 10 pg/mL to about 100 pg/mL, about 50 pg/mL to about 500 pg/mL, or about 100 pg/mL to about 1 ng/mL serum human interleukin-1β in the mouse.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to about 1 pg/mL, about 0.5 pg/mL to about 5 pg/mL, about 1 pg/mL to about 10 pg/mL, about 5 pg/mL to about 50 pg/mL, about 10 pg/mL to about 100 pg/mL, about 50 pg/mL to about 500 pg/mL, about 100 pg/mL to about 1 ng/mL, about 500 pg/mL to about 5 ng/mL, about 1 ng/mL to about 10 ng/mL, about 5 ng/mL to about 50 ng/mL, about 10 ng/mL to about 100 ng/mL, about 50 ng/mL to about 500 ng/mL, about 0.5 ng/mL to about 50 ng/mL, about 1 ng/mL to about 25 ng/mL, or about 0.5 ng/mL to about 20 ng/mL serum human tumor-necrosis factor in the mouse.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 1 pg/mL, about 0.5 pg/mL to about 5 pg/mL, about 1 pg/mL to about 10 pg/mL, about 5 pg/mL to about 50 pg/mL, about 10 pg/mL to about 100 pg/mL, or about 50 pg/mL to about 500 pg/mL serum human interleukin-12p70 in the mouse.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in about 0.1 pg/mL to about 1000 ng/mL, about 0.1 pg/mL to about 100 ng/mL, about 0.5 pg/mL to about 50 ng/mL, about 1 pg/mL to about 10 ng/mL, about 0.1 pg/mL to about 100 pg/mL, about 1 pg/mL to about 1 ng/mL, about 10 pg/mL to about 10 ng/mL, about 100 pg/mL to about 100 ng/mL, about 0.1 pg/mL to about 10 pg/mL, about 1 pg/mL to about 100 pg/mL, about 10 pg/mL to about 1 ng/mL, about 100 pg/mL to about 10 ng/mL, about 1 ng/mL to about 100 ng/mL, about 0.1 pg/mL to about 1 pg/mL, about 0.5 pg/mL to about 5 pg/mL, about 1 pg/mL to about 10 pg/mL, about 5 pg/mL to about 50 pg/mL, about 10 pg/mL to about 100 pg/mL, about 50 pg/mL to about 500 pg/mL, about 100 pg/mL to about 1 ng/mL, about 500 pg/mL to about 5 ng/mL, about 1 ng/mL to about 10 ng/mL, about 5 ng/mL to about 50 ng/mL, about 10 ng/mL to about 100 ng/mL, about 50 ng/mL to about 500 ng/mL, about 0.5 ng/mL to about 50 ng/mL, about 1 ng/mL to about 25 ng/mL, about 0.5 ng/mL to about 20 ng/mL, about 0.1 ng/mL to about 5 ng/mL, about 0.5 ng/mL to about 10 ng/mL, or about 2 ng/mL to about 20 ng/mL serum human interleukin-6 in the mouse.
- According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in about 5-15 ng/mL serum human interleukin-8, about 5-250 pg/mL serum human interleukin-1β, about 10-50 ng/mL serum human tumor-necrosis factor, about 20-100 pg/mL serum human interleukin-12p70, and/or about 15-30 ng/mL serum human interleukin-6 (e.g., when challenged with about 50-250 ng intravenous lipopolysaccharide) in the mouse.
- According to aspects disclosed herein, administration of xenogeneic HSC to an immunodeficient QUAD mouse results in production of xenogeneic leukocytes that migrate into a tumor, such as xenogeneic tumor-infiltrating lymphocytes and xenogeneic myeloid-derived suppressor cells, in the immunodeficient QUAD mouse. According to aspects disclosed herein, administration of human HSC to an immunodeficient QUAD mouse results in production of human leukocytes that migrate into a tumor, such as human tumor-infiltrating lymphocytes and human myeloid-derived suppressor cells, in the immunodeficient QUAD mouse. For example, such tumor-infiltrating leukocytes are selected from CD20+, CD3+, CD33+, CD14+, and CD56+ leukocytes.
- Tumor Xenograft
- Various aspects of the invention relate to administering xenogeneic tumor cells to an immunodeficient QUAD mouse.
- Xenogeneic tumor cells administered to immunodeficient QUAD mice of the present invention can be any of various tumor cells, including but not limited to, cells of a tumor cell line and primary tumor cells. The xenogeneic tumor cells may be derived from any of various organisms, preferably mammalian, including human, non-human primate, rat, guinea pig, rabbit, cat, dog, horse, cow, goat, pig and sheep.
- According to specific aspects of the present invention, the xenogeneic tumor cells are human tumor cells. According to specific aspects of the present invention, the human tumor cells are present in a sample obtained from the human, such as, but not limited to, in a blood sample, tissue sample, or sample obtained by biopsy of a human tumor.
- Tumor cells obtained from a human can be administered directly to an immunodeficient QUAD mouse of the present invention or may be cultured in vitro prior to administration to the immunodeficient QUAD mouse.
- As used herein, the term “tumor” refers to cells characterized by unregulated growth including, but not limited to, pre-neoplastic hyperproliferation, cancer in-situ, neoplasms, metastases and solid and non-solid tumors. Examples of tumors are those caused by cancer include, but are not limited to, lymphoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, triple negative breast cancer, central or peripheral nervous system cancers, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, gall bladder cancer, gastrointestinal cancer, glioblastoma, head and neck cancer, kidney cancer, liver cancer, nasopharyngeal cancer, nasal cavity cancer, oropharyngeal cancer, oral cavity cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pituitary cancer, prostate cancer, retinoblastoma, sarcoma, salivary gland cancer, skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, uterine cancer, vaginal cancer and vulval cancer.
- The tumor cells can include BR1126, MDA-MB-231, TM1149, or BL0293 cells.
- Administering the tumor cells to the immunodeficient QUAD mouse can be any method that is suitable as recognized in the art. For example, administration can include administering cells into an organ, body cavity, or blood vessel such as by injection or implantation, such as subcutaneous and/or intraperitoneal implantation. The tumor cells may be administered as a tumor mass, clumps of tumor cells or as dissociated cells.
- Tumor cells can be administered by various routes, such as, but not limited to, by subcutaneous injection, intraperitoneal injection or injection into the tail vein.
- Engraftment of xenogeneic tumor cells can be assessed by any of various methods, such as, but not limited to, visual inspection of the mouse for signs of tumor formation.
- Any of various methods can be used to measure growth of xenogeneic tumors, including but not limited to, measurement in living mice, measurement of tumors excised from living mice or measurement of tumors in situ or excised from dead mice.
- Measurements can be obtained using a measuring instrument such as a caliper, measurement using one or more imaging techniques such as ultrasonography, computed tomography, positron emission tomography, fluorescence imaging, bioluminescence imaging, magnetic resonance imaging and combinations of any two or more of these or other tumor measurement methods. The number of tumor cells in a sample obtained from a mouse bearing xenogeneic tumor cells can be used to measure tumor growth, particularly for non-solid tumors. For example, the number of non-solid tumor cells in a blood sample can be assessed to obtain a measurement of growth of a non-solid tumor in a mouse.
- The number of tumor cells administered is not considered limiting. A single tumor cell can expand into a detectable tumor in the genetically modified immunodeficient animals described herein. The number of administered tumor cells is generally in the range of 1,000-1×106 tumor cells, although more or fewer can be administered.
- Thus, a method according to aspects of the present invention can include administering about 102 (100) to about 107 (10,000,000), about 103 to about 105, about 104 to about 106, about 105 to about 107, about 1×103 to about 1×104, about 5×103 to about 5×104, about 1×104 to about 1×105, about 5×104 to about 5×105, about 1×105 to about 1×106, about 5×105 to about 5×106, about 1×106 to about 1×107, about 2×104 to about 5×105, or about 5×104 to about 2×105 xenogeneic tumor cells, such as human tumor cells, to the immunodeficient QUAD mouse. The method can include administering at least about 1×102, about 2×102, about 3×102, about 4×102, about 5×102, about 6×102, about 7×102, about 8×102, about 9×102, about 1×103, about 2×103, about 3×103, about 4×103, about 5×103, about 6×103, about 7×103, about 8×103, about 9×103, about 1×104, about 2×104, about 3×104, about 4×104, about 5×104, about 6×104, about 7×104, about 8×104, about 9×104, about 1×105, about 2×105, about 3×105, about 4×105, about 5×105, about 6×105, about 7×105, about 8×105, about 9×105, about 1×106, about 2×106, about 3×106, about 4×106, about 5×106, about 6×106, about 7×106, about 8×106, about 9×106, or about 1×107 xenogeneic tumor cells, such as human tumor cells, to the immunodeficient QUAD mouse. The method can include administering about 1×102, about 2×102, about 3×102, about 4×102, about 5×102, about 6×102, about 7×102, about 8×102, about 9×102, about 1×103, about 2×103, about 3×103, about 4×103, about 5×103, about 6×103, about 7×103, about 8×103, about 9×103, about 1×104, about 2×104, about 3×104, about 4×104, about 5×104, about 6×104, about 7×104, about 8×104, about 9×104, about 1×105, about 2×105, about 3×105, about 4×105, about 5×105, about 6×105, about 7×105, about 8×105, about 9×105, about 1×106, about 2×106, about 3×106, about 4×106, about 5×106, about 6×106, about 7×106, about 8×106, about 9×106, or about 1×107 xenogeneic tumor cells, such as human tumor cells, to the immunodeficient QUAD mouse. Those of ordinary skill will be able to determine a number of xenogeneic tumor cells that should be administered to a specific mouse using no more than routine experimentation.
- According to aspects of the present invention, xenogeneic tumor cells and xenogeneic HSC are administered to an immunodeficient QUAD mouse. The xenogeneic tumor cells and xenogeneic HSC can be administered at the same time or at different times.
- According to aspects of the present invention, the tumor cells are derived from the same species as the administered HSC. According to aspects, both the tumor cells and the HSC administered to an immunodeficient QUAD mouse are human cells.
- According to aspects of the present invention the administered HSC and tumor cells are human leukocyte antigen (HLA) matched (e.g., MHC Class I matched and/or MHC class II matched). HLA-matching may reduce the likelihood of a graft-versus-graft immune response against HLA cell-surface proteins. An immune response against HLA may falsely suggest that xenogeneic immune cells are successfully targeting xenogeneic cancer cells.
- The administered HSC and tumor cells can include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 matching HLA alleles. The administered HSC and tumor cells can include at least 2, 3, 4, 5, 6, 7, or 8 matching HLA alleles selected from the alleles for HLA-A, HLA-B, HLA-C, and HLA-DRB1. Perfect HLA matching is rarely possible without genetic engineering, and perfect HLA matching may be unnecessary. Control experiments, for example, can account for any HLA-mediated graft-versus-graft immune response.
- Assay Methods
- Methods and immunodeficient QUAD mice provided according to aspects of the present invention have various utilities such as, in vivo testing of substances directed against human cancer.
- Methods for identifying anti-tumor activity of a test substance according to aspects of the present invention include providing an immunodeficient QUAD mouse; administering xenogeneic tumor cells to the immunodeficient QUAD mouse, wherein the xenogeneic tumor cells form a solid or non-solid tumor in the immunodeficient QUAD mouse; administering a test substance to the immunodeficient QUAD mouse; assaying a response of the xenogeneic tumor and/or tumor cells to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- Methods for identifying anti-tumor activity of a test substance according to aspects of the present invention include providing an immunodeficient QUAD mouse, wherein the immunodeficient QUAD mouse has engrafted xenogeneic HSC; administering xenogeneic tumor cells to the immunodeficient QUAD mouse, wherein the xenogeneic tumor cells form a solid or non-solid tumor in the immunodeficient QUAD mouse; administering a test substance to the immunodeficient QUAD mouse; assaying a response of the xenogeneic tumor and/or tumor cells to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- Methods for identifying anti-tumor activity of a test substance according to aspects of the present invention include providing an immunodeficient QUAD mouse, wherein the immunodeficient QUAD mouse has engrafted human HSC; administering human tumor cells to the immunodeficient QUAD mouse, wherein the human tumor cells form a solid or non-solid tumor in the immunodeficient QUAD mouse; administering a test substance to the immunodeficient QUAD mouse; assaying a response of the human tumor and/or tumor cells to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity.
- An immunodeficient QUAD mouse used in an assay for identifying anti-tumor activity of a test substance according to aspects of the present invention is an NSG-QUAD mouse, an NRG-QUAD mouse or a NOG-QUAD mouse.
- The term “inhibitory effect” as used herein refers to an effect of the test substance to inhibit one or more of: tumor growth, tumor cell metabolism and tumor cell division.
- Assaying a response of the xenogeneic tumor and/or tumor cells to the test substance includes comparing the response to a standard to determine the effect of the test substance on the xenogeneic tumor cells according to aspects of methods of the present invention, wherein an inhibitory effect of the test substance on the xenogeneic tumor cells identifies the test substance as an anti-tumor composition. Standards are well-known in the art and the standard used can be any appropriate standard. In one example, a standard is a compound known to have an anti-tumor effect. In a further example, non-treatment of a comparable xenogeneic tumor provides a base level indication of the tumor growth without treatment for comparison of the effect of a test substance. A standard may be a reference level of expected tumor growth previously determined in an individual comparable mouse or in a population of comparable mice and stored in a print or electronic medium for recall and comparison to an assay result.
- Assay results can be analyzed using statistical analysis by any of various methods to determine whether the test substance has an inhibitory effect on a tumor, exemplified by parametric or non-parametric tests, analysis of variance, analysis of covariance, logistic regression for multivariate analysis, Fisher's exact test, the chi-square test, Student's T-test, the Mann-Whitney test, Wilcoxon signed ranks test, McNemar test, Friedman test and Page's L trend test. These and other statistical tests are well-known in the art as detailed in Hicks, CM, Research Methods for Clinical Therapists: Applied Project Design and Analysis, Churchill Livingstone (publisher); 5th Ed., 2009; and Freund, R J et al., Statistical Methods, Academic Press; 3rd Ed., 2010.
- A test substance used in a method of the present invention can be any chemical entity, illustratively including a synthetic or naturally occurring compound or a combination of a synthetic or naturally occurring compound, a small organic or inorganic molecule, a protein, a peptide, a nucleic acid, a carbohydrate, an oligosaccharide, a lipid or a combination of any of these. According to aspects of the present invention, the test substance is an immunotherapeutic.
- According to aspects of the present invention, a test substance is an anti-cancer agent. According to aspects of the present invention, the test substance is an anti-cancer immunotherapeutic, such as an anti-cancer antibody or antigen binding fragment thereof.
- Anti-cancer agents are described, for example, in Brunton et al. (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th Ed., Macmillan Publishing Co., 2011.
- Anti-cancer agents illustratively include acivicin, aclarubicin, acodazole, acronine, adozelesin, aldesleukin, alitretinoin, allopurinol, altretamine, ambomycin, ametantrone, amifostine, aminoglutethimide, amsacrine, anastrozole, anthramycin, arsenic trioxide, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene, bisnafide dimesylate, bizelesin, bleomycin, brequinar, bropirimine, busulfan, cactinomycin, calusterone, capecitabine, caracemide, carbetimer, carboplatin, carmustine, carubicin, carzelesin, cedefingol, celecoxib, chlorambucil, cirolemycin, cisplatin, cladribine, cobimetinib, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate, diaziquone, docetaxel, doxorubicin, droloxifene, dromostanolone, duazomycin, edatrexate, eflomithine, elsamitrucin, enloplatin, enpromate, epipropidine, epirubicin, erbulozole, esorubicin, estramustine, etanidazole, etoposide, etoprine, fadrozole, fazarabine, fenretinide, floxuridine, fludarabine, fluorouracil, flurocitabine, fosquidone, fostriecin, fulvestrant, gemcitabine, hydroxyurea, idarubicin, ifosfamide, ilmofosine, interleukin II (IL-2, including recombinant interleukin II or rIL2), interferon alfa-2a, interferon alfa-2b, interferon alfa-nl, interferon alfa-n3, interferon beta-Ia, interferon gamma-Ib, iproplatin, irinotecan, lanreotide, letrozole, leuprolide, liarozole, lometrexol, lomustine, losoxantrone, masoprocol, maytansine, mechlorethamine hydrochlride, megestrol, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotrexate, metoprine, meturedepa, mitindomide, mitocarcin, mitocromin, mitogillin, mitomalcin, mitomycin, mitosper, mitotane, mitoxantrone, mycophenolic acid, nelarabine, nocodazole, nogalamycin, ormnaplatin, oxisuran, paclitaxel, pegaspargase, peliomycin, pentamustine, peplomycin, perfosfamide, pipobroman, piposulfan, piroxantrone hydrochloride, plicamycin, plomestane, porfimer, porfiromycin, prednimustine, procarbazine, puromycin, pyrazofurin, riboprine, rogletimide, safingol, semustine, simtrazene, sparfosate, sparsomycin, spirogermanium, spiromustine, spiroplatin, streptonigrin, streptozocin, sulofenur, talisomycin, tamoxifen, tecogalan, tegafur, teloxantrone, temoporfin, teniposide, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, tiazofurin, tirapazamine, topotecan, toremifene, trestolone, triciribine, trimetrexate, triptorelin, tubulozole, uracil mustard, uredepa, vapreotide, vemurafenib, verteporfin, vinblastine, vincristine sulfate, vindesine, vinepidine, vinglycinate, vinleurosine, vinorelbine, vinrosidine, vinzolidine, vorozole, zeniplatin, zinostatin, zoledronate, and zorubicin.
- According to aspects of the present invention, an anti-cancer agent is an anti-cancer antibody. An anti-cancer antibody used can be any antibody effective to inhibit at least one type of tumor, particularly a human tumor. Anti-cancer antibodies include, but are not limited to, 3F8, 8H9, abagovomab, abituzumab, adalimumab, adecatumumab, aducanumab, afutuzumab, alacizumab pegol, alemtuzumab, amatuximab, anatumomab mafenatox, anetumab ravtansine, apolizumab, arcitumomab, ascrinvacumab, atezolizumab, bavituximab, belimumab, bevacizumab, bivatuzumab mertansine, brentuximab vedotin, brontictuzumab, cantuzumab mertansine, cantuzumab ravtansine, capromab pendetide, catumaxomab, cetuximab, citatuzumab bogatox, cixutumumab, clivatuzumab tetraxetan, coltuximab ravtansine, conatumumab, dacetuzumab, dalotuzumab, demcizumab, denintuzumab mafodotin, depatuxizumab mafodotin, durvalumab, dusigitumab, edrecolomab, elotuzumab, emactuzumab, emibetuzumab, enoblituzumab, enfortumab vedotin, enavatuzumab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, galiximab, ganitumab, gemtuzumab, girentuximab, glembatumumab vedotin, ibritumomab tiuxetan, igovomab, imab362, imalumab, imgatuzumab, indatuximab ravtansine, indusatumab vedotin, inebilizumab, inotuzumab ozogamicin, intetumumab, ipilimumab, iratumumab, isatuximab, labetuzumab, lexatumumab, lifastuzumab vedotin, lintuzumab, lirilumab, lorvotuzumab mertansine, lucatumumab, lumiliximab, lumretuzumab, mapatumumab, margetuximab, matuzumab, milatuzumab, mirvetuximab soravtansine, mitumomab, mogamulizumab, moxetumomab pasudotox, nacolomab tafenatox, naptumomab estafenatox, narnatumab, necitumumab, nesvacumab, nimotuzumab, nivolumab, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, ontuxizumab, oregovomab, oportuzumab monatox, otlertuzumab, panitumumab, pankomab, parsatuzumab, patritumab, pembrolizumab, pemtumomab, pertuzumab, pidilizumab, pinatuzumab vedotin, polatuzumab vedotin, pritumumab, racotumomab, radretumab, ramucirumab, rilotumumab, rituximab, robatumumab, sacituzumab govitecan, samalizumab, seribantumab, sibrotuzumab, siltuximab, sofituzumab vedotin, tacatuzumab tetraxetan, tarextumab, tenatumomab, teprotumumab, tetulomab, tigatuzumab, tositumomab, tovetumab, trastuzumab, tremelimumab, tucotuzumab celmoleukin, ublituximab, utomilumab, vandortuzumab vedotin, vantictumab, vanucizumab, varlilumab, vesencumab, volociximab, vorsetuzumab mafodotin, votumumab, zalutumumab and zatuximab.
- According to aspects of the present invention, a test substance is one that specifically binds one or more of: 1) a cell-surface protein such as a cluster of differentiation (CD) cell-surface molecule; 2) an intracellular protein such as a kinase; and 3) an extracellular protein such as a shed cell-surface receptor or the soluble ligand of a cell-surface receptor.
- According to aspects of the present invention, a test substance is one that specifically binds a protein that is expressed by leukocytes (e.g., lymphocytes or myeloid-lineage leukocytes). In a further option, a test substance is one that specifically binds a ligand of a leukocyte. In a still further option, a test substance is one that specifically binds a molecule that is expressed by a cancer cell.
- According to aspects of the present invention, a test substance is a chemotherapeutic agent or an immunotherapeutic agent. According to aspects of the present invention, a test substance can specifically binds PD-1, PD-L1, or CTLA-4. According to aspects of the present invention, a test substance can be an immune checkpoint inhibitor such as a PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor. According to aspects of the present invention, a test substance is an immune checkpoint inhibitor selected from atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and an antigen-binding fragment of any one of the foregoing.
- The test substance can be administered by any suitable route of administration, such as, but not limited to, oral, rectal, buccal, nasal, intramuscular, vaginal, ocular, otic, subcutaneous, transdermal, intratumoral, intravenous, and intraperitoneal.
- Embodiments of inventive compositions and methods are illustrated in the following examples. These examples are provided for illustrative purposes and are not considered limitations on the scope of inventive compositions and methods.
- Mice that constitutively express a transgene encoding human colony stimulating factor 1 (hCSF1) were generated in an NSG background using routine techniques and are referred to herein as “NSG-CSF1” mice. To make the NSG-CSF1 mice, a transgene encoding human CSF1 (hCSF1) is designed. Expression of hCSF1 is driven by a human cytomegalovirus promoter/enhancer sequence, and is followed by a human growth hormone cassette and a polyadenylation (polyA) sequence. The hCSF1 transgene is microinjected into fertilized C57BL/6×C3H/HeN oocytes. The resulting founders, carrying the hCSF1transgene are backcrossed to BALB/c-Prkdcscid mice for several generations and subsequently backcrossed to NOD.CB17-Prkdcscid mice for several generations. These mice are backcrossed to NOD.Cg-Prkdcscid Il2rgtm1Wjl mice, and are then intercrossed until all offspring are homozygous for the hCSF1 transgene and the IL2rg targeted mutation. These transgenic mice are bred to NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG mice, Jackson Laboratory Stock No. 005557) to establish the colony. Thereafter, females homozygous for Prkdcscid, homozygous for Il2rgtm1Wjl and homozygous for the hCSF1 transgene were bred with males homozygous for Prkdcscid, hemizygous for the X-linked 2rgtm1Wjl and homozygous for the hCSF1 transgene.
- NSG-CSF1 are maintained on the NOD.Cg-Prkdcscid Il2tm1Wjl/SzJ mouse (Stock No. 005557) background and constitutively produce detectable serum levels of human CSF1.
- NSG-SGM3 mice express human transgenes for stem cell factor (hSCF), granulocyte-macrophage-colony stimulating factor (hGM-CSF), and interleukin-3 (hIL-3). NSG-SGM3 mice contain three transgenes, human interleukin-3 (IL-3), human granulocyte/macrophage-stimulating factor (GM-CSF), and human Steel factor (SF) gene, each driven by a human cytomegalovirus promoter/enhancer sequence. To make the NSG-SGM3 mice, three separate transgenes were designed each carrying one of: the human interleukin-3 (IL-3) gene, the human granulocyte/macrophage-stimulating factor (GM-CSF) gene, or human Steel factor (SF) gene. Expression of each gene is driven by a human cytomegalovirus promoter/enhancer sequence, and is followed by a human growth hormone cassette and a polyadenylation (polyA) sequence. The three transgenes were microinjected into fertilized C57BL/6×C3H/HeN oocytes. The resulting founders, carrying all three transgenes (3GS) were backcrossed to BALB/c-Prkdcscid mice for several generations and subsequently backcrossed to NOD.CB17-Prkdcscid mice for at least 11 generations. These mice were bred to NOD.Cg-Prkdcscid Il2rgtm1Wjl mice, and were then intercrossed until all offspring were homozygous for 3GS and the IL2rg targeted mutation. These transgenic mice were bred to NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG mice, Jackson Laboratory Stock No. 005557) for one generation to establish the colony. Thereafter, females homozygous for Prkdcscid, homozygous for Il2rgtm1Wjl and homozygous for the 3GS transgenes were bred with males homozygous for Prkdcscid, hemizygous for the X-linked 2rgtm1Wjl and homozygous for the 3GS transgenes.
- NSG-SGM3 are maintained on the NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse (Stock No. 005557) background and constitutively produce human IL-3, GM-CSF, and SCF. NSG-SGM3 can be obtained commercially from The Jackson Laboratory (Maine; Stock No. 013062).
- NSG-Quad mice were irradiated with 50 cGy whole body radiation. NSG-SGM3 mice were irradiated with 50 cGy whole body radiation and NSG mice were irradiated with 100 cGy whole body radiation as controls. Each mouse received about 100,000 human CD34+ hematopoietic stem cells from the same donor by injection. Blood cells obtained by retro-orbital bleeding at 10 weeks post-engraftment were assessed by flow cytometry for mouse CD45, human CD45, human CD20, human CD3, human CD33, human CD14, and human CD56 (
FIG. 1A-F ). Live cells were gated using LIVE/DEAD® (ThermFisher Scientific). - NSG-Quad mice displayed fewer numbers of human CD20+ cells, increased numbers of human CD3+ cells, CD33+ cells, CD14+ cells, and CD56+ cells as a proportion of human CD45+ cells relative to NSG mice, which suggests that NSG-Quad mice are better able to differentiate human hematopoietic progenitor cells into T-lymphocytes, macrophages, and natural killer cells than NSG mice (
FIG. 1B-F ). NSG-Quad mice displayed increased numbers of human CD14+ cells and CD56+ cells as a proportion of human CD45+ cells relative to NSG-SGM3 mice, which suggests that NSG-Quad mice are better able to differentiate human hematopoietic progenitor cells into macrophages (myeloid lineage) and natural killer cells (lymphoid lineage) than NSG-SGM3 mice (FIG. 1E-F ). NSG-Quad mice trended toward increased human CD3+ cell counts and increased human CD33+ cell counts as a proportion of human CD45+ cells relative to NSG-SGM3 mice, although these trends did not display statistical significance (FIG. 1C-D ). The trend toward increased human CD3+ cell counts nevertheless suggests that the addition of CSF1, which is believed to be a myeloid-lineage cytokine, to the NSG-SGM3 mouse had an effect on lymphoid-lineage cells. - NSG-Quad mice, NSG-SGM3 hemizygous mice, NSG-SGM3 homozygous mice, and NSG mice engrafted with human CD34+ cells as described in Example 1 were administered an intravenous injection of 0.15 μg lipopolysaccharide (LPS) 10-weeks post xenograft. Serum was collected 6 hours after the LPS challenge, and human cytokine concentrations were determined using the BD™ Cytometric Bead Array (BD Biosciences). The NSG-Quad mice displayed increased concentrations of macrophage-secreted cytokines relative to NSG-SGM3 hemizygous mice, NSG-SGM3 homozygous mice, and NSG mice (
FIG. 2A-E ). - BR1126, MDA-MB-231, TM1149, and BL0293 tumor cells were separately implanted subcutaneously into NSG-Quad and NSG-SGM3 mice at 7-12 weeks post-CD34+-cell engraftment (see Example 1). Tumor sizes were measured with calipers. The BR1126, TM1149, and BL0293 tumors displayed similar growth in both the NSG-Quad and NSG-SGM3 mice (
FIG. 3A, 3C, 3D ). The NSG-Quad mice displayed significantlysmaller tumors day 15 after implantation with MDA-MB-231 tumor cells (FIG. 3B ). - Human TM1149 (breast cancer) tumors were harvested from NSG-Quad and NSG-SGM3 mice at 17-weeks post tumor-cell engraftment, and cells were analyzed by flow cytometry for mouse CD45, human CD45, human CD20, human CD3, human CD33, human CD14, and human CD56 (
FIG. 4A-F ). Live cells were gated using LIVE/DEAD® (ThermoFisher Scientific). NSG-Quad displayed significantly more intratumoral leukocytes than NSG-SGM3 mice (FIG. 4A ). Interestingly, the NSG-Quad mice trended toward increased human CD20+ cell counts, although this trend did not display statistical significance (FIG. 4C ). - NSG-Quad mice xenografted with human BL0293 tumor cells (bladder cancer cells) were grouped when tumors reached 60-100 mm3, and mice were then administered intravenous pembrolizumab at 10 mg/kg on
day 0 followed by 5 mg/kg ondays FIG. 5 ). -
FIG. 1 consists of 6 panels, labeledFIG. 1A ,FIG. 1B ,FIG. 1C ,FIG. 1D ,FIG. 1E , andFIG. 1F . Each ofFIGS. 1A, 1B, 1C, 1D, 1E, and 1F is a chart depicting percentages of flow-cytometry-gated blood cells observed in mice. Each data point corresponds to a single mouse. The x-axis labels identify three mouse strains, NSG, NSG-SGM3, and NSG-Quad, each of which is described herein. The y-axis identifies percentages of gated cells. NSG, NSG-SGM3, and NSG-Quad mice were each administered 100,000 human CD34+ hematopoietic stem cells, and blood cells were collected for flow cytometry analysis by retro-orbital bleeds 10-weeks post-engraftment. Statistically significant results are shown as p-values. The NSG-Quad mice displayed statistically significant increases in the relative number of human CD14+ cells (macrophages) and human CD56+ cells (natural killer cells) relative to NSG-SGM3 mice. Additionally, NSG-Quad mice trended toward increased human CD3+ cells (T-lymphocytes) relative to NSG-SGM3 mice, but this observation did not achieve statistical significance. -
FIG. 2 consists of 5 panels, labeledFIG. 2A ,FIG. 2B ,FIG. 2C ,FIG. 2D , andFIG. 2E . Each ofFIGS. 2A, 2B, 2C, 2D, and 2E is a chart depicting the concentration of cytokines observed in mouse serum. Each data point corresponds to a single mouse. The x-axis labels identify four mouse strains, NSG, NSG-SGM3/+, NSG-SGM3/SGM3, and NSG-Quad, each of which is described herein. The y-axis identifies concentrations of cytokines. NSG, NSG-SGM3/+, NSG-SGM3/SGM3, and NSG-Quad mice were each administered 100,000 human CD34+ hematopoietic stem cells followed by 0.15 pg intravenous lipopolysaccharide 10-weeks later. Serum cytokine concentrations were measured 6 hours after lipopolysaccharide administration using the BD™ Cytometric Bead Array for macrophage-associated cytokines. NSG-Quad mice, which constitutively express the human macrophage differentiation cytokine hCSF1, displayed elevated concentrations of macrophage-associated cytokines relative to control animals. -
FIG. 3 consists of 6 panels, labeledFIG. 3A ,FIG. 3B ,FIG. 3C , andFIG. 3D . Each ofFIGS. 3A, 3B, 3C, and 3D is a graph depicting the average tumor volume of mice having patient-derived xenografts (PDX). Each data point corresponds to an average tumor volume observed in a group of mice at a specific time-point. Circles () correspond to the NSG-Quad group of mice and squares () correspond to the NSG-SGM3 group. The x-axis identifies the number of days after a mouse received a patient-derived xenograft. The y-axis identifies the average tumor volume in mm3. Error bars correspond to standard error. Each patient-derived xenograft displayed similar growth in the NSG-Quad group and the NSG-SGM3 group except for the human MDA-MB-231 xenograft, which displayed significantly less growth in the NSG-Quad group relative to the NSG-SGM3 group beginning atday 15 post-engraftment. -
FIG. 4 consists of 6 panels, labeledFIG. 4A ,FIG. 4B ,FIG. 4C ,FIG. 4D ,FIG. 4E , andFIG. 4F . Each ofFIGS. 4A, 4B, 4C, 4D, 4E, and 4F is a chart depicting percentages of flow-cytometry-gated intratumor leukocytes observed in mice. Each data point corresponds to a single mouse. The x-axis labels identify two mouse strains, NSG-SGM3 and NSG-Quad, each of which is described herein. The y-axis identifies percentages of gated cells. NSG-SGM3 and NSG-Quad mice were each administered 100,000 human CD34+ hematopoietic stem cells followed by a subcutaneous TM1149 xenograft 7-12 weeks later. Tumors were harvested 17 weeks after the TM1149 xenograft and analyzed by flow cytometry. Statistically significant results are shown as p-values. NSG-Quad mice displayed a statistically significant increase in total human CD45+ cells (leukocytes) relative to NSG-SGM3 mice, which suggests that NSG-Quad mice may be superior to NSG-SGM3 mice for studying tumor-infiltrating lymphocyte-dependent cancer immunotherapies. NSG-Quad mice trended toward increased numbers of human CD3+ cells (T-lymphocytes) relative to NSG-SGM3 mice, but this observation did not display statistical significance. -
FIG. 5 is a graph depicting tumor volumes for NSG-Quad mice that have human CD34+ hematopoietic stem cell xenografts and BL0293 patient-derived xenografts and receiving either pembrolizumab (Keytruda®) or vehicle. Each data point corresponds to a single mouse at a specific time-point. Circles () correspond to vehicle-treated mice and squares () correspond to pembrolizumab-treated mice. The x-axis identifies the number of days after a mouse began receiving pembrolizumab or vehicle. The y-axis identifies the average tumor volume in mm3. NSG-Quad mice treated with pembrolizumab displayed slower tumor growth on average than mice receiving vehicle. - All patents and publications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
- It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
- The mice and methods described herein are presently representative of preferred embodiments, exemplary, and not intended as limitations on the scope of the invention. Modifications thereto and additional uses will occur to those skilled in the art. Such modifications and uses can be made without departing from the scope of the invention as set forth in the claims.
- Items
-
Item 1. A genetically-modified, immunodeficient mouse, comprising: (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSF1), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSF1. -
Item 2. The genetically-modified, immunodeficient mouse ofitem 1, wherein the mouse is a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse; a genetically modified NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mouse or a genetically modified NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mouse. -
Item 3. The genetically-modified, immunodeficient mouse of any one of the preceding items, wherein any one or more of the nucleotide sequences encoding hSCF, hGM-CSF, hIL-3, or hCSF1 is operably-linked to a constitutive promoter. - Item 4. The genetically-modified, immunodeficient mouse of any one of the preceding items, further comprising a human hematopoietic stem cell.
-
Item 5. The genetically-modified, immunodeficient mouse of any one of the preceding items, wherein the mouse comprises a differentiated human hematopoietic stem cell selected from the group consisting of a human myeloid progenitor cell, a human lymphoid progenitor cell, a human CD33+ myeloid cell, a human mast cell, a human monocyte, a human macrophage, human myeloid dendritic cell, a human B cell, a human plasma cell, a human T cell, a human T helper cell, a human cytotoxic T cell, a human Treg cell, and a human natural killer cell. -
Item 6. The genetically-modified, immunodeficient mouse of any one of the preceding items, wherein the mouse comprises a human leukocyte selected from the group consisting of CD45+, CD20+, CD20+CD45+, CD3+, CD3+CD45+, CD33+, CD33+CD45+, CD14+, CD14+CD45+, CD56+, and CD56+CD45+ leukocyte. - Item 7. The genetically-modified, immunodeficient mouse of
item 6, wherein said mouse comprises, in the absence of an immunological challenge one, two, three or all of: at least about 20% of the human CD45+ leukocytes of the mouse are CD3+CD45+ leukocytes; at least about 10% of the human CD45+ leukocytes of the mouse are CD33+CD45+ leukocytes; at least about 5% of the human CD45+ leukocytes of the mouse are CD14+CD45+ leukocytes; at least about 0.5% of the human CD45+ leukocytes of the mouse are CD56+CD45+ leukocytes. -
Item 8. The genetically-modified, immunodeficient mouse of any one of items 4 to 7, wherein the mouse expresses a human cytokine selected from the group consisting of human interleukin-8, human interleukin-1β, human tumor-necrosis factor, human interleukin-12p70, and human interleukin-6. - Item 9. The genetically-modified, immunodeficient mouse of any one of the preceding items, further comprising a human xenograft comprising a human tumor cell.
-
Item 10. A method of making a genetically-modified, immunodeficient humanized mouse model, comprising: providing a genetically-modified, immunodeficient mouse according to any one ofitems 1 to 3; and administering human hematopoietic stem cells to the genetically-modified, immunodeficient mouse. - Item 11. The method of
item 10, further comprising the step of: conditioning the genetically-modified, immunodeficient mouse to reduce mouse hematopoietic cells of the mouse prior to administering human hematopoietic stem cells. - Item 12. The method of item 11, wherein the conditioning step comprises irradiating the genetically-modified, immunodeficient mouse and/or administering a radiomimetic drug to the genetically-modified, immunodeficient mouse.
- Item 13. The method of any one of
items 10 to 12, further comprising the step of: administering a human xenograft comprising a human tumor cell to the genetically-modified, immunodeficient mouse. - Item 14. The method of item 13, wherein the human hematopoietic stem cell and the human tumor cell comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 matching HLA alleles.
-
Item 15. A method of identifying anti-tumor activity of a test substance, comprising: providing a genetically-modified, immunodeficient mouse according to any one ofitems 1 to 8; administering a human tumor cell to the genetically-modified, immunodeficient mouse, wherein the human tumor cell form a solid or non-solid tumor in the genetically-modified, immunodeficient mouse; administering a test substance to the genetically-modified, immunodeficient mouse; and assaying a response of the solid or non-solid tumor to the test substance, wherein an inhibitory effect of the test substance on the tumor and/or tumor cells identifies the test substance as having anti-tumor activity - Item 16. The method of
item 15, further comprising comparing the response to a standard to determine the effect of the test substance on the xenogeneic tumor cell, wherein an inhibitory effect of the test substance on the xenogeneic tumor cell identifies the test substance as having anti-tumor activity. - Item 17. The method of
item 15 or 16, wherein the test substance is an immunotherapeutic agent. - Item 18. The method of any one of
items 15 to 17, wherein the test substance is an immune checkpoint inhibitor. - Item 19. The method of item 18, wherein the immune checkpoint inhibitor is a PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor.
-
Item 20. The method of item 18 or 19, wherein the immune checkpoint inhibitor is atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, or pembrolizumab, or the immune checkpoint inhibitor comprises an antigen-binding fragment of any one of the foregoing. - Item 21. The method of any of
items 15 to 20, wherein the test substance is an antibody. - Item 22. The method of any of
items 15 to 21, wherein the test substance is an anti-cancer agent. - Item 23. A genetically-modified, immunodeficient mouse substantially as described or shown herein.
- Item 24. A method of making a genetically-modified, immunodeficient humanized mouse model substantially as described or shown herein.
-
Item 25. A method of identifying anti-tumor activity of a test substance substantially as described or shown herein. -
Sequences SEQ ID NO: 1: Homo sapiens colony stimulating factor 1 (CSF1), transcript variant 1 encoding isoform a (based on NM_000757.5), 1662 nucleotides ATGACCGCGCCGGGCGCCGCCGGGCGCTGCCCTCCCACGACATGGCTGGGCTCCCTGCT GTTGTTGGTCTGTCTCCTGGCGAGCAGGAGTATCACCGAGGAGGTGTCGGAGTACTGTA GCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCCAGT GTGCTACCTTAAGAAGGCATTTCTCCTGGTACAAGACATAATGGAGGACACCATGCGCT TCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACTCTCTTTGAGG CTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCCTGCGTCCGAACTTT CTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATGTCTTTAATGAAACAAAGA ATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAACTGCAACAACAGCTTTGCTGAA TGCTCCAGCCAAGATGTGGTGACCAAGCCTGATTGCAACTGCCTGTACCCCAAAGCCAT CCCTAGCAGTGACCCGGCCTCTGTCTCCCCTCATCAGCCCCTCGCCCCCTCCATGGCCC CTGTGGCTGGCTTGACCTGGGAGGACTCTGAGGGAACTGAGGGCAGCTCCCTCTTGCCT GGTGAGCAGCCCCTGCACACAGTGGATCCAGGCAGTGCCAAGCAGCGGCCACCCAGGAG CACCTGCCAGAGCTTTGAGCCGCCAGAGACCCCAGTTGTCAAGGACAGCACCATCGGTG GCTCACCACAGCCTCGCCCCTCTGTCGGGGCCTTCAACCCCGGGATGGAGGATATTCTT GACTCTGCAATGGGCACTAATTGGGTCCCAGAAGAAGCCTCTGGAGAGGCCAGTGAGAT TCCCGTACCCCAAGGGACAGAGCTTTCCCCCTCCAGGCCAGGAGGGGGCAGCATGCAGA CAGAGCCCGCCAGACCCAGCAACTTCCTCTCAGCATCTTCTCCACTCCCTGCATCAGCA AAGGGCCAACAGCCGGCAGATGTAACTGGTACCGCCTTGCCCAGGGTGGGCCCCGTGAG GCCCACTGGCCAGGACTGGAATCACACCCCCCAGAAGACAGACCATCCATCTGCCCTGC TCAGAGACCCCCCGGAGCCAGGCTCTCCCAGGATCTCATCACTGCGCCCCCAGGGCCTC AGCAACCCCTCCACCCTCTCTGCTCAGCCACAGCTTTCCAGAAGCCACTCCTCGGGCAG CGTGCTGCCCCTTGGGGAGCTGGAGGGCAGGAGGAGCACCAGGGATCGGAGGAGCCCCG CAGAGCCAGAAGGAGGACCAGCAAGTGAAGGGGCAGCCAGGCCCCTGCCCCGTTTTAAC TCCGTTCCTTTGACTGACACAGGCCATGAGAGGCAGTCCGAGGGATCCTCCAGCCCGCA GCTCCAGGAGTCTGTCTTCCACCTGCTGGTGCCCAGTGTCATCCTGGTCTTGCTGGCCG TCGGAGGCCTCTTGTTCTACAGGTGGAGGCGGCGGAGCCATCAAGAGCCTCAGAGAGCG GATTCTCCCTTGGAGCAACCAGAGGGCAGCCCCCTGACTCAGGATGACAGACAGGTGGA ACTGCCAGTG SEQ ID NO: 2: Homo sapiens colony stimulating factor 1 (CSF1), transcript variant 2 encoding isoform b (based on NM_172210.2), 1314 nucleotides ATGACCGCGCCGGGCGCCGCCGGGCGCTGCCCTCCCACGACATGGCTGGGCTCCCTGCT GTTGTTGGTCTGTCTCCTGGCGAGCAGGAGTATCACCGAGGAGGTGTCGGAGTACTGTA GCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCCAGT GTGCTACCTTAAGAAGGCATTTCTCCTGGTACAAGACATAATGGAGGACACCATGCGCT TCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACTCTCTTTGAGG CTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCCTGCGTCCGAACTTT CTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATGTCTTTAATGAAACAAAGA ATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAACTGCAACAACAGCTTTGCTGAA TGCTCCAGCCAAGATGTGGTGACCAAGCCTGATTGCAACTGCCTGTACCCCAAAGCCAT CCCTAGCAGTGACCCGGCCTCTGTCTCCCCTCATCAGCCCCTCGCCCCCTCCATGGCCC CTGTGGCTGGCTTGACCTGGGAGGACTCTGAGGGAACTGAGGGCAGCTCCCTCTTGCCT GGTGAGCAGCCCCTGCACACAGTGGATCCAGGCAGTGCCAAGCAGCGGCCACCCAGGAG CACCTGCCAGAGCTTTGAGCCGCCAGAGACCCCAGTTGTCAAGGACAGCACCATCGGTG GCTCACCACAGCCTCGCCCCTCTGTCGGGGCCTTCAACCCCGGGATGGAGGATATTCTT GACTCTGCAATGGGCACTAATTGGGTCCCAGAAGAAGCCTCTGGAGAGGCCAGTGAGAT TCCCGTACCCCAAGGGACAGAGCTTTCCCCCTCCAGGCCAGGAGGGGGCAGCATGCAGA CAGAGCCCGCCAGACCCAGCAACTTCCTCTCAGCATCTTCTCCACTCCCTGCATCAGCA AAGGGCCAACAGCCGGCAGATGTAACTGGCCATGAGAGGCAGTCCGAGGGATCCTCCAG CCCGCAGCTCCAGGAGTCTGTCTTCCACCTGCTGGTGCCCAGTGTCATCCTGGTCTTGC TGGCCGTCGGAGGCCTCTTGTTCTACAGGTGGAGGCGGCGGAGCCATCAAGAGCCTCAG AGAGCGGATTCTCCCTTGGAGCAACCAGAGGGCAGCCCCCTGACTCAGGATGACAGACA GGTGGAACTGCCAGTG SEQ ID NO: 3: Homo sapiens colony stimulating factor 1 (CSF1), transcript variant 3 encoding isoform c (based on NM_172211.3), 619 nucleotides ATGACCGCGCCGGGCGCCGCCGGGCGCTGCCCTCCCACGACATGGCTGGGCTCCCTGCT GTTGTTGGTCTGTCTCCTGGCGAGCAGGAGTATCACCGAGGAGGTGTCGGAGTACTGTA GCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCCAGT GTGCTACCTTAAGAAGGCATTTCTCCTGGTACAAGACATAATGGAGGACACCATGCGCT TCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACTCTCTTTGAGG CTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCCTGCGTCCGAACTTT CTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATGTCTTTAATGAAACAAAGA ATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAACTGCAACAACAGCTTTGCTGAA TGCTCCAGCCAAGGCCATGAGAGGCAGTCCGAGGGATCCTCCAGCCCGCAGCTCCAGGA GTCTGTCTTCCACCTGCTGGTGCCCAGTG SEQ ID NO: 4: Homo sapiens colony stimulating factor 1 (CSF1), transcript variant 4 encoding isoform a (based on NM_172212.2), 1662 nucleotides ATGACCGCGCCGGGCGCCGCCGGGCGCTGCCCTCCCACGACATGGCTGGGCTCCCTGCT GTTGTTGGTCTGTCTCCTGGCGAGCAGGAGTATCACCGAGGAGGTGTCGGAGTACTGTA GCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCCAGT GTGCTACCTTAAGAAGGCATTTCTCCTGGTACAAGACATAATGGAGGACACCATGCGCT TCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACTCTCTTTGAGG CTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCCTGCGTCCGAACTTT CTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATGTCTTTAATGAAACAAAGA ATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAACTGCAACAACAGCTTTGCTGAA TGCTCCAGCCAAGATGTGGTGACCAAGCCTGATTGCAACTGCCTGTACCCCAAAGCCAT CCCTAGCAGTGACCCGGCCTCTGTCTCCCCTCATCAGCCCCTCGCCCCCTCCATGGCCC CTGTGGCTGGCTTGACCTGGGAGGACTCTGAGGGAACTGAGGGCAGCTCCCTCTTGCCT GGTGAGCAGCCCCTGCACACAGTGGATCCAGGCAGTGCCAAGCAGCGGCCACCCAGGAG CACCTGCCAGAGCTTTGAGCCGCCAGAGACCCCAGTTGTCAAGGACAGCACCATCGGTG GCTCACCACAGCCTCGCCCCTCTGTCGGGGCCTTCAACCCCGGGATGGAGGATATTCTT GACTCTGCAATGGGCACTAATTGGGTCCCAGAAGAAGCCTCTGGAGAGGCCAGTGAGAT TCCCGTACCCCAAGGGACAGAGCTTTCCCCCTCCAGGCCAGGAGGGGGCAGCATGCAGA CAGAGCCCGCCAGACCCAGCAACTTCCTCTCAGCATCTTCTCCACTCCCTGCATCAGCA AAGGGCCAACAGCCGGCAGATGTAACTGGTACCGCCTTGCCCAGGGTGGGCCCCGTGAG GCCCACTGGCCAGGACTGGAATCACACCCCCCAGAAGACAGACCATCCATCTGCCCTGC TCAGAGACCCCCCGGAGCCAGGCTCTCCCAGGATCTCATCACTGCGCCCCCAGGGCCTC AGCAACCCCTCCACCCTCTCTGCTCAGCCACAGCTTTCCAGAAGCCACTCCTCGGGCAG CGTGCTGCCCCTTGGGGAGCTGGAGGGCAGGAGGAGCACCAGGGATCGGAGGAGCCCCG CAGAGCCAGAAGGAGGACCAGCAAGTGAAGGGGCAGCCAGGCCCCTGCCCCGTTTTAAC TCCGTTCCTTTGACTGACACAGGCCATGAGAGGCAGTCCGAGGGATCCTCCAGCCCGCA GCTCCAGGAGTCTGTCTTCCACCTGCTGGTGCCCAGTGTCATCCTGGTCTTGCTGGCCG TCGGAGGCCTCTTGTTCTACAGGTGGAGGCGGCGGAGCCATCAAGAGCCTCAGAGAGCG GATTCTCCCTTGGAGCAACCAGAGGGCAGCCCCCTGACTCAGGATGACAGACAGGTGGA ACTGCCAGTG SEQ ID NO: 5: Amino acid sequence of human colony-stimulating factor 1 (hCSF1) isoform a - 554 amino acids (including 32 amino acid N-terminal signal peptide) (NP_000748.3) MTAPGAAGRCPPTTWLGSLLLLVCLLASRSITEEVSEYCSHMIGSGHLQSLQRLIDSQM ETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLR LKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAE CSSQDVVTKPDCNCLYPKAIPSSDPASVSPHQPLAPSMAPVAGLTWEDSEGTEGSSLLP GEQPLHTVDPGSAKQRPPRSTCQSFEPPETPVVKDSTIGGSPQPRPSVGAFNPGMEDIL DSAMGTNWVPEEASGEASEIPVPQGTELSPSRPGGGSMQTEPARPSNFLSASSPLPASA KGQQPADVTGTALPRVGPVRPTGQDWNHTPQKTDHPSALLRDPPEPGSPRISSLRPQGL SNPSTLSAQPQLSRSHSSGSVLPLGELEGRRSTRDRRSPAEPEGGPASEGAARPLPRFN SVPLTDTGHERQSEGSSSPQLQESVFHLLVPSVILVLLAVGGLLFYRWRRRSHQEPQRA DSPLEQPEGSPLTQDDRQVELPV SEQ ID NO: 6: Amino acid sequence of human colony-stimulating factor 1 (hCSF1) without signal peptide - 522 amino acids (based on NP_000748.3) EEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQD IMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVK NVFNETKNLLDKDWNIFSKNCNNSFAECSSQDVVTKPDCNCLYPKAIPSSDPASVSPHQ PLAPSMAPVAGLTWEDSEGTEGSSLLPGEQPLHTVDPGSAKQRPPRSTCQSFEPPETPV VKDSTIGGSPQPRPSVGAFNPGMEDILDSAMGTNWVPEEASGEASEIPVPQGTELSPSR PGGGSMQTEPARPSNFLSASSPLPASAKGQQPADVTGTALPRVGPVRPTGQDWNHTPQK TDHPSALLRDPPEPGSPRISSLRPQGLSNPSTLSAQPQLSRSHSSGSVLPLGELEGRRS TRDRRSPAEPEGGPASEGAARPLPRFNSVPLTDTGHERQSEGSSSPQLQESVFHLLVPS VILVLLAVGGLLFYRWRRRSHQEPQRADSPLEQPEGSPLTQDDRQVELPV SEQ ID NO: 7: Amino acid sequence of human colony-stimulating factor 1 (hCSF1) isoform b - 438 amino acids (including 32 amino acid N-terminal signal peptide) - (NP_757349.1) encoded by transcript variant 2 MTAPGAAGRCPPTTWLGSLLLLVCLLASRSITEEVSEYCSHMIGSGHLQSLQRLIDSQM ETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLR LKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAE CSSQDVVTKPDCNCLYPKAIPSSDPASVSPHQPLAPSMAPVAGLTWEDSEGTEGSSLLP GEQPLHTVDPGSAKQRPPRSTCQSFEPPETPVVKDSTIGGSPQPRPSVGAFNPGMEDIL DSAMGTNWVPEEASGEASEIPVPQGTELSPSRPGGGSMQTEPARPSNFLSASSPLPASA KGQQPADVTGHERQSEGSSSPQLQESVFHLLVPSVILVLLAVGGLLFYRWRRRSHQEPQ RADSPLEQPEGSPLTQDDRQVELPV SEQ ID NO: 8: Amino acid sequence of human colony-stimulating factor 1 (hCSF1) isoform b without signal peptide - 406 amino acids (based on NP_757349.1) EEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQD IMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVK NVFNETKNLLDKDWNIFSKNCNNSFAECSSQDVVTKPDCNCLYPKAIPSSDPASVSPHQ PLAPSMAPVAGLTWEDSEGTEGSSLLPGEQPLHTVDPGSAKQRPPRSTCQSFEPPETPV VKDSTIGGSPQPRPSVGAFNPGMEDILDSAMGTNWVPEEASGEASEIPVPQGTELSPSR PGGGSMQTEPARPSNFLSASSPLPASAKGQQPADVTGHERQSEGSSSPQLQESVFHLLV PSVILVLLAVGGLLFYRWRRRSHQEPQRADSPLEQPEGSPLTQDDRQVELPV SEQ ID NO. 9: Amino acid sequence of human colony-stimulating factor 1 (hCSF1) isoform c - 256 amino acids- (including 32 amino acid N-terminal signal peptide) (NP_757350.1) encoded by transcript variant 3MTAPGAAGRCPPTTWLGSLLLLVCLLASRSITEEVSEYCSHMIGSGHLQSLQRLIDSQM ETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLR LKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAE CSSQGHERQSEGSSSPQLQESVFHLLVPSVILVLLAVGGLLFYRWRRRSHQEPQRADSP LEQPEGSPLTQDDRQVELPV SEQ ID NO: 10: Amino acid sequence of human colony-stimulating factor 1 (hCSF1) isoform c without signal peptide - 224 amino acids (based on NP_757350.1) EEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQD IMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVK NVFNETKNLLDKDWNIFSKNCNNSFAECSSQGHERQSEGSSSPQLQESVFHLLVPSVIL VLLAVGGLLFYRWRRRSHQEPQRADSPLEQPEGSPLTQDDRQVELPV SEQ ID NO. 11: human SCF 220 (245 aa) MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVP GMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKEN SSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKGKAK NPPGDSSLHWAAMALPALFSLIIGFAFGALYWKKRQPSLTRAVENIQINEEDNEISMLQ EKEREFQEV SEQ ID NO. 12: Nucleotide Sequence encoding human SCF 220, 738 nucleotides ATGAAGAAGACACAAACTTGGATTCTCACTTGCATTTATCTTCAGCTGCTCCTATTTAA TCCTCTCGTCAAAACTGAAGGGATCTGCAGGAATCGTGTGACTAATAATGTAAAAGACG TCACTAAATTGGTGGCAAATCTTCCAAAAGACTACATGATAACCCTCAAATATGTCCCC GGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATTGTCAGA CAGCTTGACTGATCTTCTGGACAAGTTTTCAAATATTTCTGAAGGCTTGAGTAATTATT CCATCATAGACAAACTTGTGAATATAGTGGATGACCTTGTGGAGTGCGTGAAAGAAAAC TCATCTAAGGATCTAAAAAAATCATTCAAGAGCCCAGAACCCAGGCTCTTTACTCCTGA AGAATTCTTTAGAATTTTTAATAGATCCATTGATGCCTTCAAGGACTTTGTAGTGGCAT CTGAAACTAGTGATTGTGTGGTTTCTTCAACATTAAGTCCTGAGAAAGGGAAGGCCAAA AATCCCCCTGGAGACTCCAGCCTACACTGGGCAGCCATGGCATTGCCAGCATTGTTTTC TCTTATAATTGGCTTTGCTTTTGGAGCCTTATACTGGAAGAAGAGACAGCCAAGTCTTA CAAGGGCAGTTGAAAATATACAAATTAATGAAGAGGATAATGAGATAAGTATGTTGCAA GAGAAAGAGAGAGAGTTTCAAGAAGTGTAA SEQ ID NO. 13: human SCF 248 (273 aa) MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVP GMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKEN SSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRV SVTKPFMLPPVAASSLRNDSSSSNRKAKNPPGDSSLHWAAMALPALFSLIIGFAFGALY WKKRQPSLTRAVENIQINEEDNEISMLQEKEREFQEV SEQ ID NO. 14: Nucleotide Sequence encoding human SCF 248, 822 nucleotides ATGAAGAAGACACAAACTTGGATTCTCACTTGCATTTATCTTCAGCTGCTCCTATTTAA TCCTCTCGTCAAAACTGAAGGGATCTGCAGGAATCGTGTGACTAATAATGTAAAAGACG TCACTAAATTGGTGGCAAATCTTCCAAAAGACTACATGATAACCCTCAAATATGTCCCC GGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATTGTCAGA CAGCTTGACTGATCTTCTGGACAAGTTTTCAAATATTTCTGAAGGCTTGAGTAATTATT CCATCATAGACAAACTTGTGAATATAGTGGATGACCTTGTGGAGTGCGTGAAAGAAAAC TCATCTAAGGATCTAAAAAAATCATTCAAGAGCCCAGAACCCAGGCTCTTTACTCCTGA AGAATTCTTTAGAATTTTTAATAGATCCATTGATGCCTTCAAGGACTTTGTAGTGGCAT CTGAAACTAGTGATTGTGTGGTTTCTTCAACATTAAGTCCTGAGAAAGATTCCAGAGTC AGTGTCACAAAACCATTTATGTTACCCCCTGTTGCAGCCAGCTCCCTTAGGAATGACAG CAGTAGCAGTAATAGGAAGGCCAAAAATCCCCCTGGAGACTCCAGCCTACACTGGGCAG CCATGGCATTGCCAGCATTGTTTTCTCTTATAATTGGCTTTGCTTTTGGAGCCTTATAC TGGAAGAAGAGACAGCCAAGTCTTACAAGGGCAGTTGAAAATATACAAATTAATGAAGA GGATAATGAGATAAGTATGTTGCAAGAGAAAGAGAGAGAGTTTCAAGAAGTGTAA SEQ ID NO. 15: nucleotide sequence encoding human SCF 248 including 5′ and 3′ non-coding sequences, 1405 nucleotides CCGCCTCGCGCCGAGACTAGAAGCGCTGCGGGAAGCAGGGACAGTGGAGAGGGCGCTGC GCTCGGGCTACCCAATGCGTGGACTATCTGCCGCCGCTGTTCGTGCAATATGCTGGAGC TCCAGAACAGCTAAACGGAGTCGCCACACCACTGTTTGTGCTGGATCGCAGCGCTGCCT TTCCTTATGAAGAAGACACAAACTTGGATTCTCACTTGCATTTATCTTCAGCTGCTCCT ATTTAATCCTCTCGTCAAAACTGAAGGGATCTGCAGGAATCGTGTGACTAATAATGTAA AAGACGTCACTAAATTGGTGGCAAATCTTCCAAAAGACTACATGATAACCCTCAAATAT GTCCCCGGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATT GTCAGACAGCTTGACTGATCTTCTGGACAAGTTTTCAAATATTTCTGAAGGCTTGAGTA ATTATTCCATCATAGACAAACTTGTGAATATAGTGGATGACCTTGTGGAGTGCGTGAAA GAAAACTCATCTAAGGATCTAAAAAAATCATTCAAGAGCCCAGAACCCAGGCTCTTTAC TCCTGAAGAATTCTTTAGAATTTTTAATAGATCCATTGATGCCTTCAAGGACTTTGTAG TGGCATCTGAAACTAGTGATTGTGTGGTTTCTTCAACATTAAGTCCTGAGAAAGATTCC AGAGTCAGTGTCACAAAACCATTTATGTTACCCCCTGTTGCAGCCAGCTCCCTTAGGAA TGACAGCAGTAGCAGTAATAGGAAGGCCAAAAATCCCCCTGGAGACTCCAGCCTACACT GGGCAGCCATGGCATTGCCAGCATTGTTTTCTCTTATAATTGGCTTTGCTTTTGGAGCC TTATACTGGAAGAAGAGACAGCCAAGTCTTACAAGGGCAGTTGAAAATATACAAATTAA TGAAGAGGATAATGAGATAAGTATGTTGCAAGAGAAAGAGAGAGAGTTTCAAGAAGTGT AAATTGTGGCTTGTATCAACACTGTTACTTTCGTACATTGGCTGGTAACAGTTCATGTT TGCTTCATAAATGAAGCAGCTTTAAACAAATTCATATTCTGTCTGGAGTGACAGACCAC ATCTTTATCTGTTCTTGCTACCCATGACTTTATATGGATGATTCAGAAATTGGAACAGA ATGTTTTACTGTGAAACTGGCACTGAATTAATCATCTATAAAGAAGAACTTGCATGGAG CAGGACTCTATTTTAAGGACTGCGGGACTTGGGTCTCATTTAGAACTTGCAGCTGATGT TGGAAGAGAAAGCACGTGTCTCAGACTGCATGTACCATTTGCATGGCTCCAGAAATGTC TAAATGCTGAAAAAACACCTAGCTTTATTCTTCAGATACAAACTGCAG SEQ ID NO. 16: human soluble SCF (164 aa and 25 aa N-terminal signal peptide) MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVP GMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKEN SSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRV SVTKPFMLPPVA SEQ ID NO. 17: nucleotide sequence encoding human soluble SCF (164 aa and 25 aa N-terminal signal peptide), 567 nucleotides ATGAAGAAGACACAAACTTGGATTCTCACTTGCATTTATCTTCAGCTGCTCCTATTTAA TCCTCTCGTCAAAACTGAAGGGATCTGCAGGAATCGTGTGACTAATAATGTAAAAGACG TCACTAAATTGGTGGCAAATCTTCCAAAAGACTACATGATAACCCTCAAATATGTCCCC GGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATTGTCAGA CAGCTTGACTGATCTTCTGGACAAGTTTTCAAATATTTCTGAAGGCTTGAGTAATTATT CCATCATAGACAAACTTGTGAATATAGTGGATGACCTTGTGGAGTGCGTGAAAGAAAAC TCATCTAAGGATCTAAAAAAATCATTCAAGAGCCCAGAACCCAGGCTCTTTACTCCTGA AGAATTCTTTAGAATTTTTAATAGATCCATTGATGCCTTCAAGGACTTTGTAGTGGCAT CTGAAACTAGTGATTGTGTGGTTTCTTCAACATTAAGTCCTGAGAAAGATTCCAGAGTC AGTGTCACAAAACCATTTATGTTACCCCCTGTTGCA SEQ ID NO: 18: hGM-CSF - 144 amino acids (including 17 amino acid signal peptide) MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEV ISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQII TFESFKENLKDFLLVIPFDCWEPVQE SEQ ID NO: 19: Nucleotide sequence encoding hGM-CSF (including 17 amino acid signal peptide) - 435 nucleotides atgtggctgcagagcctgctgctcttgggcactgtggcctgcagcatctctgcacccgc ccgctcgcccagccccagcacgcagccctgggagcatgtgaatgccatccaggaggccc ggcgtctcctgaacctgagtagagacactgctgctgagatgaatgaaacagtagaagtc atctcagaaatgtttgacctccaggagccgacctgcctacagacccgcctggagctgta caagcagggcctgcggggcagcctcaccaagctcaagggccccttgaccatgatggcca gccactacaagcagcactgccctccaaccccggaaacttcctgtgcaacccagattatc acctttgaaagtttcaaagagaacctgaaggactttctgcttgtcatcccctttgactg ctgggagccagtccaggagtga SEQ ID NO: 20: hGM-CSF without signal peptide - 127 amino acids APARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRL ELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIP FDCWEPVQE SEQ ID NO: 21: Nucleotide sequence encoding hGM-CSF protein without signal peptide - 352 nucleotides gccctgggagcatgtgaatgccatccaggaggcccggcgtctcctgaacctgagtagag acactgctgctgagatgaatgaaacagtagaagtcatctcagaaatgtttgacctccag gagccgacctgcctacagacccgcctggagctgtacaagcagggcctgcggggcagcct caccaagctcaagggccccttgaccatgatggccagccactacaagcagcactgccctc caaccccggaaacttcctgtgcaacccagattatcacctttgaaagtttcaaagagaac ctgaaggactttctgcttgtcatcccctttgactgctgggagccagtccaggagtga SEQ ID NO: 22: human interleukin-3 152 amino acids (including 19 amino acid signal peptide) MSRLPVLLLLQLLVRPGLQAPMTQTTPLKTSWVNCSNMIDEIITHLKQPPLPLLDFNNL NGEDQDILMENNLRRPNLEAFNRAVKSLQNASAIESILKNLLPCLPLATAAPTRHPIHI KDGDWNEFRRKLTFYLKTLENAQAQQTTLSLAIF SEQ ID NO: 23: Nucleotide sequence encoding interleukin-3 (including 19 amino acid signal peptide)-459 nucleotides atgagccgcctgcccgtcctgctcctgctccaactcctggtccgccccggactccaagc tcccatgacccagacaacgcccttgaagacaagctgggttaactgctctaacatgatcg atgaaattataacacacttaaagcagccacctttgcctttgctggacttcaacaacctc aatggggaagaccaagacattctgatggaaaataaccttcgaaggccaaacctggaggc attcaacagggctgtcaagagtttacagaacgcatcagcaattgagagcattcttaaaa atctcctgccatgtctgcccctggccacggccgcacccacgcgacatccaatccatatc aaggacggtgactggaatgaattccggaggaaactgacgttctatctgaaaacccttga gaatgcgcaggctcaacagacgactttgagcctcgcgatcttttga SEQ ID NO: 24: human interleukin-3 without signal peptide - 133 amino acids APMTQTTPLKTSWVNCSNMIDEIITHLKQPPLPLLDFNNLNGEDQDILMENNLRRPNLE AFNRAVKSLQNASAIESILKNLLPCLPLATAAPTRHPIHIKDGDWNEFRRKLTFYLKTL ENAQAQQTTLSLAIF SEQ ID NO: 25: Nucleotide sequence encoding interleukin-3 without signal peptide-402 nucleotides gctcccatgacccagacaacgcccttgaagacaagctgggttaactgctctaacatgat cgatgaaattataacacacttaaagcagccacctttgcctttgctggacttcaacaacc tcaatggggaagaccaagacattctgatggaaaataaccttcgaaggccaaacctggag gcattcaacagggctgtcaagagtttacagaacgcatcagcaattgagagcattcttaa aaatctcctgccatgtctgcccctggccacggccgcacccacgcgacatccaatccata tcaaggacggtgactggaatgaattccggaggaaactgacgttctatctgaaaaccctt gagaatgcgcaggctcaacagacgactttgagcctcgcgatcttttga
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/465,006 US20190320633A1 (en) | 2016-11-30 | 2017-11-30 | Humanized mouse model with improved human innate immune cell development |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662428131P | 2016-11-30 | 2016-11-30 | |
US201762565783P | 2017-09-29 | 2017-09-29 | |
US16/465,006 US20190320633A1 (en) | 2016-11-30 | 2017-11-30 | Humanized mouse model with improved human innate immune cell development |
PCT/US2017/063948 WO2018102546A1 (en) | 2016-11-30 | 2017-11-30 | Humanized mouse model with improved human innate immune cell development |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190320633A1 true US20190320633A1 (en) | 2019-10-24 |
Family
ID=60935945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/465,006 Pending US20190320633A1 (en) | 2016-11-30 | 2017-11-30 | Humanized mouse model with improved human innate immune cell development |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190320633A1 (en) |
EP (1) | EP3547831A1 (en) |
JP (2) | JP7458185B2 (en) |
CN (1) | CN110740641A (en) |
WO (1) | WO2018102546A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024006965A1 (en) | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
WO2024054904A1 (en) * | 2022-09-08 | 2024-03-14 | The Jackson Laboratory | Humanized immunodeficient mouse models |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3621433B1 (en) | 2017-05-12 | 2022-07-27 | The Jackson Laboratory | Nsg mice lacking mhc class i and class ii |
US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
US20210355501A1 (en) * | 2018-09-24 | 2021-11-18 | Albert Einstein College Of Medicine | Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof |
EP3950949A4 (en) * | 2019-03-28 | 2022-12-28 | Central Institute For Experimental Animals | Immunodeficient rodent |
WO2021027737A1 (en) * | 2019-08-09 | 2021-02-18 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
CN111705082A (en) * | 2020-04-14 | 2020-09-25 | 澎立生物医药技术(上海)有限公司 | Construction method of humanized immune mouse with marrow immune cells |
CN114853871B (en) * | 2021-04-20 | 2024-04-05 | 百奥赛图(北京)医药科技股份有限公司 | Humanized non-human animal of CSF1 and/or CSF1R gene, construction method and application thereof |
WO2024091902A1 (en) * | 2022-10-25 | 2024-05-02 | Lapix Therapeutics, Inc. | Immune cell-engrafted non-human animals and non-human animal models |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012112544A2 (en) * | 2011-02-15 | 2012-08-23 | Regeneron Pharmaceuticals, Inc. | Humanized m-csf mice |
WO2016189799A1 (en) * | 2015-05-27 | 2016-12-01 | 公益財団法人実験動物中央研究所 | Human il-15-secreting immunodeficient mouse |
US20190016778A1 (en) * | 2017-06-30 | 2019-01-17 | Xencor, Inc. | TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508038A (en) | 1999-08-31 | 2003-03-04 | ジェネンコア インターナショナル インコーポレーテッド | Transgenic mammals that can facilitate the production of donor-specific functional immunity |
PT1802193E (en) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Method for generating a mouse homozygous for a genetic modification |
KR102594390B1 (en) | 2012-09-07 | 2023-10-27 | 예일 유니버시티 | Genetically modified non-human animals and methods of use thereof |
EP4389764A2 (en) * | 2012-11-05 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
KR102627332B1 (en) * | 2014-05-19 | 2024-01-26 | 리제너론 파마슈티칼스 인코포레이티드 | Genetically modified non-human animals expressing human epo |
KR20240068768A (en) * | 2015-06-23 | 2024-05-17 | 더 잭슨 래보라토리 | Non-hla matched humanized nsg mouse model with patient-derived xenograft |
-
2017
- 2017-11-30 US US16/465,006 patent/US20190320633A1/en active Pending
- 2017-11-30 EP EP17825653.3A patent/EP3547831A1/en active Pending
- 2017-11-30 WO PCT/US2017/063948 patent/WO2018102546A1/en unknown
- 2017-11-30 CN CN201780083557.8A patent/CN110740641A/en active Pending
- 2017-11-30 JP JP2019529204A patent/JP7458185B2/en active Active
-
2022
- 2022-10-17 JP JP2022166015A patent/JP2023015064A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012112544A2 (en) * | 2011-02-15 | 2012-08-23 | Regeneron Pharmaceuticals, Inc. | Humanized m-csf mice |
WO2016189799A1 (en) * | 2015-05-27 | 2016-12-01 | 公益財団法人実験動物中央研究所 | Human il-15-secreting immunodeficient mouse |
US20190016778A1 (en) * | 2017-06-30 | 2019-01-17 | Xencor, Inc. | TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS |
Non-Patent Citations (7)
Title |
---|
Ito WO 2016189799 translation, 2016 * |
Jackson Labs description of Congenic, 2022 * |
Jackson Labs description of Genetic Drift, 2022 * |
Kwant-Mitchell (PLoS, 2009, Vol. 4, No. 12, e8379) (Year: 2009) * |
Nagatani, Exp. Anim., 2019, Vol. 68, No. 4, pg 471-482 * |
Wikipedia definition of NOG mouse, 2022 * |
Wikipedia definition of NSG mouse, 2022 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024006965A1 (en) | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
WO2024054904A1 (en) * | 2022-09-08 | 2024-03-14 | The Jackson Laboratory | Humanized immunodeficient mouse models |
Also Published As
Publication number | Publication date |
---|---|
CN110740641A (en) | 2020-01-31 |
WO2018102546A8 (en) | 2018-08-02 |
JP2019536457A (en) | 2019-12-19 |
WO2018102546A1 (en) | 2018-06-07 |
JP2023015064A (en) | 2023-01-31 |
JP7458185B2 (en) | 2024-03-29 |
EP3547831A1 (en) | 2019-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190320633A1 (en) | Humanized mouse model with improved human innate immune cell development | |
JP7130012B2 (en) | Genetically modified non-human animals expressing human EPO | |
Tremml et al. | Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene | |
ES2938342T3 (en) | Genetically modified mice and methods of using the same | |
EP2618656B1 (en) | HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE | |
EP3664603B1 (en) | Immunodeficient mice expressing human interleukin 15 | |
US11778994B2 (en) | NSG mice lacking MHC class I and class II | |
US8431767B2 (en) | Transgenic non-human animal and methods for stem cell engraftment | |
Oravecz-Wilson et al. | Huntingtin Interacting Protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts | |
US20180325085A1 (en) | Compositions and methods relating to tumor analysis | |
WO2024006677A1 (en) | Non-human animals having a humanized clec9a gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: THE JACKSON LABORATORY, MAINE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHULTZ, LEONARD D.;KECK, JAMES G.;REEL/FRAME:061556/0073 Effective date: 20210802 Owner name: UNIVERSITY OF MASSACHUSETTS, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GREINER, DALE L.;BREHM, MICHAEL A.;REEL/FRAME:061556/0184 Effective date: 20210802 |
|
AS | Assignment |
Owner name: LABORATORY, THE JACKSON, MAINE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ERROR IN SERIAL NUMBER 16/456,006 PREVIOUSLY RECORDED ON REEL 061556 FRAME 0073. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT SERIAL NUMBER IS 16/465,006;ASSIGNORS:LEONARD D. SHULTZ;KECK, JAMES G.;REEL/FRAME:061832/0349 Effective date: 20210802 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |